Case 2:15-md-02641-DGC Document 10594 Filed 03/30/18 Page 1 of 135

UNITED STATES DISTRICT COURT DISTIRCT OF ARIZONA

CIVIL	EXHIBIT	LIST
-------	----------------	------

FILED RECEIVED	LODGED
MAR 3	0 2018
CLERK USD DISTRICT BY	ISTRICT COURT OF ARIZONA DEPUTY

☐ Preliminary Injunction	☐ TRO	☐ Non-Jury Trial	X Jury Trial
Case Number 2:15-md-0264	1-DGC	Judge Code 7020	Date March 14, 2018
Sherr-una Book	ter vs. C. R	. Bard, Inc. and Bard l	Peripheral Vascular
☐ Plaintiff/Petition	ner	☐ Defendant	Respondent

Exhibit	Marked for	Admitted in	Description
	ID	Evidence	Email from D. Uelmen to J. Hudnall, et al re: Physician Panel
5000			Agenda
		2 77 00	Dec. 2004 Dear Doctor Letter
5001		3-7218	Feb. 4, 2005 Conference FDA and BPV re DCL and Recovery
5002			
			Retrievable (K031328) Feb. 8, 2005 Conference FDA and BPV re Recovery
5003		33518	
		20018	Retrievable (K031328) July welactions
5004			Recovery Filter IFU 2003
5005			Recovery Filter DFMEA 070010, Rev. 2 DFMEA070010 Rev.
			2 Recovery Filter DFMEA 070010, Rev. 2
5006			Design Review Assessment Status Memo
5007			Oct 18, 2002 letter to the FDA responding to the questions
			posed by Dr. Harvey at the FDA about RNF
5008			ETR-04-08-04 (G2 Arm Fatigue Testing Report) ETR-04-08-04
			(G2 Arm Fatigue Testing Report)
5009			TM1133800 (G2 Filter Arm Fatigue Test Method)
5010			Recovery Filter Fault Tree Analysis
5011			SPA-04-04 (Remedial Action Plan re RNF Fractures)
5012			HHE of Dr. Ciavarella July 9, 2004
5013			May 21, 2002 Memo from Doug Uelmen (re Fracture
3013			Investigation)
5014			ETR-04-06 (RF Migration Resistance DOE and Hook
3014			Radius Change)
5015			ETR-04-10-21 (G2® Acute Animal Feasibility Study)
5016			ETR-02-12-01, Rev. 00 (Recovery Filter Magnetic Resonance
3010			Safety and Compatibility Report)
5017		, d	5 1000 D.O.D.T. Laisel Demont DNE Migration Study
5017		2-26-18	Design Verification (RD-RPT-100)
5010		J	RD-RPT-104 (Analysis of RNF Migration Resistance) (FEA)
5018			RNF Wire Tensile Test Report
5019			ICINI: WITC TOUSING TOST ROPOTE

Exhibit	Marked for ID	Admitted in Evidence	Description
5020	110	- Dynamics	Aug. 9, 1999 RD-RPT-102 RNF Radial Strength Report
5020			ETR-04-10-04 (Feasibility: RNF v. G2 and Competitive
3021			Product migration resistance)
5022		3-26-18	RD-LNB-087 Laboratory Notebook
5023			Aug. 12, 1999 RD-RPT-095 Test Results for RD-SOP-057
3023			Simulated Use
5024			Recovery Filter DFMEA 070010, Rev. 4 Recovery Filter
5021			DFMEA 070010, Rev. 4
5025			ETR-05-03-01 G1A Jugular/Subclavian System Design
3023			Verification and Validation Phase 2 Report
5026			ETR-05-05-21 G1A Jugular/Subclavian System Design
3020			Verification and Validation Phase 3 Report
5027			ETR-05-03-02 G1A Acute Animal Study Report
5028			Recovery Filter G1A Femoral System-Design Failure Mode and
3020			Effect Analysis (DFMEA070022, Rev. 4)
5029			ETR-05-03-11 (G2 Migration Resistance Evaluation of NEPG
3027			Manufactured Filters)
5030			Lab notebook 7013 (Recovery Arm Fatigue Feasibility)
5031			Lab notebook 7013 (Recovery Arm Fatigue Feasibility) Lab
3031			notebook 7013 (Recovery Arm Fatigue Feasibility)
5032			ETR-05-01-06 (G2® Femoral System Acute Animal Study
3032			Report) (followed TPR-04-12-20)
5033			TPR-04-12-20 (Protocol for Animal Model Evaluation of G2)
5034			G1A Filter and Femoral Delivery System PPS Revision 0
5035			G1A Filter and Femoral Delivery System PPS Revision 1
5036			ETR-05-02-11 (Chronic Animal Model Evaluation of Recovery
5050			G1A Femoral System Report) (followed TPR-04-09-11)
5037			ETR-05-02-02 (Effects of Changes to the Recovery Filter &
		3-20-18	The Femoral Delivery System on Filter Stresses Based on FEA
		500	Analysis)
5038			Dec 5, 2003 Recovery Filter Design Review Materials
5039			12.04.03 Special Design Review Objectives for Recovery FMR
			Launch
5040			Aug. 11, 1999 RD-RPT-094 Pusher Wire Integrity Test Report
5041			Aug. 18, 1999 RD-RPT-103 RNF Clot Trapping Efficiency
			Report
5042			TM1134800 (G2® Filter Migration Resistance Testing Test
			Method)
5043			RNF Animal Experiment Notes for RD-SOP-050.00 (Animal
			511)
5044			ETR-05-05-21 (G2® DV&V Report Phase III [for jugular
			system])
5045			ETR-05-03-02 (Recovery Filter Jugular/Subclavian System
	1		Acute Animal Study Report)

Exhibit	Marked for ID	Admitted in Evidence	Description
5046			MAUDE and sales data through Q1 2004
5047			Aug. 2004 Altran Report (Preliminary SEM of Failed Hooks
			and Legs) (Fracture)
5048			RA-STD-002, Rev. 08
5049			Recovery Filter DFMEA (DFMEA070010, Rev. 2)
5050			Sept. 2004 Altran Report (Draft Failure Analysis for 11
			Complaint Filters) (Fracture)
5051			Sept. 2004 Altran Report (Draft Evaluation of Two Production
5051			Lot Filters and One Test Piece) (Fracture)
5052			Feb. 14, 2005 Conference FDA and BPV re DDL and Recovery
5002			Retrievable (K031328)
5053			Recovery Filter Design/Development Files Recovery Filter
5055			Design/Development Files Cover Sheet
5054			NMT Filter Drawing RD-10261, Rev. 00 (Arms Up)
5055			RD-SOP-033 (Rotating-Beam Corrosion Fatigue Testing of
			Nitinol Wire)
5056			RD-RPT-029 Technical Review of Phase I Development
5050			Activities for RNF (Sept. 2, 1997)
5057			Dec. 30, 1997 RD-RPT-038 Corrosion Fatigue Testing Report
5058			March 23, 1998 RD-RPT-041 Feasibility Animal Study
3000			Summary Results
5059			April 13, 1998 RD-RPT-045 Feasibility Animal Study
			Summary Results
5060			June 17, 1999 RD-RPT-085 Determination of Optimum
			Welding Parameters Report
5061			Feb. 15, 2000 RD-RPT-115 Straight .013 Pusher Wire
• • • •			Deployment Testing and Analysis
5062			Oct. 16, 2001 R&D Technical Report Evaluation of RNF Hook
• • • •			Strength Test (RD-RPT-162)
5063			June 15, 2000 RD-RPT-123 Creep Evaluation of RNF
5064			June 11, 2001 RD-RPT-158 RNF Recovery Sheath Bioburden
			Test Report
5065			Arms Up Design History File Table of Contents Table of
			Contents for Removable Nitinol Filter Design History File
			(Phase II)
5066			RM-0045, Nitinol Sleeve RM-0045, Nitinol Sleeve
5067			Nov. 24, 2004 Email FDA to BPV re Recovery IFU and DDL
5068			Recovery IFU Supporting Documentation
5069			Recovery Filter Fact Book, Volume 01 of 13 Recovery Filter
			Fact Book, Volume 01 of 13 Cover Sheet for Recovery Filter
			Fact Book, volume 1 of 13
5070			NMT Design Inputs, Rev. 03 10/04/99
5071			Sept. 1997 NMT Design Input Approval

Strength Protocol	Exhibit	Marked for ID	Admitted in Evidence	Description	
Fact Book, Volume 03 of 13 Fact Book Project 7081 - Volume 3 of 13 5074 RD-RPT-025 (Test Report for Biocompatibility for SNF) 8075 Recovery Filter Fact Book, Volume 04 of 13 8076 Recovery Filter Fact Book, Volume 05 of 13 8077 Recovery Product Development Operating Plan 8078 Recovery Filter Fact Book, Volume 06 of 13 8079 Recovery Filter Fact Book, Volume 06 of 13 Recovery Filter Fact Book Volume 06 of 13 Recovery Filter Fact Book Volume 06 of 13 Recovery Filter Eact Book. Volume 10 Fact Book Volume 10 Fact Book Volume 10 Fact Bo	5072			Fact Book, Volume 02 of 13 Project 7081 Fact Book,	
Recovery Filter Fact Book, Volume 04 of 13	5073			Fact Book, Volume 03 of 13 Fact Book Project 7081 -	
S075 Recovery Filter Fact Book, Volume 04 of 13	5074			RD-RPT-025 (Test Report for Biocompatibility for SN	F)
S076 Recovery Filter Fact Book, Volume 05 of 13	5075				
S077 Recovery Product Development Operating Plan	5076				
Recovery Filter Fact Book, Volume 06 of 13 Recovery Filter Fact Book, Volume 06 of 13 Recovery Filter Fact Book, Volume 06 of 13 Recovery Faller Book, Volume 15 Recovery Faller Book, Volume 16 of 13 Recovery Faller Faller Book, Volume 16 of 13 Recovery Faller	5077				
RD-SOP-035.03 (SOP re migration resistance testing NMT) R&D SOP: RD-SOP-035.3, IVC Filter Migration Study May 13, 1998 RD-SOP-048 In-Vivo Evaluation of Thrombogenic Response to RNF Implant RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 379) RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558) RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558) Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experimen	5078			Recovery Filter Fact Book, Volume 06 of 13 Recovery	Filter
May 13, 1998 RD-SOP-048 In-Vivo Evaluation of Thrombogenic Response to RNF Implant RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes for RD-SOP-050.00 (Animal S58) RNF Animal Experiment Notes for RD-SOP-050.00 (Animal S58) RNF Design Animal Verification Study: In-Vivo Occlusion Migration Resistance Data Sheets (animal #558) Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747) RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment RNF Animal Experiment RNF Anima	5079			RD-SOP-035.03 (SOP re migration resistance testing N	,
RNF Animal Experiment Notes, Feasibility Animal Experiment Notes RNF Animal Experiment Notes	5080			May 13, 1998 RD-SOP-048 In-Vivo Evaluation of	
RNF Animal Experiment Notes, Feasibility Animal Experiment RD-SOP-050.00, RNF Design Verification: In-vivo Occlusion Migration Resistance and Deployment Study RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 511) RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558) RNF Design Animal Verification Study: In-Vivo Occlusion Migration Resistance Data Sheets (animal #558) Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747) RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication RNF Animal Experiment Notes, Feasibility Animal Experiment	5081				neriment
RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes, Feasibility Animal Experiment RD-SOP-050.00, RNF Design Verification: In-vivo Occlusion Migration Resistance and Deployment Study RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 379) RNF Animal Experiment Notes for RD-SOP-050.00 (Animal S58) RNF Animal Experiment Notes for RD-SOP-050.00 (Animal S58) RNF Design Animal Verification Study: In-Vivo Occlusion Migration Resistance Data Sheets (animal #558) Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747) RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication RNF Animal Experiment Notes, Feasibility Animal Experiment	5082				
RNF Animal Experiment Notes, Feasibility Animal Experiment Solution RD-SOP-050.00, RNF Design Verification: In-vivo Occlusion Migration Resistance and Deployment Study	5083			RNF Animal Experiment Notes, Feasibility Animal Ex	periment
RD-SOP-050.00, RNF Design Verification: In-vivo Occlusion Migration Resistance and Deployment Study RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 511) RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558) RNF Design Animal Verification Study: In-Vivo Occlusion Migration Resistance Data Sheets (animal #558) Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747) RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes, Feasibility Animal Experiment RD-SOP-052.00, RNF Hook Creep Study June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol	5084			RNF Animal Experiment Notes Feasibility Notes Feasibility Animal Experiment Notes Feasibility Notes Feasibility Animal Experiment Notes Feasibility Notes Fe	periment
RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 379) Data Sheet for RD-SOP-050.00 (Animal 511) RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558) RNF Design Animal Verification Study: In-Vivo Occlusion Migration Resistance Data Sheets (animal #558) Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747) RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication RNF Animal Experiment Notes, Feasibility Animal Experiment Notes, Feasibility Animal Experiment Sops RD-SOP-053.00, RNF Hook Creep Study June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol	5085			RD-SOP-050.00, RNF Design Verification: In-vivo Oc	clusion
5087Data Sheet for RD-SOP-050.00 (Animal 379)5088Data Sheet for RD-SOP-050.00 (Animal 511)5089RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558)5090RNF Design Animal Verification Study: In-Vivo Occlusion Migration Resistance Data Sheets (animal #558)5091Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication5092RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747)5093RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication5094RNF Animal Experiment Notes, Feasibility Animal Experiment5095RD-SOP-053.00, RNF Hook Creep Study5096June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol5097July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol	5086			RNF Animal Experiment Notes for RD-SOP-050.00 (A	nimal
5088Data Sheet for RD-SOP-050.00 (Animal 511)5089RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558)5090RNF Design Animal Verification Study: In-Vivo Occlusion Migration Resistance Data Sheets (animal #558)5091Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication5092RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747)5093RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication5094RNF Animal Experiment Notes, Feasibility Animal Experiment5095RD-SOP-053.00, RNF Hook Creep Study5096June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol5097July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol	5087				
RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558) RNF Design Animal Verification Study: In-Vivo Occlusion Migration Resistance Data Sheets (animal #558) Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747) RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RD-SOP-053.00, RNF Hook Creep Study June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol					
RNF Design Animal Verification Study: In-Vivo Occlusion Migration Resistance Data Sheets (animal #558) Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747) RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RPF Animal Experiment Notes, Feasibility Animal Experiment RD-SOP-053.00, RNF Hook Creep Study June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol				RNF Animal Experiment Notes for RD-SOP-050.00 (A	nimal
Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747) RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RD-SOP-053.00, RNF Hook Creep Study June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol	5090			RNF Design Animal Verification Study: In-Vivo Occlu	sion
RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747) RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RD-SOP-053.00, RNF Hook Creep Study June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol	5091			Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification	In-Vivo
RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication RNF Animal Experiment Notes, Feasibility Animal Experiment RD-SOP-053.00, RNF Hook Creep Study June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol	5092			RNF Animal Experiment Notes, Feasibility Animal Exp	eriment
RNF Animal Experiment Notes, Feasibility Animal Experiment RD-SOP-053.00, RNF Hook Creep Study June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol	5093			RD-SOP-052.00, RNF Design Verification: In-Vivo Ev	aluation
5095 RD-SOP-053.00, RNF Hook Creep Study 5096 June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol 5097 July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol	5094				ariment
June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol				RD-SOP-053.00. RNF Hook Creen Study	CHINCIR
July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol				June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fa	itigue
	5097	į		July 29, 1999 RD-SOP-072 RNF Design Verification Ra	adial
	5098			Recovery Filter Fact Book, Volume 07 of 13	

Exhibit	Marked for ID	Admitted in Evidence	Description
5099			Aug. 20, 1999 RD-RPT-088 In-Vivo Testing of RNF for
			Permanent Use and Early Removal
5100			RNF Pivotal Animal Clinical Study, Permanent Implant In-Situ
			Sacrifice Data Sheets (Animal #32)
5101			RNF Pivotal Animal Clinical Study Permanent Implant Data
			Sheets (Animal #48)
5102			Recovery Filter Fact Book, Volume 08 of 13
5103			NMT Medical R&D Technical Report Document #RD-RPT-
			089, Creep Study of RNF Hooks
5104			July 30, 1999 RD-RPT-091 RNF Wire Integrity Report
5105			Aug. 13, 1999 RD-RPT-093 Crimp and Bond Integrity Test
			Report
5106			Aug. 4, 1999 R&D Technical Report EnduraTEC
			Corrosion/Fatigue Testing of RNF Filters, Design Verification
			(RD-RPT-099)
5107			Recovery Filter Fact Book, Volume 09 of 13
5108			Aug. 9, 1999 R&D Technical Report RNF Hook Strength,
			Design Verification (RD-RPT-101)
5109		**	Aug. 23, 1999 R&D Technical Report Analysis of RNF
			Migration Resistance (RD-RPT-104)
5110			Recovery Filter Fact Book, Volume 10 of 13
5111			Final Pathology Report: In-vivo Evaluation of the RNF for
			Permanent & Intra-Procedural Removal Indications - A Study
			of 15 Sheep
5112			In-Vivo Evaluation of the Removable Nitinol Filter System for
	-		Permanent & Intra-Procedural Removal Indications
5113			Final Pathology Report: In-vivo Evaluation for Permanent
			Indication (Vena Cava Filters in 8 sheep)
5114			Pathology Report: In-vivo Evaluation of the RNF for Long-term
			Removal Indications (Pathology Associates)
5115			Recovery Filter Fact Book, Volume 11 of 13
5116			April 24, 2000 RD-RPT-121 In-Vivo Technical Testing of RNF
			for Long-Term Removal
5117			In-Vivo Evaluation of the Removable Nitinol Filter System for
			Long-Term Removal Indication
5118			Pivotal Animal Clinical Study: RNF Filter Implant Data Sheets
			(Animal #26)
5119			Recovery Filter Fact Book, Volume 12 of 13
5120			Recovery Filter DFMEA 070010, Rev. 3
5121			Recovery Filter Fact Book, Volume 13 of 13
5122			March 28, 2003 Design Review Report
5123			Design Review II Summary of Design Verification Studies
5124			Oct. 16, 2003 Risk Assessment RA070011, Rev. 0

Exhibit	Marked for ID	Admitted in Evidence	Description
5125			FM-0010.02 FM-0010.02 Recovery Filter FMEA: Implant and Delivery System
5126		37318	Guidance for Industry and FDA Reviewers/Staff - Guidance for Cardiovascular Intravascular Filter 510(k) Submissions
5127			November 26, 1999 FDA Guidance for Cardiovascular Intravascular Filter 510(k) Submissions
5128			Dec. 20, 2002 Design Review Assessment Status (Phase 1)
5129			Design Review Element Compliance to Design Input (validating statistical relevance of migration testing)
5130			FIR-04-09-01 (Recovery Filter Fractures) (includes some Altran Reports)
5131			FIR-04-09-0 1 Failure Investigation report - Recovery Filter
5132			SPA-04-12-01: Addendum 2 (Remedial Action Plan re RNF Migration)
5133			G2 Filter Stability Rationale (includes info re FEA and fatigue resistance)
5134			RNF Design Review Summary Table Sept. 19, 2002
5135			12.09.03 Special Design Review Meeting Minutes
5136			CAE FEA (Nonlinear Structural Simulation of RNF Filter
			Device Delivery Tube Insertion)
5137			Recovery Filter DFMEA 070010, Rev. 0
5138			DFMEA070010 Rev. 4
5139			June 25, 2004 Multidisciplinary Focus Group Meeting Transcript
5140			Memo re RNF Inventory Swap-Out (inventory exchange) for G2
5141			Summary of Feb. 12, 2005 Bariatric Surgeon Meeting Summary of Feb. 12, 2005
5142			Jan. 10, 2005 Conference FDA and BPV re DDL and Recovery Retrievable (K031328)
5143			Dec. 2004 BPV begins distributing DDL
5144			Feb. 8, 2005 Fax BPV to FDA re DDL and Recovery Retrievable (K031328)
5145			Jan. 14, 2004 Design Review Meeting Minutes Response (From Rob Carr to File)
5146			TPR-05-01-13 (G2® DV&V Protocol)
5147			RA-STD-002, Rev. 08
5148			Article re Long-Term Retrieval of RNF Article entitled A New Optional Vena Cava Filter: Retrievable at 12 Weeks in An Animal Model
5149			Dr. Asch Article re Asch Study Article entitled Initial Experiences in Humans with a New Retrievable Inferior Vena Cava Filter
5150			8/25/2005 - FDA Conference Call Meeting Minutes

Exhibit	Marked for ID	Admitted in Evidence	Description
5151			Feb. 28, 2005 Conference FDA and BPV re new submission
5152			March 2005 Emails with FDA
5153			Oct. 13, 2005 Email FDA to BPV re G2 Filter - Jugular
			Subclavian Delivery Kit (K052578)
5154			Revised 03/03 F-8020 Rev.0 (Bard Peripheral Technologies)
5155			Oct. 14, 2005 Letter FDA to BPV re G2 Filter - Jugular
			Subclavian Delivery Kit (K052578)
5156			TPR-05-01-05 (G2 Filter Arm Fatigue DV&V Protocol)
5157			Data Sheet (for G2® DV&V Migration Resistance Testing in
			28mm IVC)
5158			2001 Bard acquires filter line from NMT
5159	1.00		December 10, 1999 Letter from FDA re Recovery K993809
5160			ETR-02-06-02 (Failure Investigation Report re Fracture in Asch
			Study) (with Rob Carr memo)
5161			RD-RPT-128 (Investigation re Asch patient migration)
5162			RD-SOP-059.00 (SOP re Wire Integrity)
5163			In-Vivo Evaluation of the Removal Nitinol Filter System for
	•		Permanent & Intra-Procedural Removal Indications
5164		3-26-8	July 8, 2003 Fax IMPRA to FDA re Recovery Retrievable (K031328)
5165			July 1, 2003 Email FDA to BPV re Recovery Retrievable (K031328)
5166			July 23, 2003 Email FDA to BPV re Recovery Retrievable (K031328)
5167			July 23, 2003 Letter BPV to FDA re Recovery Retrievable (K031328)
5168		M-	July 24, 2003 Letter BPV to FDA re Recovery Retrievable (K031328)
5169		37348	Apr. 25, 2003 Recovery Retrievable Abbreviated 510(k) (K031328)
5170			Patient 33 Note (w/fracture) (submitted to FDA)
5171			RD-SOP-071.00 (SOP re Hook Strength)
5172			Aug. 2, 1999 RD-RPT-092 Weld Integrity Report
5173			RD-RPT-088 (Report on RNF In-vivo Testing for Permanent
			Use and Early Removal) (followed SOP-051)
5174			NMT Due Diligence Materials from Bard Sept. 24, 2001
5175			Hand-written Annotations on response to FDA of Aug. 30,2002
5176			November 27, 2002 Letter from FDA re Recovery K022236
5177		3-73-19	Nov. 27, 2002 FDA Clearance Letter re Recovery Permanent
5178		3-76-18	Oct. 25, 2002 Letter IMPRA to FDA re Recovery (K022236) Sulf
5179		3-26-18	Oct. 4, 2002 Letter FDA to IMPRA re Recovery (K022236)
5180		7	Draft response to October 3, 2002 FDA Teleconference
2100		1	1

7

Exhibit	Marked for ID	Admitted in Evidence	Description
5181			September 30, 2002 Fax from FDA
5182		3-26-18	Aug. 30, 2002 Letter IMPRA to FDA re Recovery (K022236) Subjected
5183		7 0 0	August 30, 2002 Draft Letter to FDA
5184			September 1997 NMT Cyclic Polarization Testing of Seven Sets of Wire
5185			RD-SOP-058.00, RNF Weld Integrity, Design Verification
5186			August 5, 2002 Letter from FDA re Recovery K022236
5187		3-26-18	Aug. 5, 2002 Letter FDA to IMPRA re Recovery (K022236)
5188		7 7 9 0 0	July 10, 2002 Recovery 510(k) Application Letter
5189		37338	July 10, 2002 IMPRA Recovery Permanent Special 510(k)
5190		7.0	July 8, 2002 Recovery 510(k) Submission (partial)
5191			November 27, 2002 Letter from FDA re Recovery K022236
5192			July 25, 2003 Abbreviated Recovery 510(k) Submission K031328
5193		3-73-18	Feb. 28, 2005 Letter BPV to FDA re FDA AI re Recovery Retrievable (K031328) Sub, to veclactures
5194			Feb. 8, 2005 Letter FDA to BPV re Recovery Retrievable (K031328)
5195		2.93-18	Nov. 30, 2004 Letter FDA to BPV re Recovery IFU and DDI.
5196		2-27/5	Oct. 5, 2004 Letter BPV to FDA re Recovery IFU and DDL
5197		2735-18	July 25, 2003 FDA Clearance Letter re Recovery Retrievable (K031328) (Substantial Equivalence)
5198		/-	August 29, 2002 Email to FDA
5199			August 26, 2002 email re FDA letter response
5200			Draft Clinical Testing Questions
5200			Feb. 29, 2000 Letter NMT to FDA re Recovery (K993809)
5202			Feb. 10, 2000 Conference FDA and NMT re Recovery (K993809)
5203			Notes re Asch Live Case
5204			Aug. 12, 2002 Conference IMPRA and FDA re Recovery (K022236)
5205			August 12, 2002 FDA teleconference
5206			RNF Brochure Timeless Performance Complete Compliance Folder
5207			RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558)
5208			G2 Filter Sales Training Manual G2 Filter Sales Training Manual
5209			Dec. 17, 2002 Letter BPV to FDA requesting conference re Recovery Retrievable
5210			RD-RPT-122 Migration Study of 30-31 mm Leg span
		1	

June 9, 2000 R&D Technical Report Fatigue Evaluation of RNF (RD-RPT-120)	Exhibit	Marked for ID	Admitted in Evidence	Description	
S212 RD-RPT-126 (Lake Region SNF Migration Resistance Study)	5211				of RNF
SOP-RD-006 (NMT SOP re Design Control)	5212				Study)
Dec. 10, 1999 Letter FDA to NMT re Recovery (K993809 Nov. 1, 1999 NMT's Recovery Filter System Special 5 10(k) (K993809)					orday)
Source S					200
S216 RD-LNB-097 (Misc. Vena Cava Filter Research Projects: Includes Results of Early NMT Competitive Migration Testing) Lab Notebook RD-SOP-035.02 (SOP re migration resistance testing NMT					
Includes Results of Early NMT Competitive Migration Testing) Lab Notebook RD-SOP-035.02 (SOP re migration resistance testing NMT) 5218 Data Sheet for Early NMT Competitive Migration Testing (raw data) Lab Notebook 097 RD-LNB-097 5219 June 23, 1998 NMT Memo re Removable Filter Concepts 5220 June 15, 1998 Memo re Removable Filter Issues 5221 June 1, 1999 NMT Meeting Minutes 5222 January 7, 1999 NMT Meeting Minutes 5223 April 14, 2000 NMT RNF Design Review II Minutes 5224 June 12, 1998 NMT Meeting Minutes 5225 April 30, 1998 NMT RNF Meeting Minutes 5226 RNF Meeting Notes RNF Meeting notes 5227 April 30, 1998 Memo re Justification for Restarting Pivotal Animal Study 5228 April 8, 1998 Memo re Summary of Animal Experiments to be Performed for RNF 5229 RNF Meeting Notes RNF Meeting notes 5230 RD-RPT-137 (SNF Substantial Equivalence Report) 5231 Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release 5232 RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-116 5233 RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT) 5234 RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) 5235 Recovery Filter DFMEA070010 Rev. 1 5236 Email from Hudson to Benware re Starguide testing	0210				O(K)
Includes Results of Early NMT Competitive Migration Testing) Lab Notebook RD-SOP-035.02 (SOP re migration resistance testing NMT) 5218 Data Sheet for Early NMT Competitive Migration Testing (raw data) Lab Notebook 097 RD-LNB-097 5219 June 23, 1998 NMT Memo re Removable Filter Concepts 5220 June 15, 1998 Memo re Removable Filter Issues 5221 June 1, 1999 NMT Meeting Minutes 5222 January 7, 1999 NMT Meeting Minutes 5223 April 14, 2000 NMT RNF Design Review II Minutes 5224 June 12, 1998 NMT Meeting Minutes 5225 April 30, 1998 NMT RNF Meeting Minutes 5226 RNF Meeting Notes RNF Meeting notes 5227 April 30, 1998 Memo re Justification for Restarting Pivotal Animal Study 5228 April 8, 1998 Memo re Summary of Animal Experiments to be Performed for RNF 5229 RNF Meeting Notes RNF Meeting notes 5230 RD-RPT-137 (SNF Substantial Equivalence Report) 5231 Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release 5232 RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-116 5233 RP-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT) 5234 RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) 5235 Recovery Filter DFMEA070010 Rev. 1 5236 Email from Hudson to Benware re Starguide testing	5216			RD-LNB-097 (Misc. Vena Cava Filter Research Project	ls:
S217 RD-SOP-035.02 (SOP re migration resistance testing NMT					
Data Sheet for Early NMT Competitive Migration Testing (raw data) Lab Notebook 097 RD-LNB-097				Lab Notebook	<i>C</i> ,
Data Sheet for Early NMT Competitive Migration Testing (raw data) Lab Notebook 097 RD-LNB-097	5217			RD-SOP-035.02 (SOP re migration resistance testing N	MT
data) Lab Notebook 097 RD-LNB-097	5218				
June 15, 1998 Memo re Removable Filter Issues June 1, 1999 NMT Meeting Minutes January 7, 1999 NMT Meeting Minutes January 7, 1999 NMT Meeting Minutes January 7, 1999 NMT Meeting Minutes June 12, 1998 NMT Meeting Minutes June 12, 1998 NMT Meeting Minutes June 12, 1998 NMT RNF Meeting Minutes June 12, 1998 NMT RNF Meeting Minutes June 13, 1998 NMT RNF Meeting Minutes RNF Meeting Notes RNF Meeting notes April 30, 1998 Memo re Justification for Restarting Pivotal Animal Study April 8, 1998 Memo re Summary of Animal Experiments to be Performed for RNF RNF Meeting Notes RNF Meeting notes RD-RPT-137 (SNF Substantial Equivalence Report) Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release Process Qualification & Pre-Market Release S232 RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02) RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02 RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- O35.02 RD-R					Č (
5221June 1, 1999 NMT Meeting Minutes5222January 7, 1999 NMT Meeting Minutes5223April 14, 2000 NMT RNF Design Review II Minutes5224June 12, 1998 NMT Meeting Minutes5225April 30, 1998 NMT RNF Meeting Minutes5226RNF Meeting Notes RNF Meeting notes5227April 30, 1998 Memo re Justification for Restarting Pivotal Animal Study5228April 8, 1998 Memo re Summary of Animal Experiments to be Performed for RNF5229RNF Meeting Notes RNF Meeting notes5230RD-RPT-137 (SNF Substantial Equivalence Report)5231Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release Design Review III & IV G2 Femoral 	5219			June 23, 1998 NMT Memo re Removable Filter Concep	ots
5222January 7, 1999 NMT Meeting Minutes5223April 14, 2000 NMT RNF Design Review II Minutes5224June 12, 1998 NMT Meeting Minutes5225April 30, 1998 NMT RNF Meeting Minutes5226RNF Meeting Notes RNF Meeting notes5227April 30, 1998 Memo re Justification for Restarting Pivotal Animal Study5228April 8, 1998 Memo re Summary of Animal Experiments to be Performed for RNF5229RNF Meeting Notes RNF Meeting notes5230RD-RPT-137 (SNF Substantial Equivalence Report)5231Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release5232RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-1165233RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-1165234RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT)5235Recovery Filter DFMEA070010 Rev. 15236Email from Hudson to Benware re Starguide testing	5220			June 15, 1998 Memo re Removable Filter Issues	
January 7, 1999 NMT Meeting Minutes	5221			June 1, 1999 NMT Meeting Minutes	
5224June 12, 1998 NMT Meeting Minutes5225April 30, 1998 NMT RNF Meeting Minutes5226RNF Meeting Notes RNF Meeting notes5227April 30, 1998 Memo re Justification for Restarting Pivotal Animal Study5228April 8, 1998 Memo re Summary of Animal Experiments to be Performed for RNF5229RNF Meeting Notes RNF Meeting notes5230RD-RPT-137 (SNF Substantial Equivalence Report)5231Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release5232RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- 035.02) RD-RPT-1165233RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT)5234RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT)5235Recovery Filter DFMEA070010 Rev. 15236Email from Hudson to Benware re Starguide testing	5222				
5224June 12, 1998 NMT Meeting Minutes5225April 30, 1998 NMT RNF Meeting Minutes5226RNF Meeting Notes RNF Meeting notes5227April 30, 1998 Memo re Justification for Restarting Pivotal Animal Study5228April 8, 1998 Memo re Summary of Animal Experiments to be Performed for RNF5229RNF Meeting Notes RNF Meeting notes5230RD-RPT-137 (SNF Substantial Equivalence Report)5231Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release5232RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP- 035.02) RD-RPT-1165233RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT)5234RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT)5235Recovery Filter DFMEA070010 Rev. 15236Email from Hudson to Benware re Starguide testing	5223			April 14, 2000 NMT RNF Design Review II Minutes	
RNF Meeting Notes RNF Meeting notes	5224				
S226 RNF Meeting Notes RNF Meeting notes	5225			April 30, 1998 NMT RNF Meeting Minutes	
Animal Study 5228	5226				
Animal Study 5228	5227				otal
Performed for RNF RNF Meeting Notes RNF Meeting notes RD-RPT-137 (SNF Substantial Equivalence Report) Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-116 RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT) RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) Recovery Filter DFMEA070010 Rev. 1 Email from Hudson to Benware re Starguide testing					
Performed for RNF RNF Meeting Notes RNF Meeting notes RD-RPT-137 (SNF Substantial Equivalence Report) Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-116 RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT) RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) Recovery Filter DFMEA070010 Rev. 1 Email from Hudson to Benware re Starguide testing	5228			April 8, 1998 Memo re Summary of Animal Experimen	ts to be
RD-RPT-137 (SNF Substantial Equivalence Report)				Performed for RNF	
Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release 8D-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-116 8D-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT) 8D-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) 8235 Recovery Filter DFMEA070010 Rev. 1 8D-RPT-099 (Recovery Filter DFMEA070010 Rev. 1 8D-RPT-099 (Recovery Filter DFMEA070010 Rev. 1 8D-RPT-099 (Recovery Filter DFMEA070010 Rev. 1	5229			RNF Meeting Notes RNF Meeting notes	
Pre-Market Release Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release 8D-RPT-116 (RNF Migration Study) (Test report for RD-SOP- 035.02) RD-RPT-116 8D-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT) 8D-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) 8235 8 Recovery Filter DFMEA070010 Rev. 1 8 Email from Hudson to Benware re Starguide testing	5230			RD-RPT-137 (SNF Substantial Equivalence Report)	
Process Qualification & Pre-Market Release RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-116 RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT) RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) Recovery Filter DFMEA070010 Rev. 1 Email from Hudson to Benware re Starguide testing	5231			Design Review III & IV G2 Femoral Process Qualificat	ion &
RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-116 RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT) RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) Recovery Filter DFMEA070010 Rev. 1 Email from Hudson to Benware re Starguide testing				Pre-Market Release Design Review III & IV G2 Femora	ıl
5233 RD-RPT-116 SOP NMT) SOP NMT) RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) Recovery Filter DFMEA070010 Rev. 1 Email from Hudson to Benware re Starguide testing				Process Qualification & Pre-Market Release	
RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT) RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) Recovery Filter DFMEA070010 Rev. 1 Email from Hudson to Benware re Starguide testing	5232			RD-RPT-116 (RNF Migration Study) (Test report for R	D-SOP-
SOP NMT) 5234 RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) 5235 Recovery Filter DFMEA070010 Rev. 1 5236 Email from Hudson to Benware re Starguide testing				· · · · · · · · · · · · · · · · · · ·	
RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT) S235 Recovery Filter DFMEA070010 Rev. 1 Email from Hudson to Benware re Starguide testing	5233				esting
Report NMT) 5235 Recovery Filter DFMEA070010 Rev. 1 5236 Email from Hudson to Benware re Starguide testing					
5235 Recovery Filter DFMEA070010 Rev. 1 5236 Email from Hudson to Benware re Starguide testing	5234				ing
5236 Email from Hudson to Benware re Starguide testing					
5					
5027 Dun A Chaussi 1 D					
	5237			Draft Starguide Report	
Slides from Bariatric Surgeons Panel Meeting on Feb. 12, 2005					
Jan. 21, 2005 Conference FDA and BPV re DDL and Recovery Retrievable (K031328)	5239				covery
5240 MAUDE and Sales data through Q2 2005	5240				

5211 5212 5213 5214		June 9, 2000 R&D Technical Report Fatigue Evaluation of R	
5213 5214			NF
5213 5214	 <u></u>	(RD-RPT-120)	
5214		RD-RPT-126 (Lake Region SNF Migration Resistance Study)
		SOP-RD-006 (NMT SOP re Design Control)	
		Dec. 10, 1999 Letter FDA to NMT re Recovery (K993809	
5215		Nov. 1, 1999 NMT's Recovery Filter System Special 510(k) (K993809)	
5216		RD-LNB-097 (Misc. Vena Cava Filter Research Projects; Includes Results of Early NMT Competitive Migration Testin	g)
		Lab Notebook	
5217		RD-SOP-035.02 (SOP re migration resistance testing NMT	
5218		Data Sheet for Early NMT Competitive Migration Testing (radata) Lab Notebook 097 RD-LNB-097	W
5219		June 23, 1998 NMT Memo re Removable Filter Concepts	
5220		June 15, 1998 Memo re Removable Filter Issues	
5221		June 1, 1999 NMT Meeting Minutes	
5222		January 7, 1999 NMT Meeting Minutes	
5223		April 14, 2000 NMT RNF Design Review II Minutes	********
5224		June 12, 1998 NMT Meeting Minutes	
5225		April 30, 1998 NMT RNF Meeting Minutes	
5226		RNF Meeting Notes RNF Meeting notes	
5227		April 30, 1998 Memo re Justification for Restarting Pivotal Animal Study	
5228		April 8, 1998 Memo re Summary of Animal Experiments to b Performed for RNF	e
5229		RNF Meeting Notes RNF Meeting notes	
5230	-	RD-RPT-137 (SNF Substantial Equivalence Report)	
5231		Design Review III & IV G2 Femoral Process Qualification &	
		Pre-Market Release Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release	
5232	320-18	RD-RPT-116 (RNF Migration Study) (Test report for RD-SOI 035.02) RD-RPT-116)_
5233	31518	RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT)	·
5234	3-15-18	RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT)	
5235		Recovery Filter DFMEA070010 Rev. 1	
5236		Email from Hudson to Benware re Starguide testing	\dashv
5237		Draft Starguide Report	
5238		Slides from Bariatric Surgeons Panel Meeting on Feb. 12, 200.	5
5239	2000	Jan. 21, 2005 Conference FDA and BPV re DDL and Recover Retrievable (K031328)	
5240		MAUDE and Sales data through Q2 2005	\dashv

Exhibit	Marked for ID	Admitted in Evidence	Description	
5241			MAUDE and Sales Data through Q2 2004	
5242			Sep. 28, 2004 Conference FDA and BPV re Recovery IFU an DDL	d
5243				
5244			Sep. 17, 2004 FDA Contact Report re Recovery IFU and DDI Mar. 24, 2005 Conference FDA and BPV re DCL and Modifi	
J277			Recovery (K050558)	ea
5245			Jan. 27, 2005 Conference BPV and FDA Phoenix Investigator	
			re DCL and Recovery Retrievable (K031328)	
5246			Aug. 5, 2005 Conference FDA and BPV re G2 Everest Study (G050134)	
5247		3 2718	May 11, 2005 BPV began distributing DCL	
5248			TD-00012 (Characterization of G2® Filter Migration	
			Resistance When Legs are Crossed)	
5249			SPA-04-04-01 (Revised Remedial Action Plan re RNF	
			Fractures)	
5250			Nov. 28, 2004 Internal BPV Email chain re Recovery IFU and DDL	l
5251			ETR-04-03-19 (RNF Radial Strength v. Competitive Product)	
5252		٠,	ETR-04-03-19 (RNF v. Competitive Product) ETR-04-03-02 (RNF v. Competitive Product migration	
3232		3-26-18	resistance)	
5253			HHE of Dr. Ciavarella November 17, 2004	
5254			DOPQ0700020, Rev. 4	
5255			FDA concurrence letter for K940489	
5256			NMT's 510(k) (K940489) for the Modified SNF	
5257			FDA concurrence letter for K944353	
5258			NMT's 510(k) (K944353) to the Simplified SNF (Straight Line	
			System)	3
5259			Recovery Filter Design/Development Files	
5260			NMT's 510(k) (K912144) for the SNF for antecubital insertion	
5261			Letter from FDA to NMT regarding K912144	
5262			Letter from NMT to FDA regarding K912144 and FDA's June	
			25, 1991 questions	
5263			Letter from Hogan & Hartson to FDA regarding K912144	
5264			Letter from Hogan & Hartson to FDA regarding K940489 and FDA's March 4, 1994 questions	
5265			Letter from FDA to Hogan & Hartson regarding K940489	
5266			FDA concurrence letter for K963016	
5267			Letter from Hogan & Hartson to FDA regarding October 7, 1996 conference	
5268			NMT's 510(k) (K963016) for modifications to the SNF	
5269			(submitted by Hogan & Hartson) NMT's 510(k) (K970099) for modifications to the SNF and SNF/Straight Line System	

Exhibit	Marked for ID	Admitted in Evidence	Description
5270			Revised Recovery Filter IFU as of December 2004
5271			NMT Sept. 12, 2000 Memo re Clinical Discussion of Migration from Asch Study
5272			Nov. 23, 2009 BPV's Eclipse Filter System Special 510(k) (K093659)
5273			Jan. 14, 2010 FDA Clearance Letter Eclipse Filter (K093659) (Substantial Equivalence)
5274			July 2, 2008 Letter BPV to FDA Responses re AI Demand re G2 Express (K080668)
5275			June 25, 2008 Conference FDA and BPV re AI Demand re G2 Express (K080668)
5276			TD-00272 (Addendum to TD-00192 Product Comparisons through Finite Element Analysis and Testing by William James Harrison, WJH Engineering)
5277			TD-00553 (Finite Element Analysis Comparing the G2/G2 Express Filter with Two Loading Scenarios)
5278			G2 IFU PK5100030, Rev. 2 08/05 (Femoral)
5279			G2 IFU (Femoral) PK5100030 Rev. 3 09/05
5280			G2 IFU PK5014091, Rev. 0 09/05 (Jugular)
5281			G2 IFU PK5100030, Rev. 4 04/06 (Femoral)
5282			G2 IFU PK5100030, Rev. 5 10/06 (Femoral)
5283		3-26-18	G2 IFU (Femoral) PK5250500 Rev. 0 01/08
5284		20015	G2 IFU PK5260600, Rev. 0 01/08 (Jugular)
5285			G2 IFU PK5250500, Rev. 1 07/09 (Femoral)
5286			G2 IFU PK5260600, Rev. 1 07/09 (Jugular)
5287			Project 8041: Design History File; Everest- Recovery G2, Vol. 1 of 2
5288			Sept. 6, 2005 EVEREST Clinical Study Protocol
5289			Project 8041: Design History File; Everest- Recovery G2, Vol. 2 of 2
5290		3-26-18	TD-00456 (EVEREST Study Final Report)
5291			Project File; Project 8002: G2 Recovery Filter; Jugular/Subclavian System, Vol. 1 of 3
5292			Project File; Project 8002: G2 Recovery Filter; Jugular/Subclavian System, Vol. 2 of 3
5293			Project File; Project 8002: G2 Recovery Filter; Jugular/Subclavian System, Vol. 3 of 3
5294			Fact Book; Project 8027: US: G2 Filter System (RF-310F) OUS Recovery Filter System (RF-210F), Vol. 1 of 2
5295			G2 Filter Project Initiation Request Form (Project 8027)
5296		3-26-18	G2 Filter Product Performance Specification, v.2
5297		-	G2 Filter Regulatory and Clinical Strategy Determination (Jan. 2005)
5298			G2 Filter Drawings and Labels

Exhibit	Marked for ID	Admitted in Evidence	Description
5299			Fact Book; Project 8027: US: G2 Filter System (RF-310F) OUS Recovery Filter System (RF-210F), Vol. 2 of 2
5300			TPR-04-09-11 An Acute and Chronic In-Vivo Evaluation of the Bard Recovery Filter (G2)
5301		3-26-18	ETR-05-01-06 Animal Model Evaluation of Recovery Filter G1A Femoral System Report
5302		2-26-18 22018	TPR 05-01-13 G1A Recovery Filter Femoral System Design Verification and Validation Protocol
5303		3-21-18	ETR-05-02-05 (G2® DV&V summary testing)
5304		3-26-18	ETR 05-02-11 G1A Recovery Filter Femoral System Chronic Animal Study Report
5305			RA070025 Risk Assessment for the G1A Filter, v.1
5306			DFMEA070022, v.1 (for the G1A)
5307		~	PFMEA for the G1A Recovery Filter Femoral System
5308			PV-RF210F G1A Process Qualification Final Report, G1A Filters, RF210F
5309			ETR 05-03-11 Migration Resistance Evaluation of New England Precision Grinding G1A Manufactured Filters (RF210F) and Multiple Loading
5310			FIR 05-03-05 G1A Filter (RF210F) Process Qualification Failure Investigation for Crossed or Twisted Leg
5311			Stability Rationale for G1A
5312			E05-009 Adoption for the G1A Recovery Filter Femoral System, v.0
5313			Phase 0 Design Review G1A Recovery Filter Femoral Delivery System
5314			Phase 1 Design Review G1A Recovery Filter Femoral Delivery System
5315		3-71/18	Phase 2 Design Review G1A Recovery Filter Femoral Delivery System
5316		324	Phase 3 Design Review (Design Review 3 & 4) G1A Recovery Filter Femoral Delivery System
5317			G1A Authorization for Market Release (Domestic)
5318			G2 Filter Internal Product Information Bulletin (Sept. 7, 2005)
5319			Recovery Filter Internal Product Information Bulletin (Sept. 7. 2005)
5320			Dec. 4, 2006 Conference FDA and BPV re future G2 Filter Retrievable Traditional 510(k)
5321			Dec. 11, 2007 Conference FDA and BPV re G2 Everest Study (G051304)
5322			Nov. 2, 2005 FDA Grants Full Approval of G2 Everest Study (G051304)
5323		3-87-16	Aug. 8, 2005 FDA Grants BPV Conditional Approval for G2 Everest Study (G050134)

Exhibit	Marked for ID	Admitted in Evidence	Description
5324		3-73-18	July 8, 2005 BPV's original IDE submission re G2 Everest Study (G050134)
5325		373718	Oct. 3, 2005 Letter BPV to FDA re G2 Everest Study (G051034) and Conditional Approval Sub to reduce
5326		3 0 7 1 2	Aug. 25, 2005 Conference FDA and BPV re G2 Everest Study (G050134) and Conditional Approval
5327			Dec. 2, 2005 Letter BPV to FDA re G2 Everest Study (G051304) Notice of IDE Change
5328			July 11, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement
5329			June 21, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement
5330			June 21, 2006 Letter BPV to FDA re G2 Everest Study (G051304)
5331			Dec. 6, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement
5332			Dec. 8, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement
5333		シャケシィグ	Feb. 2, 2007 Letter BPV to FDA re G2 Everest Study (G051304) Annual Progress Report
5334		3-26-18	Sept. 21, 2007 Letter FDA to BPV Questions re G2 Everest Study (G051304)
5335		3-26-18	Aug. 23, 2007 Letter BPV to FDA re G2 Everest Study (G051304) Annual Progress Report
5336		3-26-18	Oct. 25, 2007 Letter BPV to FDA re Responses to FDA re G2 Everest Study (G051304)
5337			Mar. 12, 2008 Letter FDA to BPV re G2 Everest Study (G051304) Closing IDE
5338			Feb. 12, 2008 Letter BPV to FDA re G2 Everest Study (G051304) Final IDE Report
5339		273-18	Jan. 15, 2008 FDA Clearance Letter G2 Filter Retrievable (K073090) (Substantial Equivalence)
5340		3-23-18 3-26-18	Oct. 31, 2007 BPV's G2 Filter Retrievable Traditional 510(k) (K073090)
5341		700 10	ETR-06-05-02 G2 Filter Clot Trapping Efficiency Report
5342			Special 510(k) Submission K050558- 3/2/2005
5343		3-22-18	Aug. 29, 2005 FDA Clearance Letter re G2 Permanent (K050558) (Substantial Equivalence)
5344		3-27-18	July 28, 2005 Letter FDA to BPV re AI re Modified Recovery (K050558)
5345			June 3, 2005 Email BPV to FDA re proposed IDE G2 Everest Study
5346			Apr. 28, 2005 Letter FDA to BPV 30 day extension re FDA AI re Modified Recovery (K050558)

Exhibit	Marked for ID	Admitted in Evidence	Description	
5347			Apr. 27, 2005 Letter BPV to FDA 30 day extension re	FDA AI
			re Modified Recovery (K050558)	
5348			Mar. 30, 2005 Letter FDA to BPV re Modified Recove	ry
			(K050558)	
5349		12218	Mar. 2, 2005 BPV's Modified Recovery Filter Special	510(k)
		3-73-18	June 3, 2005 Letter BPV to FDA re Modified Recovery	,
5350		23318	June 3, 2005 Letter BPV to FDA re Modified Recovery	Y
		50511	conversion Traditional 510(k) (K050558) Sub 10400	hach -
5351			May 6, 2005 Conference FDA and BPV re Modified R	ecoverv
			(K050558)	
5352			Aug. 10, 2005 Letter BPV to FDA Responses to AI re	G2
			(K050558)	- -
5353		0 - 14	Nov. 25, 2005 FDA Clearance Letter G2 Filter - Jugula	ır
		13718	(K052578) (Substantial Equivalence)	•
5354		3-25-18	Sept. 19, 2005 BPV's G2 Filter - Jugular Subclavian De	elivery
		3-23-18	Kit Special 510(k) (K052578) Sub, torodoch	livery
5355			Sept. 21, 2005 Letter BPV to FDA re G2 Filter - Jugula	ır
			Subclavian Delivery Kit (K052578)	••
5356			Oct. 25, 2005 Letter BPV to FDA Responses to FDA A	I
			Demand re G2 Filter - Jugular (K052578)	.1
5357			Oct. 14, 2005 Conference FDA and BPV re G2 Filter -	Inquior
			Subclavian Delivery Kit (K052578)	Jugulai
5358			Oct. 14, 2005 Email FDA to BPV re G2 Filter - Jugular	
			Subclavian Delivery Kit (K052578)	
5359			Nov. 14, 2005 Conference FDA and BPV re Responses	C2
			Filter - Jugular (K052578)	re G2
5360			Nov. 16, 2005 Letter BPV to FDA Responses to FDA A	T
'			Demand re G2 Filter - Jugular (K052578)	7.1
5361		1.00	Sept. 25, 2006 BPV's G2 Filter - Femoral Delivery Kit S	
		3-83-18	510(k) (K062887)	speciai
5362			Oct. 26, 2006 FDA Clearance Letter G2 Filter - Femora	1
		7 2418	Delivery Kit (K062887)	I
5363		7 0 7 0	G2 Filter System Brochure	
5364			G2 Filter System Patient Questions & Answers	
5365				
			Dr. Binkert Article re EVEREST Study G2 Filter Prosp Multicenter Study	ective,
5366				
			May 8, 2008 Letter BPV to FDA Responses to AI Dema G2 Express (K080668)	ind re
5367				
			June 26, 2008 Letter BPV to FDA Request 30 Day Exte G2 Express (K080668)	nsion re
5368				
2300			July 30, 2008 FDA Clearance Letter G2 Express Filter	
5369			(K080668) (Substantial Equivalence)	
			July 1, 2008 Letter FDA to BPV Granting Extension re	ئ2
			Express (K080668)	

Exhibit	Marked for ID	Admitted in Evidence	Description
5370			June 6, 2008 Letter FDA to BPV re AI Demand re G2 Express (K080668)
5371			May 6, 2008 Letter FDA to BPV Granting extension re G2 Express (K080668)
5372			Apr. 8, 2008 Letter FDA to BPV re AI Demand re G2 Express (K080668)
5373			Mar. 7, 2008 BPV's G2 Express Filter Special 510(k) (K080668)
5374			Sept. 29, 2008 Letter BPV to FDA re Responses to FDA AI Demand re G2X (K082305)
5375			May 5, 2008 Letter BPV to FDA Request 30 day extension re G2 Express (K080668)
5376			Oct. 31, 2008 FDA Clearance Letter G2X Filter (K082305) Substantial Equivalence
5377			Sept. 4, 2008 Email FDA to BPV re FDA AI Demand re G2X (K082305)
5378			Sept. 8, 2008 Letter FDA to BPV re FDA AI Demand re G2X (K082305)
5379			Aug. 12, 2008 BPV's G2X Filter Special 510(k) (K082305)
5380			G2 Express Filter Design/Development Files
5381			Conference between FDA and BPV regarding I050537
5382			G2 Express BR-8058 Biocompatibility Requirements G2 Express BR-8058 Biocompatibility Requirements
5383			G2 Express Flat Plate Fatigue and Corrosion Testing TR-07-02- 12 G2X Flat Plate Fatigue Test Various G2 Express Testing
5384			G2 Express Feasibility Acute Animal study Report TR-07-05-
5385			G2 Express Filter Arm Fatigue Comparison TR-07-07-04
5386			G2 Express v. G2 Tilt Assessment in Varying Cava Sizes TD-00463
5387			G2 IFU PK5100085, Rev. 0 (Femoral)
5388			G2 IFU (Jugular) PK5100090 Rev. 0 03/09
5389			G2 IFU PK5014091, Rev. 2 10/08 (Jugular)
5390		(G2 IFU PK5100085, Rev. 2 (Femoral)
5391		(G2 IFU PK5260600, Rev. 2 10/09 (Jugular)
5392		1	Recovery G2 Filter system 1 G2 filter system: indicated for retrieval
5393		2	2008 - G2 Filter system: Patient Q+A 2008 - G2 Filter system:
5394			10/2009 - G2 IFU 10-2009
5395			G2 DFMEA (Recovery Jugular) 070021, Rev. 0
5396		(G2 DFMEA (Recovery Jugular) 070021, Rev. 1
5397			G2 DFMEA (Recovery Jugular) 070021, Rev. 2
5398			G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 3

Exhibit	Marked for ID	Admitted in Evidence	Description	
5399			G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 4	
5400			G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 5	
5401			G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 6	
5402			G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 7	
5403			G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 6 Si	~
			page	ignature
5404			G2 DFMEA (G2 Jugular) 070021, Rev. 7	
5405			G2 DFMEA (G2 Jugular) 070021, Rev. 8	
5406			G2 DFMEA (G2 Jugular) 070021, Rev. 9	
5407			G2 DFMEA (Femoral) 070021, Rev. 9	
5408			G2 DFMEA (Femoral) 070022, Rev. 1	
5409			G2 DFMEA (Femoral) 070022, Rev. 2	
5410			G2 DFMEA (Femoral) 070022, Rev. 2	
5411			G2 DFMEA (Femoral) 070022, Rev. 3	
5412	,		G2 DEMEA (Femoral) 070022, Rev. 4	
5413			G2 DFMEA (Femoral) 070022, Rev. 5	
5414			G2 DFMEA (Femoral) 070031, Rev. 0	
5415			G2 DFMEA (Femoral) 070031, Rev. 1	
5416			G2 DFMEA (Femoral) 070031, Rev. 2	
5417			G2 DFMEA (Femoral) 070031, Rev. 3	
5418			G2 DFMEA (Femoral) 070031, Rev. 4	
5419			G2 DFMEA (Femoral) 070031, rev. 5	
5420			G2 DFMEA (Femoral) 070031, Rev. 6	
3420			Society of Interventional Radiology Responds to FDA	Blood
5421			Clot Device (IVC Filter) Advisory	
			Aug. 23, 2010 Letter from SIR to Shuren Aug. 23, 2010 from SIR to Shuren) Letter
5422			FDA Safety Advisory	
5423			Dec. 17, 2009 Email from Schulz to Moffett Nicholson	
			documents received from Bard 2/11/11	
5424			Dec. 15, 2009 Email from Schulz to Moffett	
5425			Nov. 9, 2009 Email from Chavez to Nicholson	
5426]]	Nov. 9, 2009 Email from Nicholson to Chavez	
5427]	Dec. 9, 2009 Email from Schulz to Rhinehart	
5428			Chart reflecting information on complaint files	
5429		I	Dec. 1, 2009 Email from Chavez to DelioCox	
5430		I	Dec. 8, 2009 Email from Schulz to Nicholson	<u> </u>
5431			Dec. 7, 2009 email chain with FDA re IVC filters	
5432		I	Dec. 2, 2009 email chain with FDA re Nicholson and Meridian®	
5433		F	DA re Removing Retrievable Inferior Vena Cava Filter	s:
5434		E	nitial Communication Establishment Inspection Report May 20, 2003 Establishment Report May 20, 2003	ishment

	Exhibit	Marked for ID	Admitted in Evidence	Description
	5435			Establishment Inspection Report April 5, 2006 Establishment
				Inspection Report April 5, 2006 Establishment
	5436			Establishment Inspection Report May 4, 2009 Establishment
				Inspection Report May 4, 2009 Establishment
	5437			Eclipse(Femoral) 12.09 - PK100600 Rev. 0a IFU
	5438			G2 Express (femoral) IFU 02.08 - PK5022940 Rev. 0
	5439			G2X(Femoral) 06.09 - PK5100060 Rev. 4 IFU
	5440			CQA-STD-24 Rev 08 Standard for Product Complaint
				Handling
	5441			SOPQ0153100 Rev 00 BPV Complaint Handling System
	5442			sopq0153100 Rev 01 BPV Complaint Handling System
	5443			sopq0153100 Rev 02 BPV Complaint Handling System
	5444			sopq0153100 Rev 03 BPV Complaint Handling System
	5445			sopq0153100 Rev 04 BPV Complaint Handling System
i	5446			sopq0153100 Rev 05 BPV Complaint Handling System
	5447			sopq0153100 Rev 06 BPV Complaint Handling System
	5448			sopq0153100 Rev 07 BPV Complaint Handling System
	5449			sopq0153100 Rev 08 BPV Complaint Handling System
	5450			sopq0153100 Rev 09 BPV Complaint Handling System
	5451			sopq0153100 Rev 10 BPV Complaint Handling System
	5452			sopq0153100 Rev 11 BPV Complaint Handling System
	5453			sopq0153100 Rev 12 BPV Complaint Handling System
)	5454			sopq0153100 Rev 13 BPV Complaint Handling System
	5455			sopq0153100 Rev 14 BPV Complaint Handling System
-	5456			sopq0153100 Rev 15 BPV Complaint Handling System PMA
L				Related System PMA
	5457		3	sopq0153100 Rev 16 BPV Complaint Handling System PMA
]	Related System Fivia
	5458		5	SOPQ0153100 Rev 17 BPV Complaint Handling System
F	7.170		1	FMA Related
	5459		S	SOPQ0153100 Rev 18 BPV Complaint Handling System
-	7.1.60		i	MA Related
-	5460		S	SOPQ0700200 Rev 00 Complaint Investigation Procedures
-	5461		S	opq0/00200 Rev 01 Complaint Investigation Procedures
_	5462		S	opq0/00200 Rev 02 Complaint Investigation Procedures
1-	5463		S	opq0/00200 Rev 03 Complaint Investigation Procedures
	5464		S	opq0/00200 Rev 04 Complaint Investigation Procedures
-	3465		S	opq0/00200 Rev 05 Complaint Investigation Procedures
_	3466		SO	opq0700200 Rev 06 Complaint Investigation Procedures
-	3467		S(Opq0/00200 Rev 07 Complaint Investigation Procedures
)	468		SC	pq0/00200 Rev 08 Complaint Investigation Procedures
<u> </u>			P	MA Related

Exhibit	Marked for ID	Admitted in Evidence	Description	
5469			sopq0700200 Rev 09 Complaint Investigation Procedure: PMA Related	S
5470			sopq0700200 Rev 10 Complaint Investigation Procedures PMA Related	S
5471			SOPQ0700200 Rev 11 Complaint Investigation Procedur PMA Related	es
5472			SOPQ0700200 Rev 12 Complaint Investigation Procedur PMA Related	es
5473			sopq0735600 Rev 0 Failure Investigation	
5474			sopq0735600 Rev 1 Failure Investigation	
5475			sopq0735600 Rev 2 Failure Investigation	
5476			song0735600 Pov 2 Failure Investigation	
5477			sopq0735600 Rev 3 Failure Investigation	
5478			sopq0735600 Rev 4 Failure Investigation	
5479			sopq0735600 Rev 5 Investigation Procedure	
5480			sopq0735600 Rev 6 Investigation Procedure	
5481			SOPQ0735600 Rev 7 Investigation Procedure PMA Relat	ed
3401			sopq1402000 Rev 5 Subject Product Analysis and Remed	ial
1			Action Assessment sopq1402000 Rev 5 Subject Product	
5400			Analysis and Remedial Action Assessment	
5482			sopq1413000 Rev 15 CAPA Procedure PMA Related	
			sopq1413000 Rev 15 CAPA Procedure PMA Related	
5483		vel	sopq1417500 Rev 1 Statistical Complaint Trending Process	lure
		3568	PMA Related sopq1417500 Rev 1 Statistical Complaint	
		_50	Trending Procedure PMA Related	
5484			Recovery Cone® Removal System IFU and related	
			documentation	
5485			Recovery Cone® IFU and related documentation	
5486			Dec. 17, 2009 Letter from BPV to FDA re Eclipse Filter Syst	tom
			Response to FDA Questions (K093659)	lem
5487			Dec. 17, 2009 Letter BPV to FDA re Responses to FDA AI	
			Demand re Eclipse (K093659)	
5488			June 21, 2010 Letter from BPV to FDA re Eclipse Filter Syst	
		1	Response to FDA Questions (K101431)	em
5489			Meridian Filter System Femoral Delivery Kit Special 510(1	
			(K112497), Aug. 27, 2011 (Vol. I & II)	()
5490			Sept. 30, 2011 Letter from FDA to BPV re Meridian Filter	
			System - Femoral Delivery Vit Special 510(1) (V.112407)	
3491			System Femoral Delivery Kit Special 510(k) (K112497)	
			Sept. 30, 2011 Letter from FDA to BPV re Meridian Filter	
492			System Femoral Special 510(k) (K112497)	
.,]]	Letter from BPV to FDA re Meridian Filter System Response	to
493			FDA Questions, Sept. 30, 2011	
175			Oct. 24, 2011 Letter from FDA to BPV re Meridian Filter	
			System Femoral Delivery Kit Special 510(k) (K112497)	
			(Substantial Equivalence)	

Exhibit	Marked for ID	Admitted in Evidence	Description
5494			Oct. 24, 2011 Letter re Meridian Filter System (K112497)
			(Substantial Equivalence)
5495			Meridian IFU (Femoral) 2011.01 - PK5372100 rev. 1
5496			Meridian IFU (Femoral) 2011.02 - PK5372100 rev. 2
5497			Meridian IELI (Femoral) 2011.02 - PK5372100 rev. 2
5498			Meridian IFU (Femoral) 2011.06 - PK5372100 rev. 3
5499			Meridian(Femoral) 08.11 - PK5372100 Rev. 4 IFU
5500			Meridian IFU (Jugular) 2011.06 - PK5372400 rev. 2
5501			Meridian IFU (Jugular) 2011.08 - PK5372400 rev. 3
3301			Meridian Jugular Subclavian Delivery Kit Traditional 510(k)
5502			(K102511) August 31, 2010
3302			CQA-STD-24 Rev 0 Standard for Product Complaint
5503			Handling
3303			CQA-STD-24 Rev 1 Standard for Product Complaint
5504			Handling
5504			CQA-STD-24 Rev 2 Standard for Product Complaint
5.50.5			Handling
5505			CQA-STD-24 Rev 3 Standard for Product Complaint
			Handling
5506			CQA-STD-24 Rev 4 Standard for Product Complaint
			Handling Handling
5507			CQA-STD-24 Rev 5 Standard for Product Complaint
			Handling
5508			CQA-STD-24 Rev 6 Standard for Product Complaint
1			Handling
5509			
			CQA-STD-24 Rev 7 Standard for Product Complaint Handling
5510			Pecovory Filter C. 1. , P. 1
			Recovery Filter Subject Product Analysis Migration SPA-04-
			12-01 Addendum I SPA-04-12-01: Amendment 1 (Remedial
			Action Plan re RNF Migration) Recovery Filter Subject Product
511			Analysis: Migration (SPA-04-12-01) Addendum I
			Attachment A to SPA-04-12-01: Amendment 1 (Remedial
512			Action Plan re RNF Migration)
		-	Attachment B to SPA-04-12-01: Amendment 1 (Remedial
513			Action Plan re RNF Migration)
		4	Attachment C to SPA-04-12-01: Amendment 1 (Remedial
514			Action Plan re RNF Migration)
14		1	Attachment D to SPA-04-12-01: Amendment 1 (Remedial
515		<i>F</i>	Action Plan re RNF Migration)
010	ĺ	l A	Attachment E to SPA-04-12-01: Amendment 1 (Remedial
116		F	Action Plan re RNF Migration)
516		A	Attachment F to SPA-04-12-01: Amendment 1 (Remedial
17		<i>F</i>	Action Plan re RNF Migration)
17		A	Attachment G to SPA-04-12-01: Amendment 1 (Remedial
		A	action Plan re RNF Migration)

Exhibit	Marked for ID	Admitted in Evidence	Description
5518			Attachment H to SPA-04-12-01: Amendment 1 (Remedial
			Action Plan re RNF Migration)
5519			July 12, 2004 Addendum to the Recovery; Filter Migration
			Events Spreadsheet (by Doug Uelmen)
5520			June 25, 2004 Multidisciplinary Focus Group Meeting PPT
			Slides Slides
5521			June 25, 2004 Multidisciplinary Focus Group Meeting PPT
			Slides
5522			June 25, 2004 Multidisciplinary Focus Group Meeting PPT
			Slides
5523		7 1	ETR-04-03-05 (RNF Characterization testing comparing GFO
		3-20-18	v. NMT manufactured filters) (followed TPR-04-02-02)
5524			March 10, 2004 Health Hazard Evaluation
5525			Action Items from March 4, 2004 RNF Migration Meeting
5526			TPR-04-02-02 (Protocol for RNF Migration Testing v.
		= 210-1X	Competitive) Test Protocol Number TPR-04-02-02 (Rev. 0)
		3-26-18	Characterization of the Recovery Filter (RF) - Migration
			Resistance
5527			March 26, 2014 Recovery Filter Migration Physician Review
			Panel PPT
5528			Agenda for Feb. 12, 2004 RNF Migration Meeting
5529			2004 Notebook of Materials re Migration (includes various
			meeting minutes)
5530			IFU Comparison Chart IFU Comparison Chart
5531			March 4, 2004 RNF Migration Meeting Minutes
5532			April 16, 2004 RNF Migration Meeting Minutes
5533			Feb. 2004 Notebook of Materials re Migration (includes various
			meeting minutes)
5534			Picture of Clot from Feb. 2004 RNF Migration
5535			G2 Caudal Migration Failure Investigation Presentation Slides
5536			Meeting Summary from Filter Expert Panel June 1, 2006
5537			June 2006 Expert Panel Meeting Slides
5538			June 19, 2006 EVEREST Medical Monitor Adjudication
			Meeting Minutes
539			G2 Caudal Migration Failure Investigation Report Aug. 4, 2005
		33-18	G2 Filter Caudal Migration Failure Investigation Report (FIR-
		20210	06-01-01) G2 Caudal Migration Failure Investigation Report
540			BPV Quality Manual Rev. 0
541			BPV Quality Manual Rev 1
542			BPV Quality Manual Rev 2
543			BPV Quality Manual Rev 3
544			BPV Quality Manual Rev 4
545			BPV Quality Manual Rev 5

Exhibit	Marked for ID	Admitted in Evidence	Description
5546			BPV Quality Manual - DOPQ0700300 Rev 6 BPV Quality Manual - DOPQ0700300 Rev 6
5547			SOPN0700080, Rev. 0 (Design Review)
5548			Standard Operating Procedure / Division Operating Procedure - SOPN0700080 Rev 6
5549			Department of Health and Human Services NOI 2003 Notice of Inspection
5550			Standard Operating Procedures / Division Operating Procedures CQA-STD-31 Rev 1
5551			Standard Operating Procedures / Division Operating Procedures DOPQ1102100 Rev 12
5552			Establishment Inspection Report FDA July 2011
5553			Standard Operating Procedures / Division Operating Procedures SOPQ1413000 Rev 15
5554			Standard Operating Procedures / Division Operating Procedures DOPQ0700000 Rev 8
5555			Standard Operating Procedures / Division Operating Procedures DOPQ0700020 Rev 13
5556			Standard Operating Procedures / Division Operating Procedures DOPQ0700040 Rev 4
5557			Standard Operating Procedures / Division Operating Procedures DOPQ0700300 Rev 5
5558			Standard Operating Procedures / Division Operating Procedures CQA-STD-54 Rev 00
5559			Standard Operating Procedures / Division Operating Procedures CQA-STD-54 Rev 01
5560		376/5	Standard Operating Procedures / Division Operating Procedures CQA-STD-R002 Rev 11
5561			Standard Operating Procedures / Division Operating Procedures CQA-STD-R002 Rev 12
5562			Standard Operating Procedures / Division Operating Procedures CQA-STD-R002 Rev 13
5563			Standard Operating Procedures / Division Operating Procedures CQA-STD-R002 REv 14
5564			Standard Operating Procedures / Division Operating Procedures CQA-STD-R002 Rev 15
5565			Standard Operating Procedures / Division Operating Procedures RA-STD-002 Rev 10
5566			Standard Operating Procedures / Division Operating Procedures RA-STD-002 Rev 9
5567			Lab notebook 7102 (G2 Express ELF Test) Lab Notebook LAB-7102 JOB
5568			Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 0

Exhibit	Marked for ID	Admitted in Evidence	Description
5569			Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 1
5570			Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 2
5571			Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 3
5572			Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 4
5573			Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 5
5574			Standard Operating Procedures / Division Operating Procedures - SOPQ0700190 Rev 0
5575			Standard Operating Procedures / Division Operating Procedures - SOPQ0700190 Rev 1
5576			Standard Operating Procedures / Division Operating Procedures - SOPQ0700190 Rev 2
5577			Standard Operating Procedures / Division Operating Procedures - SOPQ0700190 Rev 3
5578			Standard Operating Procedures / Division Operating Procedures - SOPQ1417500 Rev 0
5579			Standard Operating Procedures / Division Operating Procedures - SOPQ1417500 Rev 1
5580			Standard Operating Procedures / Division Operating Procedures - CQA-STD-15 rev 2
5581			02.28.13 Letter from FDA to BPV re PRESERVE Study 522 Eclipse
5582			02.28.13 Letter from FDA to BPV re PRESERVE Study 522 G2
5583			02.28.13 Letter from FDA to BPV re PRESERVE Study 522 G2X
5584			02.28.13 Letter from FDA to BPV re PRESERVE Study 522 Recovery
5585			02.28.13 Letter from FDA to BPV re PRESERVE Study 522 Simon Nitinol
5586			
5587			May 20, 2010 BPV's Eclipse Filter Special 510(k) (K101431) June 18, 2010 Letter FDA to BPV re FDA AI Demand re Eclipse (K101431)
5588		1	Dec. 15, 2009 Letter FDA to BPV re FDA AI Demand re Eclipse (K093659)
5589		J	June 22, 2010 FDA Clearance Letter for Eclipse Filter K101431) (Substantial Equivalence)
590		N	Meridian Clearance August 24, 2011 (K102511)
591		F	FDA CONTACT REPORT 11-18-2010 Meridian 510(k)

Exhibit	Marked for ID	Admitted in Evidence	Description
5592			FDA CONTACT REPORT 2-4-2011_MERIDIAN AI Letter
			and DENALI IDE
5593			Aug. 14, 2009 Conference FDA and BPV re future Eclipse
			Filter 510(k)
5594			FDA CONTACT REPORT December 3 2010_Denali pre-IDE
			supplement & Meridian AI Response
5595			FDA CONTACT REPORT December 7 2010 Denali IDE and
			Meridian AI Response
5596			FDA CONTACT REPORT December 8 2010_Meridian
5500			AI_Fatigue
5597			Dec. 8, 2010 FDA Contact Report re Meridian
5598			Feb. 10, 2011 FDA Contact Report (Denali Pre IDE)
5599			Feb. 10, 2011 FDA Contact Report (Meridian)
5600			FDA CONTACT REPORT Feb 16 2010 Prophylactic
			Indication
5601			Feb. 17, 2011 (Meridian)
5602		3-26-18	FDA CONTACT REPORT January 7 2010 FINAL
5603			Jan. 8, 2010 (Meridian Pre IDE)
5604			FDA CONTACT REPORT June 29 2010 ASLT for IDE
5605			FDA CONTACT REPORT March 31 2009 Pre-IDE Meeting
5606			Minutes_G2 Platinum
5606			FDA CONTACT REPORT May 17 2011 Meridian
5607			May 17, 2011 (Meridian)
5608			May 20, 2010 (Denali Pre IDE)
5609			May 5, 2010 (Denali Pre IDE)
5610			Nov. 12, 2010 (Meridian)
5611			FDA CONTACT REPORT Nov 17 2009 CRT Online
5612			Nov. 17, 2009 (Filters and future submissions)
5613			FDA CONTACT REPORTJune 22 2011 Meridian
5614			June 22, 2011 (Meridian)
5615			FDA CONTACT REPORTSeptember 27 2011_IVC Filter
5616			Discussion and Meridian
5616			Standard Operating Procedure / Division Operating Procedure -
5617			R-004 Rev 03
5617			Standard Operating Procedure / Division Operating Procedure -
5(10			SOPR0700000 Rev.17
5618			Standard Operating Procedure / Division Operating Procedure -
5610			SOPR0700010 Rev. 12
5619			Preserve Materials 12-8-10 IVC Filter study
5620			Bard.Preserve.LOI Bard.Preserve.LOI
5621			ETR-06-08-29, Rev. 0 (Caudal Migration Test Method
			Development and G2 Filter Resistance Test Report)

Exhibit	Marked for ID	Admitted in Evidence	Description
5622			TPR-06-08-29, Rev. 0 (Caudal Migration Test Method
			Development and G2 Filter Resistance Test Protocol)
5623			Recovery Filter Product Performance Specification (PPS070016
			Rev. 0)
5624			Filter Action Items PPT
5625			Design History File: 8088 Platinum - G2 Complaints
5626			Spreadsheet of Complications
5627			BPV EIR 2007 Establishment Inspection Report FDA
			January 2007
5628			BPV EIR 2007 Establishment Inspection Report FDA
			January 2009
5629			Nov. 28 2011 EIR Establishment Inspection Report FDA
			August 2011
5630			Bard Signed Agreement Bard Signed Agreement
5631			DOPN0700010, Rev. 0 (DOP re Risk Assessment)
5632			Standard Operating Procedure / Division Operating Procedure -
			SOPN0700120 Rev 00
5633			Standard Operating Procedure / Division Operating Procedure -
			SOPN0700120 Rev 01
5634			Standard Operating Procedure / Division Operating Procedure -
			SOPN0700120 Rev 02
5635			Standard Operating Procedure / Division Operating Procedure -
5.60.6			SOPN0/00120 Rev 03
5636			Standard Operating Procedure / Division Operating Procedure -
5.625			SOPN0700120 Rev 04
5637			Standard Operating Procedure / Division Operating Procedure -
5.620			SOPN0/00120 Rev 05
5638		li li	Standard Operating Procedure / Division Operating Procedure -
5(20			SOPN0/00120 Rev 06
5639			Standard Operating Procedure / Division Operating Procedure -
5640			SOPN0/00120 Rev 07
5640			Standard Operating Procedure / Division Operating Procedure -
5641			SOPN0/00120 Rev 08
0041			Standard Operating Procedure / Division Operating Procedure -
5642		, i	SOPN0/00120 Rev 09
0042			Standard Operating Procedure / Division Operating Procedure -
5643			SOPN0/00120 Rev 10
043			Standard Operating Procedure / Division Operating Procedure -
644			SOPN0700120 Rev 11
VT-1			Standard Operating Procedure / Division Operating Procedure -
645			OPN0/00120 Rev 12
646			QMBRApril 2013
647			QMBRNov. 2013
UT/		<u> T</u>	D-03970 – Eclipse and G2X Migration Resistance Test Data

Exhibit	Marked for ID	Admitted in Evidence	Description
5648			Jan. 5, 2015 FDA 483 Letter to BPV.pdf
5649			July 13, 2015 FDA Warning Letter to Bard.pdf
5650			Nov. 25, 2014 FDA 483 Letter to Glens Falls.pdf
5651			GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Letter.pdf
5652			GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Exhibit 1.pdf
5653			GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Exhibit 1.pdf
5654			GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Exhibit 2.pdf
5655			GFO FDA 483 Response (1) Dec 17 2014 (Initial) Exhibit 3.pdf
			(Initial)\Attachments\09-01.pdf
5656			GFO FDA 483 Response (2) Jan 15 2015 Update\FedEx
			Tracking and Letter.pdf
5657			GFO FDA 483 Response (2) Jan 15 2015 Update\Exhibit 1.pdf
5658			GFO FDA 483 Response (2) Jan 15 2015 Update\Exhibit 1.pdf
5659			GFO FDA 483 Response (2) Jan 15 2015 Update\Exhibit 3.pdf
5660			GFO FDA 483 Response (3) Feb 18 2015 Update\Exhibit 3.pdf
			Response Document Receipt, FedEx Tracking and Letter.pdf
5661			GFO FDA 483 Response (3) Feb 18 2015 Update\Exhibit 1.pdf
5662			GFO FDA 483 Response (3) Feb 18 2015 Update\Exhibit 2.pdf
5663			GFO FDA 483 Response (3) Feb 18 2015 Update\Exhibit 3.pdf
5664			GFO FDA 483 Response (4) Mar 16 2015 Update\Exhibit 3.pdf
			Tracking and Letter.pdf
5665			GFO FDA 483 Response (4) Mar 16 2015 Update\Exhibit 1.pdf
5666			GFO FDA 483 Response (4) Mar 16 2015 Update\Exhibit 2.pdf
5667			GFO FDA 483 Response (4) Mar 16 2015 Update\Exhibit 3.pdf
5668			GFO FDA 483 Response (5) Apr 17 2015 Update\Exhibit 3.pdf
			Tracking and Letter.pdf
5669			GFO FDA 483 Response (5) Apr 17 2015 Update\Exhibit 1.pdf
5670			GFO FDA 483 Response (5) Apr 17 2015 Update\Exhibit 2.pdf
5671			GFO FDA 483 Response (5) Apr 17 2015 Update\Exhibit 3.pdf
5672			GFO FDA 483 Response (6) May 6 2015 Update\Exhibit 3.pdf
			Tracking and Letter.pdf
5673			GFO FDA 483 Response (6) May 6 2015 Update\Exhibit 1.pdf
5674		(GFO FDA 483 Response (6) May 6 2015 Update\Exhibit 2.pdf
5675		(GFO FDA 483 Response (6) May 6 2015 Update\Exhibit 3.pdf
5676		(GFO FDA 483 Response (7) Jun 19 2015 Update\FedEx
			Fracking and Letter.pdf
5677		(GFO FDA 483 Response (7) Jun 19 2015 Update\Exhibit 1.pdf
678		(GFO FDA 483 Response (7) Jun 19 2015 Update\Exhibit 2.pdf
679			GFO FDA 483 Response (7) Jun 19 2015 Update\Exhibit 3.pdf
680		C	GFO FDA 483 Response (8) July 17 2015 Update\FedEx
		Т	racking and Letter.pdf
681		G	FO FDA 483 Response (8) July 17 2015 Update\Exhibit 1.pdf
682		G	FO FDA 483 Response (8) July 17 2015 Update\Exhibit 2.pdf

Exhibit	Marked for ID	Admitted in Evidence	Description	
5683			GFO FDA 483 Response (8) July 17 2015 Update\Ext	nibit 3 ndf
5684			BPV FDA 483 Response Cover letter and response Ja	nuary 26
			2014	, , , , , , , , , , , , , , , , , , ,
5685			BPV FDA 483 Response 1 - Attachments.pdf	
5686			Jan. 2015 Retrospective Review of Death Complaints	
5687			Jan. 2015 Retrospective Review of Death Complaints	(Serious
			Injury v. Malfunction)	(= 1113 815
5688			BPV FDA 483 Response 2 - Attachments.pdf	
5689			BPV FDA 483 Response 3 - Attachments.pdf	
5690			BPV FDA 483 Update Response February 26, 2015 po	lf
5691		3.2818	BPV FDA 483 Update Response March 26, 2015.pdf	12. Klar
5692			BPV FDA 483 Update Response April 24, 2015.pdf	OP TO JAGI
5693			BPV FDA 483 Update Response May 22, 2015.pdf	
5694			BPV FDA 483 Update Response June 25, 2015.pdf	
5695			Bard Warning Letter Response (August 3 2015) 01 Co	ver
			Letter.pdf	
5696			Bard Warning Letter Response (August 3 2015) 02 W	arning
			Letter Response.pdf	
5697			Bard Warning Letter Response (August 3 2015) 03 Ap	pendix
			0.pdf	Policia
5698			Bard Warning Letter Response (August 3 2015) 04 Ap	pendix
			1.pdf	-
5699			Bard Warning Letter Response (August 3 2015) 05 Ap	pendix
			2.pdf	
5700			Bard Warning Letter Response (August 3 2015) 06 Ap	pendix
			3.pdf	
5701		1	Bard Warning Letter Response (August 3 2015) 10 Ap	pendix
5700			7.pdf	
5702			Bard Warning Letter Response (August 3 2015) 11 Ap	pendix
5500			8.pdf	
5703			October 6 2015 Update Response to Warning Letter Iss	ued July
5704			13 2015.pdf	
5704			September 3 2015 Update Response to Form 483 issued	January
5705			5 2015.pdf	
5705			September 3 2015 Update Response to Form 483 issued	
5706			November 25 2014.pdf	
5706		3-28-18	September 3 2015 Update Response to Warning Letter i	ssued
5707		7000	July 13 2015.pdf Coulomb Recovery Cone Materials 001 Recovery Cone	
5707			Recovery Cone Materials 001_Recovery Cone	
5700			510(k)_FINAL.pdf	
5708			Recovery Cone Materials FW Continued Distribution	of the
5700			Recovery Cone Removal System.msg	
5709]]	Recovery Cone Materials RC15 Customer Letter.pdf	

Exhibit	Marked for ID	Admitted in Evidence	Description
5710			Recovery Cone Materials Recovery Cone Customer
			Letter.pdf
5711			Recovery® Cone IFU and related documentation
5712			FDA Submissions and Correspondence Files Regarding
			Recovery® Cone
5713			Recovery Cone Materials Dr Bilek letter.pdf
5714			Recovery Cone Materials FDA Meeting K152136 Recovery
			Cone_Question 8.pdf
5715			July 13 2015 FDA Warning Letter to Bard (unredacted)
5716			October 6 2015 Update Response to 483 Issued November 25
			2014.pdf
5717			November 20 2015 Update Response to Form 483 issued
			November 25 2014.pdf
5718			November 20 2015 Update Response to Warning Letter issued
			July 13 2015.pdf
5719			Sept. 2015 Retrospective Review re Follow Up
5720			RE Bard Peripheral Vascular - clarification question.msg
5721			FDA response letter 121415.pdf
722			FDA Warning Letter Materials December 22 2015 GFO 483
			Update Submission.pdf
5723			FDA Warning Letter Materials December 22 2015 WL
			Update Response.pdf
724			Internal Quality Audit Worksheet (attached to FDA WL
			response Dec. 2015)
725			FDA Warning Letter Materials Transmittal Letter.pdf
726			FDA 483 #2020394 BPV February 2016.PDF
727			FDA 483 GFO March 2016.PDF
728			
			Recovery Cone Materials - K152136 Letter SE FINAL_Sent001.pdf
729			
730			Denali Design Input Summary Rev. 2
			Denali 510(k) submission (K130366) Narrative
731			Submission.pdf Densili 510(1) and a single (11000 fg)
732			Denali 510(k) submission (K130366) Appendices Part 1.pdf
733			Denali 510(k) submission (K130366) Appendices Part 2.pdf
734			Denali 510(k) submission (K130366) Appendices Part 3.pdf
735			Denali 510(k) submission (K130366) Appendices Part 4.pdf
736			Denali 510(k) submission (K130366) Appendices Part 5.pdf
737		I	Denali 510(k) submission (K130366) Appendices Part 6.pdf
738		1 1	Denali 510(k) submission (K130366) Appendices Part 7.pdf
739			Denali 510(k) submission (K130366) Appendices Part 8.pdf
740			Denali 510(k) submission (K130366) Appendices Part 9 pdf
770		1	Denali 510(k) submission (K130366) Appendices Part 10
			Section 1.pdf

Exhibit	Marked for ID	Admitted in Evidence	Description
5741			Denali 510(k) (K130366) Clearance Letter dated May 15,
			2013.pdf
5742			Denali 510(k) submission (K130366) Appendices Part 10
			Section 2.pdf
5743			Denali Special 510(k) (K143208).pdf
5744			Dec. 9, 2014 Denali Clearance Letter (K143208).PDF
5745			Dec. 30, 2010 IDE for Denali
5746			Aug. 9, 2011 BPV 5th IDE Supplement
5747			Oct. 3, 2011 BPV 7th IDE Supplement
5748			Nov. 11, 2011 BPV 9th IDE Supplement
5749			Denali Materials – Clinical Study Materials – Denali Final
			Clinical Study Report.pdf
5750			Standard Operating Procedures / Division Operating Procedures
			- CQA-STD-54.doc
5751			Standard Operating Procedures / Division Operating Procedures
			- CQA-STD-R002.doc Rev 15
5752			G2 DFMEA (Femoral) 070022, Rev. 6
5753			G2 DFMEA (Femoral) 070031, Rev. 7
5754			DFMEAs – Exam Key (Parts I & Part II).pdf
5755			DFMEAs – TD-04451 Rev 0.pdf
5756			Audit Materials – Assessment Report 7766817 7737901A.pdf
5757			Audit Materials – Assessment Report 78787507864713 9-13-
			13.pdf
5758			Audit Materials – BSI Assessment Report 8043354 9-19-
			14A.pdf
5759			Audit Materials – AUD-14-11-14 Final Report.pdf
5760			Audit Materials – 2015 BSI Assessment Report.pdf
5761			Audit Materials – AUD-15-12-04 Complaint Audit Final
			Report.pdf
5762			QMBRApril 2014
5763			QMBRNov. 2014
5764			QMBRMay 2015
5765			QMBROct. 2015
5766			QMBRFeb. 2016
5767			May 10, 2013 FDA email to BPV re revised IFU
5768			April 6, 2013 email from FDA requesting additional
7.60			information
5769			Denali Materials – K130366 FDA Correspondence – K130366
770			remoral IFU FDA coments.pdf
5770		I	Denali Materials – K130366 FDA Correspondence – K130366
771		I	Patient Brochure FDA comments.pdf
771		N	May 6, 2013 email to FDA responding to questions

Exhibit	Marked for ID	Admitted in Evidence	Description
5772		ZVIGOREC	Denali Materials – K130366 FDA Correspondence – Denali
			Femoral IFU_PE rate of 1.1%.pdf
5773			Denali Materials – K130366 FDA Correspondence – Denali
			Femoral IFU_PE rate of 1.6%.pdf
5774			Denali Materials – K130366 FDA Correspondence – Denali
			IFU Clinical Experience red-lines.docx
5775			Denali Materials V120266 EDA C
			Denali Materials – K130366 FDA Correspondence – Denali Jugular IFU_PE rate of 1.1%.pdf
5776			Denali Materials V12026CEDA C
			Denali Materials – K130366 FDA Correspondence – Denali
5777			Jugular IFU_PE rate of 1.6%.pdf
5778			April 24, 2013 email to FDA responding to questions
5779			April 15, 2013 email to FDA responding to questions
			Denali Materials – K130366 FDA Correspondence – Femoral
5780			IFU Red-line.pdf
			Denali Materials – K130366 FDA Correspondence – Femoral
5781			IFU.pdf
3701			Denali Materials – K130366 FDA Correspondence – Femoral
5782			Label Set.pdf
3762			Denali Materials – K130366 FDA Correspondence – Jugular
5783			IFU Red-line.pdf
3763			Denali Materials – K130366 FDA Correspondence – Jugular
5784			IFU.pdf
3/84			Denali Materials – K130366 FDA Correspondence – Jugular
5785			Label Set.pdf
3763			Denali Materials – K130366 FDA Correspondence – Patient
5786			Brochure and Implant Card.pdf
5787			May 6, 2013 email to FDA responding to questions
3/8/			Denali Materials – K130366 FDA Correspondence – Femoral
5700			1FU FDA 050213.pdf
5788			May 8, 2013 email to FDA with redlined IFU
5789			Denali Materials – K130366 FDA Correspondence – Denali
5700			IFU Clinical Experience red-lines.docx
5790			May 14, 2013 emails with FDA re animal study description in
5701			510(k) summary
5791			May 10, 2013 email to FDA with revised 510(k) summary
5792			April 15, 2013 email to FDA responding to questions
5793			March 14-19 emails with FDA re Denali 510(k)
5794			Denali Materials – Clinical Study Materials – Denali Final
			Clinical Study Report.pdf
5795			Feb. 16, 2011 BPV IDE Supplement #1 appendices
796		I	Feb. 16, 2011 BPV IDE Supplement #1
5797		J	an. 31, 2012 IDE Annual Report
798		N	Nov. 13, 2012 BPV 13th IDE Supplement

Exhibit	Marked for ID	Admitted in Evidence	Description
5799			March 1, 2013 BPV response to FDA questions re annual IDE
			report report
5800			Jan. 10, 2013 BPV Annual IDE Report
5801			Jan. 30, 2014 BPV IDE Annual Report
5802			Jan. 30, 2015 BPV Annual IDE Report
5803			Jan. 29, 2016 BPV IDE Final Annual Report
5804			Sept. 9, 2011 FDA letter conditional approval of IDE
5805			Feb. 7, 2013 FDA Letter with questions re IDE annual report
5806			March 17, 2011 FDA letter with conditional approval of IDE
5807			Dec. 14, 2012 FDA Letter approving IDE change
5808			Feb. 16, 2016 FDA email re final IDE and annual report
5809			Feb. 26, 2016 FDA letter closing Denali IDE
5810			Feb. 18, 2016 BPV email responding to questions of Feb. 16
5811			Audit Materials – Bard PV Re-assessment Report 10-19-
			2010.pdf
5812			Audit Materials – Assessment Report 7597321B 12-15-11.pdf
5813			Audit Materials – Assessment Report 759/321B 12-15-11.pdf Audit Materials – AUD-16-03-02 Complaint Files Internal
			Audit Report
5814			BPV Response - March 11, 2016.pdf
5815			483 Response March 22, 2016.pdf
5816			RE BPV 483 Response.msg
5817			Additional materials related to the EDA W.
			Additional materials related to the FDA Warning Letter and 483s
5818			BPV 483 Response Update 20160414.pdf
5819			Denali (Femoral) 2011.08 - PK5410500 rev. 1 IFU
5820			Denali (Femoral) 2012 02 - PK5410500 rev. 1 IFU
5821			Denali (Femoral) 2012.02 - PK5410500 rev. 2 IFU
5822			Denali (Femoral) 2013.03 - PK5410500 rev. 3 IFU
5823			Denali (Femoral) 2013.04 - PK5410500 rev. 4 IFU
5824			Denali (Jugular) 2011.08 - PK5380500 rev. 1 IFU
5825			Denali (Jugular) 2012.02 - PK5380500 rev. 2 IFU
5826			Denali (Jugular) 2013.03 - PK5380500 rev. 3 IFU
5827			Denali (Jugular) 2013.04 - PK5380500 rev. 4 IFU
5828			G2X (Femoral) 2008.06 - PK5100060 rev. 1 IFU
829			Meridian (Femoral) 2013.02 - PK5372100 rev. 5 IFU
5830			Meridian (Jugular) 2013.02 - PK5372400 rev. 4 IFU
			Denali Materials – Clinical Study Materials – Audits – Denali
831		a	udit March 2013.pdf
			Denali Materials – Clinical Study Materials – Audits – Denali
832		T a	udit September 2011.pdf
			Denali Materials – Clinical Study Materials – Audits – Denali ite Audit.pdf
833			
			stablishment Inspection Reports (EIRs) – AUD-14-02-01 EIR eb 2014.pdf

Exhibit	Marked for ID	Admitted in Evidence	Description
5834			Establishment Inspection Reports (EIRs) – FDA Establishment
			Inspection Report Dated 2.19.16.pdf
5835			FDA Warning Letter Materials – BPV 483 Response Update
			20160527.pdf
5836			FDA Warning Letter Materials – Signed Final - Cover and
			Response to FDA's 5-25-16 Letter.pdf
5837			SNF Materials – K963014 Clearance Letter.pdf
5838			SNF Materials – K970099 Clearance Letter.pdf
5839			SNF Materials – All Filter Data 8-20-12 Draft.xls
5840			SNF Materials – Competitor Rate Analysis.xls 8-22-12.xls
5841			SNF Materials – Filter Analysis 8-23-12.PPTX
5842			FDA Warning Letter Materials – Feb. 3, 2016 updated response
			to Warning Letter
5843			FDA Warning Letter Materials – May 25, 2016 Letter from
			FDA with follow-up re Warning Letter
5844			Standard Operating Procedures / Division Operating Procedures
			CQA-STD-24 Rev 9.pdf
5845			Standard Operating Procedures / Division Operating Procedures
			CQA-STD-24 Rev 10.pdf
5846			Standard Operating Procedures / Division Operating Procedures
			CQA-STD-24 Rev 11.pdf
5847			Standard Operating Procedures / Division Operating Procedures
			CQA-STD-54 Rev 3.pdf
5848			G2 DFMEA (G2 Jugular) 070021, Rev. 10
5849			SOPN0700120 Rev 13.docx
5850			SOPN0700120 Rev 14.docx
5851			TD-04698 Re Retrospective IVC Filter Review.pdf
5852			FDA Communications FDA Ltr Denali IVC Filter
			9.28.16.pdf
5853			FDA Communications FDA Ltr Denali -Juglar Sub Del Sys
			9.28.16.pdf
5854			FDA Communications
			001_SimonNitinolFilterSystem_PS140002.pdf
5855			FDA Communications PS140002A7 - Bard Peripheral
]	Perivascular - email receipt.msg
5856		1	FDA Communications RE PRESERVE - please provide
			contact for SAEs.msg
5857		I	FDA Communications 001 Denali Special 510(k).pdf
5858		I	DA Communications Acceptance Review From FDA pdf
5859		I	FDA Communications FDA Decision Letter - Bard Peripheral
		I	Perivascular - PS140002A7.msg
860		F	FDA Communications PS140002.A7 - OTHER2 - 8.3 16 pdf
861		F	FDA Communications FW K160866 Review Complete.msg

Exhibit	Marked for ID	Admitted in Evidence	Description
5862			FDA Communications
			K160866.510kSummary.Final_Sent001.pdf
5863			FDA Communications K160866.IFU.FINAL Sent001.pdf
5864			FDA Communications
			K160866.Letter.SE.FINAL Sent001.pdf
5865			FDA Communications RE K160866 Special 510(k) to add 2-
			year study data to label (1).msg
5866			FDA Communications Femoral IFU Redlined.docx
5867			FDA Communications RE K160866 Special 510(k) to add 2-
			year study data to label (2).msg
5868			FDA Communications Femoral IFU Updated Redlines.docx
5869			FDA Communications RE K160866 Special 510(k) to add 2-
			year study data to label (3).msg
5870			FDA Communications Femoral IFU FDA comments.docx
5871			FDA Communications RE K160866 Special 510(k) to add 2-
			year study data to label.msg
5872		35874	FDA Warning Close Out Letter
5873			FDA Establishment Inspection Report EIR (01/05/2015)
5874		37818	Bard filter rate information December 2016
5875		7000	Bard filter rate information December 2016
5876			COOKFOIA Materials downloaded from Cook Medical IVC
			Filter Litigation PACER Docket (FDA Price Memos)
5877		2-23-14	1996 Memo from Veronica Price
5878			2004 Memo from Veronica Price
5879		3-23-18	April 11, 2006 Letter to FDA re Caudal Migration
5880		3-23-18	March 23, 2006 Letter to FDA re G2 Caudal Migration
5881		3.03-18	May 11, 2006 Letter to FDA re Caudal Migration
5882			May 12, 2004 Email from Carr re RNF jigs
5883			July 26, 2005 Conference FDA and BPV re Modified Recovery (K050558)
5884			May, 27, 2005 Conference FDA and BPV re Modified
			Recovery (K050558)
5885			Conference between BPV and FDA regarding K050558
5886			Aug. 29. 2005 Email BPV to FDA re G2 (K050558)
5887			Aug. 19, 2005 Email BPV to FDA re G2 (K050558)
5888			July 28, 2005 Conference FDA and BPV re AI re Modified
			Recovery (K050558)
5889			Aug. 22, 2005 Email BPV to FDA re G2 (K050558)
5890			G2 IFU PK5100030, Rev. 0 05/08 (Femoral)
5891			July 27, 2005 Email chain BPV and FDA re Modified Recovery (K050558)
5892			Email from BPV to FDA regarding K050558
5893			Conference between FDA and BPV regarding K050558

Exhibit	Marked for ID	Admitted in Evidence	Description
5894			Email from BPV to FDA K050558
5895			Email from BPV to FDA regarding K050558
5896			Conference between BPV and FDA regarding K050558
5897			Email chain between BPV and FDA regarding K050558
5898			Conference between BPV and FDA regarding K050558
5899			July 26, 2005 Contact Report, BPV and FDA regarding K050558
5900			Oct. 21, 2005 Conference FDA and BPV re G2 Everest Study (G051034) and future submission
5901			ETR-04-03-10 (RNF Characterization testing Migration
			Resistance when Legs are Crossed or Hooks Removed)
5902			Article Entitled US FDA Clinical Data Summary of the Simon
			Nitinol Filter Article Entitled US FDA Clinical Data Summary
			of the Simon Nitinol Filter
5903		100000	Email from BPV to FDA regarding K031328 and DCL
5904			Ian 22 2005 Email from PDV to EDA to DCL and D
3701			Jan. 22, 2005 Email from BPV to FDA re DCL and Recovery Retrievable (K031328)
5905		3-03-18	
5906		<i>3 03</i> (6	March 24, 2005, Meeting with FDA Agenda
3,000			PPT with Summary of Design Modifications for G2 PPT with
5907			Summary of Design Modifications for G2
5908			PPT Entitled Recovery Filter Design Enhancements (re G2)
5909			G2 IFU PK5100030, Rev. 1 05/08 (Femoral)
3909			ETR-04-03-18 (RNF Characterization testing of Migration
5910			Resistance when Filter is Tilted)
3910			Email from Benware to Hudson, Carr (cc to Fitzpatrick)
5011			enclosing final Starguide Report
5911			EPRO-02-01 (BPT SOP re DFMEA)
5912			Testing PPT re Migration Testing in 2004
5913			June 9, 2005 email with Dear Colleague Letter Tracking Chart
5914			June 7, 2005 email with Dear Colleague Letter Tracking Chart
5915			May 11, 2005 Dear Colleague Letter
5916			Dear Colleague Letter DCL Tracking Chart
5917			Data Chart used by Natalie Wong in May 2004 email chain with Doug Uelmen regarding draft data set for statisician
5918			May 27, 2004 Email chain between Natalie Wong and Doug Uelmen regarding draft data set for statistician
5919			U.S. Patent No. US 6,258,026 B1 for Removable Embolus Blood Clot Filter and Filter Delivery Unit, submitted by Ravenscroft et al., dated 7/10/2001
5920			Reformatted version of the data chart used by Natalie Wong in May 2004 email chain with Doug Uelment regarding draft data set for statistician.
5921			Graphs and statistical summary forwarded to Doug Uelmen by Natalie Wong in May 2004 email chain.

Exhibit	Marked for ID	Admitted in Evidence	Description	
5922			Dec. 9, 2004 email re Dear Doctor Letter	
5923		3-26-18	September 2010 Letter to Clinicians re FDA PHN	
5924			Sept 2, 2010 Bard Filter Clinical Overview to Sales For	rce
			(Cover Letter Packet)	
5925			G2X IFU (Jugular) 2008.07 - PK5100070 rev. 1	
5926			G2X IFU (Jugular) 2009.06 - PK5100070 rev. 4	111.
5927			G2 Risk Benefit Analysis (RBA-0003, Rev. 2)	
5928			TP-07-12-01 (DV& V Flat Plate Fatigue and Corrosion	
			Examination Test Protocol G2 Express Filter)	•
5929			TR-07-12-01 (Test Report re G2 Express DV& V Flat I	Plate
			Fatigue and Corrosion)	1410
5930			TM1141300 (Filter Wire Weld Tensile Strength Testing	o)
5931			G2X (Jugular) 2009.10 - PK5100070 rev. 5 IFU	<i>⊃/</i>
5932			QMBRJan. 2011	
5933			April 24, 2009 email noting withdrawal of G2® Expand	1.510(k)
5934			TP 07-02-12 (Flat Plate Fatigue Testing Protocol)	1 310(K)
5935			TD-00275 (Comparison of Nonsymmetrical Loading or	the G2
			Filter Device in Two Orientations Using FEA by Willia	m lames
			Harrison, WJH Engineering)	in Janies
5936			TD-00468 (G2 Flat Plate Baseline Characterization Tes	t
			Analysis of Detached Arm)	
5937			TD-00192 (Product Comparisons through Finite Elemen	
			Analysis and Testing by William James Harrison, WJH	
			Engineering)	
5938			April 3, 2006 G2 Caudal Migration Meeting Minutes	
5939			March 31, 2006 Meeting Minutes re G2 caudal migration	n
5940			PowerPoint slide regarding filter failure investigations	
5941			April 11, 2006 G2 Caudal Migration Meeting Minutes	
5942		3-26-18	January 7, 2010 FDA PowerPoint Presentation	
5943		77018	Filters Complaint History PPT	
5944			June 25, 2004 Multidisciplinary Focus Group Meeting	
			Summary	
5945			April 2006 letter to FDA re G2 caudal migration	
5946			QMBRJuly 2006	
5947			QMBRDec. 2005	
5948			April 1, 2009 letter from FDA requesting additional info	rmation
			re G2® for prophylactic indication	nination
5949			ETR-06-05-02 (Test report re G2® Clot Trapping Efficient	ency)
5950		7 0 th 10	TP-07-04 (G2® Express Filter Arm Fatigue Compari	son
			Study)	3011
5951			Nov. 16, 2010 email to FDA enclosing fatigue testing in	fore
			Meridian	io io
5952			QMBRJan. 2007	

Exhibit	Marked for ID	Admitted in Evidence	Description	
5953			TR-07-08-16 (G2® Express Acute GLP Animal Study	Report)
5954			June 30, 2006 G2 Caudal Migration Meeting Minutes	
5955			May 9, 2006 Email from Natalie Wong to Brian Hudse	on
			forwarding responses to FDA requests for information	
5956			June 12, 2006 G2 Caudal Migration Meeting Minutes	
5957			June 21, 2006 G2 Caudal Migration Meeting Minutes	
5958			March 3, 2006 Caudal Migration Meeting Minutes	
5959			April 18, 2006 G2 Caudal Migration Meeting Minutes	
5960			April 28, 2006 G2 Caudal Migration Meeting Minutes	
5961			May 18, 2006 G2 Caudal Migration Meeting Minutes	
5962			TD-00060 (formerly ETR-04-05-06) (RNF Characteriz	zation
			testing of Migration Resistance in Oval and D shaped	(VC)
5963			November 20, 2008 Presentation entitled G2 and G2X	Fracture
			Analysis	
5964			TM1141700 (Filter Flat Plate Fatigue Test Method)	
5965			QMBRFeb. 2008	
5966			Oct. 26, 2010 Letter from FDA to BPV re Meridian Ju	gular
			(K102511)	
5967			G2 Risk Benefit Analysis (RBA-0003, Rev. 0)	
5968			Meridian (Jugular) 2010.10 - PK5372400 rev. 0 IFU	
5969			Email chain with McDermott and Allen re G2 Investiga	ators
			Meeting and Sale of RNF and G2	
5970			HHE re G2 Caudal Migration February 15, 2006	
5971			February 8, 2006 Email re Micky Graves	
5972			Feb. 12, 2004 email re sales communique and rate info	rmation
5973			Feb. 1, 2011 Letter from FDA to BPV re Meridian Juga	ılar
			(K102511)	
5974			Complication Rate Chart	
5975			QMBR Jan. 2010	
5976			QMBR Feb. 2009	
5977			QMBR May 2011	
5978			QMBR April 2012	
5979			QMBR Sept. 2012	
5980			Eclipse (Jugular) 2010.02 - PK5100700 rev. 1 IFU	
5981			G2X (Jugular) 2009.03 - PK5100100 rev. 0 IFU	
5982			Complication Rate Chart (2010) – page from BPVEFIL 01-00050487	TER-
5983			EVEREST Adjudication Manual of Operations	
5984			TPR-06-05-02 (SOP re G2® Clot Trapping Efficiency)	
5985			Meridian (Jugular) 2011.08 - PK5372400 rev. 3 IFU	
5986			May 17, 2011 PPT to FDA re Meridian®	
5987			May 17, 2011 PPT to FDA re Meridian	
5988			Filters Complaint History PPT	

Exhibit	Marked for ID	Admitted in Evidence	Description
5989			FM1287100 Rev. 0 (MDR Reportability Guidelines)
5990			FM1287100 Rev. 2 (MDR Reportability Guidelines)
5991		3-28-18	FM1287100 Rev. 5 (MDR Reportability Guidelines)
5992			FM1287100 Rev. 1 (MDR Reportability Guidelines)
5993	The state of the s		TD-04382 Rev. 1 (List of Actions for MDR and Complaint
			Handling in Response to WL and 483)
5994		37818	TD-04316 Nov. 4, 2015 FDA and Bard Teleconference (edock-
5995		378.98	TD-04326 Oct. 26, 2015 FDA and Bard Teleconference vedact
5996			FM1287100 Rev. 3 (MDR Reportability Guidelines)
5997			FM1287100 Rev. 0 (MDR Reportability Guidelines)
5998			Feb. 1, 2011 FDA Conditional Approval of IDE with 31
			questions
5999			August 2010 Letter to Clinicians re FDA PHN
6000			March 21, 2011 email from FDA re Questions 18 and 24
6001			May 5, 2010 email enclosing PPT slides for meeting
6002			Filters Complaint History PPT
6003			May 13, 2010 email and meeting minutes re Denali Pre-IDE
6004			Sept. 30, 2011 email to FDA enclosing responses to AI (K112497)
6005			March 19, 2010 email to FDA enclosing Denali Pre-IDE
6006			June 16, 2011 email from custodial file of Joni Creal with Appendix 1-6
6007			March 16, 2011 email confirming FDA re biocompatibility
6008			Nov. 3, 2011 letter from FDA requesting more info
6009			June 27, 2011 email from custodial file of Joni Creal with Appendix 14 Part A
6010			Dec. 10, 2010 email to FDA confirming Denali regulatory strategy
6011			Feb. 22, 2011 email to FDA re biocompatibility questions 27-31
6012			Dec. 4, 2012 email and attachment to FDA responding to
			informal questions
6013	:		Dec. 27, 2010 Letter from BPV to FDA re Meridian
6014			March 11, 2011 email to FDA with proposed response to Nos. 18 and 24
6015			Feb. 22, 2011 email with FDA re chromosomal aberration testing (Question 3 from Feb. 1 letter)
6016			Nov. 5, 2015 email to Chad Modra re FDA and MDRs
6017			Dec. 3, 2009 Meridian Pre-IDE Meeting Request
6018			May 20-23, 2011 email chain re deficiencies 8 and 9
6019			June 27, 2011 email from custodial file of Joni Creal with Appendix 3-5
6020			22 June 27, 2011 email from custodial file of Joni Creal with Appendix 1 & 2

May 23, 2011 Letter to FDA re Meridian FDA Questions F 1, 2011 Nos 1-7, 10-13	
6022May 23, 2011 Letter to FDA (Appendix 6)6023May 23, 2011 Letter from BPV to FDA (Appendix 8)6024May 23, 2011 Letter from BPV to FDA (Appendix 8)6025August 17, 2011 email with FDA re Meridian IFU changes6026June 27, 2011 email from custodial file of Joni Creal with Appendix 12 & 136027June 27, 2011 email from custodial file of Joni Creal with Appendix 10 & 116028Native Attachment6029June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9603024 June 27, 2011 email from custodial file of Joni Creal with Appendix 6 & 76031Dec. 27, 2010 Appendices to Letter to FDA6032RNF Filter Drawing SA-0030, Rev. 006033NMT Table of Contents for RNF Design History File Phas (Arms Up)6034December 20, 2006 EVEREST Medical Monitor Adjudicat Meeting Minutes Signature Page6035August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page6036June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 30, 2015 email to Chad Modra re FDA and MDRs6038Nov. 30, 2015 email to Chad Modra re FDA and MDRs6039TM1139500 Caudal Migration Push Test Method6040TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method6041TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol6042G2 (Jugular) 2008.01 - PK\$260600 Rev. 0 IFU6043June 2014 Clinical Evaluation Report of SNF Filter6044June 2014 Clinical Evaluation Report of SNF Filter	eb.
6023May 23, 2011 Letter from BPV to FDA (Appendix 8)6024May 23, 2011 Letter from BPV to FDA (Appendix 8)6025August 17, 2011 email with FDA re Meridian IFU changes6026June 27, 2011 email from custodial file of Joni Creal with Appendix 12 & 136027June 27, 2011 email from custodial file of Joni Creal with Appendix 10 & 116028Native Attachment6029June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9603024 June 27, 2011 email from custodial file of Joni Crea with Appendix 6 & 76031Dec. 27, 2010 Appendices to Letter to FDA6032RNF Filter Drawing SA-0030, Rev. 006033NMT Table of Contents for RNF Design History File Phas (Arms Up)6034December 20, 2006 EVEREST Medical Monitor Adjudical Meeting Minutes Signature Page6035August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page6036June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Mov. 5, 2015 email to Chad Modra re FDA and MDRs6038Nov. 5, 2015 email to Chad Modra re FDA and MDRs6039TM1139500 Caudal Migration Push Test Method6040TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method6041TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol6042G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU6043June 2014 Clinical Evaluation Report of SNF Filter6044June 2014 Clinical Evaluation Report of SNF Filter	
6024May 23, 2011 Letter from BPV to FDA (Appendix 8)6025August 17, 2011 email with FDA re Meridian IFU changes6026June 27, 2011 email from custodial file of Joni Creal with Appendix 12 & 136027June 27, 2011 email from custodial file of Joni Creal with Appendix 10 & 116028Native Attachment6029June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9603024 June 27, 2011 email from custodial file of Joni Creal with Appendix 6 & 76031Dec. 27, 2010 Appendices to Letter to FDA6032RNF Filter Drawing SA-0030, Rev. 00NMT Table of Contents for RNF Design History File Phase (Arms Up)6034December 20, 2006 EVEREST Medical Monitor Adjudicat Meeting Minutes Signature Page6035August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page6036June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Mov. 5, 2015 email to Chad Modra re FDA and MDRs6038Nov. 5, 2015 email chain with FDA re MDR Reporting6039TM1139500 Caudal Migration Push Test Method6040TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficiency Test Method6041TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol6042G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU5043June 2014 Clinical Evaluation Report of SNF Filter6044June 2014 Clinical Evaluation Report of SNF Filter	
6025August 17, 2011 email with FDA re Meridian IFU changes6026June 27, 2011 email from custodial file of Joni Creal with Appendix 12 & 136027June 27, 2011 email from custodial file of Joni Creal with Appendix 10 & 116028Native Attachment6029June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9603024 June 27, 2011 email from custodial file of Joni Creal with Appendix 6 & 76031Dec. 27, 2010 Appendices to Letter to FDA6032RNF Filter Drawing SA-0030, Rev. 006033NMT Table of Contents for RNF Design History File Phase (Arms Up)6034December 20, 2006 EVEREST Medical Monitor Adjudicate Meeting Minutes Signature Page6035August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page6036June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 5, 2015 email to Chad Modra re FDA and MDRs6038Nov. 30, 2015 email chain with FDA re MDR Reporting6039TM1139500 Caudal Migration Push Test Method6040TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficiency Test Method6041TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol6042G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU6043June 2014 Clinical Evaluation Report of SNF Filter6044June 2014 Clinical Evaluation Report of SNF Filter	
June 27, 2011 email from custodial file of Joni Creal with Appendix 12 & 13 June 27, 2011 email from custodial file of Joni Creal with Appendix 10 & 11 Native Attachment June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9 6029 June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9 6030 24 June 27, 2011 email from custodial file of Joni Creal with Appendix 6 & 7 Dec. 27, 2010 Appendices to Letter to FDA RNF Filter Drawing SA-0030, Rev. 00 NMT Table of Contents for RNF Design History File Phase (Arms Up) December 20, 2006 EVEREST Medical Monitor Adjudicat Meeting Minutes Signature Page 4035 August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page 4036 June 7, 2010 FDA Contact Report (Denali Pre-IDE Meeting Minutes Signature Page 4037 Nov. 5, 2015 email to Chad Modra re FDA and MDRs 4038 Nov. 30, 2015 email chain with FDA re MDR Reporting 4039 TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficiency Protocol 4040 TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol 4041 TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol 4042 G2 (Jugular) 2008.01 - PK\$260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter	
June 27, 2011 email from custodial file of Joni Creal with Appendix 12 & 13 June 27, 2011 email from custodial file of Joni Creal with Appendix 10 & 11 Native Attachment June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9 4029 June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9 24 June 27, 2011 email from custodial file of Joni Creal with Appendix 6 & 7 Dec. 27, 2010 Appendices to Letter to FDA RNF Filter Drawing SA-0030, Rev. 00 NMT Table of Contents for RNF Design History File Phase (Arms Up) December 20, 2006 EVEREST Medical Monitor Adjudicated Meeting Minutes Signature Page 4035 August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meeting Minutes Signature Page June 7, 2015 email to Chad Modra re FDA and MDRs Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficiency Protocol TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK\$260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter	1
Appendix 12 & 13 June 27, 2011 email from custodial file of Joni Creal with Appendix 10 & 11 Native Attachment June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9 24 June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 7 Dec. 27, 2010 Appendices to Letter to FDA RNF Filter Drawing SA-0030, Rev. 00 NMT Table of Contents for RNF Design History File Phase (Arms Up) December 20, 2006 EVEREST Medical Monitor Adjudicated Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meeting Minutes Signature Page June 7, 2015 email to Chad Modra re FDA and MDRs Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficiency Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter	
Appendix 10 & 11 6028 Native Attachment 1 June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9 6030 24 June 27, 2011 email from custodial file of Joni Crea with Appendix 8 & 7 6031 Dec. 27, 2010 Appendices to Letter to FDA 6032 RNF Filter Drawing SA-0030, Rev. 00 6033 NMT Table of Contents for RNF Design History File Phase (Arms Up) 6034 December 20, 2006 EVEREST Medical Monitor Adjudical Meeting Minutes Signature Page 6035 August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page 6036 June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Mov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email to Chad Modra re FDA re MDR Reporting 6039 TM1139500 Caudal Migration Push Test Method 6040 TM139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method 6041 TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU 6043 June 2014 Clinical Evaluation Report of SNF Filter 6044 June 27, 2011 email from custodial file of Joni Creal with	
Appendix 10 & 11 Native Attachment June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9 6030 24 June 27, 2011 email from custodial file of Joni Crea with Appendix 8 & 7 Dec. 27, 2010 Appendices to Letter to FDA RNF Filter Drawing SA-0030, Rev. 00 NMT Table of Contents for RNF Design History File Phase (Arms Up) 6034 December 20, 2006 EVEREST Medical Monitor Adjudicate Meeting Minutes Signature Page 6035 August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page 6036 June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Mov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email contain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	
June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9 6030 24 June 27, 2011 email from custodial file of Joni Crea with Appendix 6 & 7 Dec. 27, 2010 Appendices to Letter to FDA RNF Filter Drawing SA-0030, Rev. 00 NMT Table of Contents for RNF Design History File Phas (Arms Up) December 20, 2006 EVEREST Medical Monitor Adjudicat Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Mov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter	
June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9 24 June 27, 2011 email from custodial file of Joni Crea with Appendix 6 & 7 Dec. 27, 2010 Appendices to Letter to FDA RNF Filter Drawing SA-0030, Rev. 00 NMT Table of Contents for RNF Design History File Phase (Arms Up) December 20, 2006 EVEREST Medical Monitor Adjudicated Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter	
Appendix 8 & 9 24 June 27, 2011 email from custodial file of Joni Crea with Appendix 6 & 7 Dec. 27, 2010 Appendices to Letter to FDA RNF Filter Drawing SA-0030, Rev. 00 NMT Table of Contents for RNF Design History File Phase (Arms Up) December 20, 2006 EVEREST Medical Monitor Adjudicate Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficiency Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	
with Appendix 6 & 7 Dec. 27, 2010 Appendices to Letter to FDA RNF Filter Drawing SA-0030, Rev. 00 NMT Table of Contents for RNF Design History File Phase (Arms Up) December 20, 2006 EVEREST Medical Monitor Adjudicated Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	
with Appendix 6 & 7 Dec. 27, 2010 Appendices to Letter to FDA RNF Filter Drawing SA-0030, Rev. 00 NMT Table of Contents for RNF Design History File Phase (Arms Up) December 20, 2006 EVEREST Medical Monitor Adjudicated Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	al
Dec. 27, 2010 Appendices to Letter to FDA	
RNF Filter Drawing SA-0030, Rev. 00 NMT Table of Contents for RNF Design History File Phase (Arms Up) December 20, 2006 EVEREST Medical Monitor Adjudicated Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meeting Monitor Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficiency Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	
NMT Table of Contents for RNF Design History File Phase (Arms Up) December 20, 2006 EVEREST Medical Monitor Adjudicate Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	
(Arms Up) December 20, 2006 EVEREST Medical Monitor Adjudicat Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	e II
December 20, 2006 EVEREST Medical Monitor Adjudicate Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meeting Mov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficiency Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	
Meeting Minutes Signature Page August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	tion
August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	
Meeting Minutes Signature Page June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficience Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	1
June 7, 2010 FDA Contact Report (Denali Pre-IDE Meetin Nov. 5, 2015 email to Chad Modra re FDA and MDRs Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	
6037Nov. 5, 2015 email to Chad Modra re FDA and MDRs6038Nov. 30, 2015 email chain with FDA re MDR Reporting6039TM1139500 Caudal Migration Push Test Method6040TM1139200 Rev 0, In Vitro Filter Clot Trapping EfficiencTest MethodTPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol6041G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU6043June 2014 Clinical Evaluation Report of SNF Filter6044June 27, 2011 email from custodial file of Joni Creal with	<u>g)</u>
Nov. 30, 2015 email chain with FDA re MDR Reporting TM1139500 Caudal Migration Push Test Method TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	
6039TM1139500 Caudal Migration Push Test Method6040TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficienc Test Method6041TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol6042G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU6043June 2014 Clinical Evaluation Report of SNF Filter6044June 27, 2011 email from custodial file of Joni Creal with	
TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficiency Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	
Test Method TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	y
6041TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol6042G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU6043June 2014 Clinical Evaluation Report of SNF Filter6044June 27, 2011 email from custodial file of Joni Creal with	
6042 G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU 6043 June 2014 Clinical Evaluation Report of SNF Filter 6044 June 27, 2011 email from custodial file of Joni Creal with	
June 2014 Clinical Evaluation Report of SNF Filter June 27, 2011 email from custodial file of Joni Creal with	
June 27, 2011 email from custodial file of Joni Creal with	
Appendix 14 Part B	
6045 December 20, 2006 EVEREST Medical Monitor Adjudica	tion
Meeting Minutes	
August 28, 2006 EVEREST Medical Monitor Adjudication	n
3-33-18 August 28, 2000 EVEREST Wedlear Workfor August 28, 2000 EVEREST Wedlear Wedlea	
Booker Complaint MDR	
6048 Booker Device History Record	nere :
6049 2007.02.20 Response to Questions about the Recall of G2	Filter
System- Jugular/ Subclavian Delivery Kit	
6050 2006.12.01 Health Hazard Evaluation - Updated	

Exhibit	Marked for ID	Admitted in Evidence	Description			
6051			2006.12.22 G2 Filter System – Jugular/ Subclavian Delivery Kit			
6052			2008.10.23 Summary and Termination Validation			
6053			2008.09.22 Bard Peripheral Vascular (BPV) Recalls			
6054			2007.01.16 Bard G2 Filter System – Jugular/ Subclavian			
			Delivery Kit			
6055			2006.12.20 Urgent Production Recall Notification			
6056			2007.02.02 Recall Z-0393-2007 Bard G2 Filter System –			
			Jugular/ Subclavian Delivery Kit, Catalog Number RF-320J			
6057			2006.12.12 Recall Enterprise System Recall Details			
6058			K050558			
6059			Aug. 29, 2005 Fax BPV to FDA re G2 (K050558)			
6060			Aug. 26, 2005 Fax FDA to BPV re G2 (K050558)			
6061		\2 .S/	Aug. 22, 2005 Internal FDA memo reviewing BPV's Responses			
		77 23-18	to FDA AI re G2 (K050558) Subj. to redaction			
6062			Aug. 22, 2005 Bard email to FDA enclosing revised IFU			
6063			July 26, 2005 FDA Reviewer Memo for G2 510(k) (K050558)			
6064		0.32.366	July 26, 2005 Internal FDA memo re BPV Responses to FDA			
		3-23-18	AI re Modified Recovery (K050558) Sub, to sedaction			
6065			May 2, 2005 Internal FDA memo reviewing animal study re			
			Modified Recovery (K050558)			
6066			Apr. 19, 2005 BPV's Informal Responses to FDA AI Letter re			
			Modified Recovery (K050558)			
6067			BPV's Informal Responses to FDA AI Letter re Modified			
			Recovery (K050558)			
6068			March 28, 2005 FDA Reviewer Memo for G2 510(k)			
			(K050558)			
6069			Mar. 29, 2005 Internal FDA memo re Modified Recovery			
			(K050558)			
6070			2005.08.29 Summary of Safety and Effectiveness			
6071			Maude Adverse Event Report: Bard Peripheral Vascular Bard			
			G2 Filter System Femoral IVC Filter			
6072			2006.12.22 G2 Filter System – Jugular/ Subclavian Delivery Kit			
6073			FDA file re Recovery; Filter obtained from FOIA services			
6074			Nov. 29, 2004 FDA Reviewer Memo re Dear Doctor Letter			
6075			Nov. 10, 2004 FDA Internal Memo re Dear Doctor Letter			
6076			Nov. 10, 2004 Internal FDA Email chain re Recovery IFU and DDL			
6077			July 25, 2003 Internal FDA Memo re Recovery Retrievable (K031328)			
6078			July 22, 2004 Internal FDA Memorandum re Recovery Retrievable (K031328)			
6079			Internal FDA Memorandum re Recovery Retrievable (K031328)			

Exhibit	Marked for ID	Admitted in Evidence	Description	
6080			July 17, 2003 Email strings re FDA request for information	ation
			concerning sterilization	
6081			Email chain FDA and BPV re Recovery Retrievable (K	031328)
6082			FDA_PRODUCTION_00001288 July 2, 2003 Emai	chain
			FDA and BPV re Recovery Retrievable (K031328)	
6083			July 2003 FDA Internal Reviewer Memo re Recovery; 510(k)	Filter
6084			FDA file re Eclipse Filter obtained from FOIA services	
6085			K022236.pdf	
6086			K080669 - 510K G2 Express Filter System.pdf	
6087			K101431 - Eclipse.pdf	
6088			K894703.pdf	<u> </u>
6089			Product Development Cycle PPT	
6090			Selected medical records for York Hospital study patie	nt 87
6091			Selected medical records for York Hospital study patie	
6092			Selected medical records for York Hospital study patie	
6093			Selected medical records for York Hospital study patie	
6094			Selected medical records for York Hospital study paties	
6095			Selected medical records for York Hospital study paties	
6096			Selected medical records for York Hospital study paties	
6097			York Hospital procedure log from surgical suite	11. 67
6098			York Hospital procedure log from interventional radiol	ogy suite
6099			Selected records for York Hospital study patient 40	ogy suite
6100			Selected medical records for York Hospital study patient	nt 87
6101			IVC filter insertion records on the 13 patients with filte	
0101			fractures listed in Table 2 of the Nicholson study	
6102			IVC filter insertion records on the 13 patients with filte	r
0102			fractures listed in Table 2 of the Nicholson study	
6103			IVC filter insertion records on the 13 patients with filte	
0105			fractures listed in Table 2 of the Nicholson study	
6104			IVC filter insertion records on the 13 patients with filte	r
			fractures listed in Table 2 of the Nicholson study	
6105			IVC filter insertion records on the 13 patients with filter	<u>-</u>
			fractures listed in Table 2 of the Nicholson study	
6106			IVC filter insertion records on the 13 patients with filter	
			fractures listed in Table 2 of the Nicholson study	
6107			Selected medical records for York Hospital Study patie	nt 36
6108			Selected records for York Hospital study patient 40	-
6109			IVC filter insertion records on the 13 patients with filter	•
			fractures listed in Table 2 of the Nicholson study	
6110			IVC filter insertion records on the 13 patients with filter	
			fractures listed in Table 2 of the Nicholson study	

Exhibit	Marked for ID	Admitted in Evidence	Description			
6111			IVC filter insertion records on the 13 patients with filter			
			fractures listed in Table 2 of the Nicholson study			
6112			IVC filter insertion records on the 13 patients with filter			
			fractures listed in Table 2 of the Nicholson study			
6113			Selected medical records for York Hospital Study patient 76			
6114			Selected medical records for York Hospital Study patient 76			
6115			Selected medical records for York Hospital Study patient 77			
6116			Selected medical records for York Hospital Study patient 84			
6117			Selected medical records for York Hospital study patient 85			
6118			Selected medical records for York Hospital study patient 85			
6119			Selected medical records for York Hospital study patient 85			
6120			IVC filter insertion records on the 13 patients with filter			
			fractures listed in Table 2 of the Nicholson study			
6121			Selected medical records for York Hospital study patient 87			
6122			Letters from FDA to Dr. Nicholson regarding complaints			
6123			Letter from FDA to Dr. Nicholson regarding complaint			
6124			Letter from FDA to Dr. Nicholson regarding MedWatch report			
6125			Email between York Hospital researchers regarding assessment			
			of rate of fracture			
6126			York Hospital November 11, 2009, Meeting Minutes			
6127			York Hospital January 14, 2009, Meeting Minutes			
6128			Letter from York Hospital to Dr. Nicholson regarding IRB			
			review and oversight of York Hospital Study			
6129			Letter from Schulz to Moffett regarding visit at York			
6130			Email from Bard to York Hospital regarding York Hospital			
			Study			
6131			Emails between Bard and Barbara Delio-Cox regarding York			
			Hospital Study			
6132			Emails between Bard and Barbara Delio-Cox regarding York			
			Hospital Study			
6133			Emails between York Hospital employees regarding meeting			
			with Dr. Nicholson and FDA			
6134			Emails between York Hospital employees about non-consenting			
			patients			
6135			Chart of York Hospital study patients			
6136			Chart of York Hospital study patients			
6137			Selected medical records for York Hospital Study patient 86			
6138			Selected medical records for York Hospital Study patient 86			
6139			Selected medical records for York Hospital study patient 85			
5140]	Emails between York Hospital and Dr. Nicholson regarding			
			press coverage of publication of York Hospital Study			
5141		Î	Emails between Dr. Nicholson and FDA regarding York			
		I I	Hospital Study			

procedure log Emails between York Hospital and Dr. Nicholson regarding number of Bard filters used at the hospital Email from JAMA to Dr. Nicholson regarding publication of York Hospital Study manuscript Email to Nicholson from Walcott regarding FDA Med Watch Report Email from Delio Cox to Walcott regarding fracture report Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters Email from Bard to Dr. Nicholson regarding Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from FDA to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from York Hospital to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Emails between Dr. Nicholson and Colleague regarding publication of York Hospital Study	Exhibit	Marked for ID	Admitted in Evidence	Description	
Section	6142			Email from FDA to Dr. Nicholson regarding Study	
6144 Emails between York Hospital researchers regarding study protocol 6145 Emails between Dr, Nicholson and colleague regarding study publication Dec. 17, 2009 Email to Nicholson re Embolized Filters 6146 Email from FDA to Dr. Nicholson regarding Study 6147 Email from Bard to Dr. Nicholson regarding York Hospital Study 6148 Email from Bard to Dr. Nicholson regarding York Hospital Study 6149 Email from FDA to Dr. Nicholson regarding Bard IVC filters 6150 Email from York Hospital to Dr. Nicholson attaching surgical procedure log 6151 Email from York Hospital to Dr. Nicholson regarding number of Bard filters used at the hospital 6152 Emails between York Hospital and Dr. Nicholson regarding number of Bard filters used at the hospital 6153 Email from JAMA to Dr. Nicholson regarding publication of York Hospital Study manuscript 6154 Email to Nicholson from Walcott regarding FDA MedWatch Report 6155 Email from Delio Cox to Walcott regarding fracture report 6156 Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and 62 Filters 6158 Email from Dr. Nicholson to FDA regarding Study 6159 Email from Bard to Dr. Nicholson regarding York Hospital Study 6160 Email from Bard to Dr. Nicholson regarding York Hospital Study 6160 Email from Bard to Dr. Nicholson regarding patients in study 6161 Email from NEJM to Dr. Nicholson regarding patients in study 6162 Email from Bard to Dr. Nicholson regarding Pork Hospital Study 6163 Email from Bard to Dr. Nicholson regarding Pork Hospital Study 6164 Email from Bard to Dr. Nicholson regarding Vork Hospital Study 6165 Email from Bard to Dr. Nicholson negarding Pork Hospital Study 6166 Email from Dr. Nicholson and Dr. Lynch regarding Pork Hospital Study 6167 Emails between Dr. Nicholson and Colleague regarding publication of York Hospital Study 6168 Emails between Dr. Nicholson and Colleague regarding publication of York Hospital Study 6169 Emails between Dr. Nicholson and Colleague regarding publication of York Hospital Study	6143			York Hospital Study Protocol	
publication Dec. 17, 2009 Email to Nicholson re Embolized Filters Email from FDA to Dr. Nicholson regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Dr. Nicholson to co-author of York Hospital Study Email from PDA to Dr. Nicholson regarding Bard IVC filters Email from York Hospital to Dr. Nicholson attaching surgical procedure log Emails between York Hospital and Dr. Nicholson regarding number of Bard filters used at the hospital Email from JAMA to Dr. Nicholson regarding publication of York Hospital Study manuscript Email to Nicholson from Walcott regarding FDA Med Watch Report Email from Delio Cox to Walcott regarding fracture report Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters Email from Dr. Nicholson to FDA regarding Study Email from Bard to Dr. Nicholson regarding patients in study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from Bard to Dr. Nicholson and Dr. Lynch regarding Pork Hospital Study Email from Bard to Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson and colleague regarding publication of York Hospital Study	6144			Emails between York Hospital researchers regarding s	tudy
Email from Archives of Internal Medicine to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Dr. Nicholson to co-author of York Hospital Study Email from PDA to Dr. Nicholson regarding Bard IVC filters Email from York Hospital to Dr. Nicholson attaching surgical procedure log Emails between York Hospital and Dr. Nicholson regarding number of Bard filters used at the hospital Email from JAMA to Dr. Nicholson regarding publication of York Hospital Study manuscript Email from Delio Cox to Walcott regarding FDA MedWatch Report Email from Delio Cox to Walcott regarding fracture report Email from Delio Cox to Walcott regarding fracture report Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters Email from Bard to Dr. Nicholson to FDA regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding Policial Study Email from Bard to Dr. Nicholson regarding Policial Study Email from Bard to Dr. Nicholson regarding Policial Email from Policial Dr. Nicholson regarding Policial Email from Bard to Dr. Nicholson Policial Study Email from Bard to Dr. Nicholson Regarding York Hospital Study Email from Bard to Dr. Nicholson Regarding York Hospital Study Email Setween Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson and Colleague regarding publication of York Hospital Study				publication Dec. 17, 2009 Email to Nicholson re Embo	g study olized
Email from Bard to Dr. Nicholson regarding York Hospital Study	6146			Email from FDA to Dr. Nicholson regarding Study	
Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Dr. Nicholson to co-author of York Hospital Study Email from PDA to Dr. Nicholson regarding Bard IVC filters Email from York Hospital to Dr. Nicholson attaching surgical procedure log Emails between York Hospital and Dr. Nicholson regarding number of Bard filters used at the hospital Email from JAMA to Dr. Nicholson regarding publication of York Hospital Study manuscript Email to Nicholson from Walcott regarding FDA Med Watch Report Email from Delio Cox to Walcott regarding fracture report Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters Email from Bard to Dr. Nicholson regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding Political Study Email from Bard to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson regarding Vork Hospital Study Email from Sard to Dr. Nicholson regarding Political Email from NEJM to Dr. Nicholson regarding Political Email from Sard to Dr. Nicholson regarding Vork Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding INC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6147			Email from Archives of Internal Medicine to Dr. Niche	olson
Email from FDA to Dr. Nicholson regarding Bard IVC filters	6148			Email from Bard to Dr. Nicholson regarding York Hos	
Email from FDA to Dr. Nicholson regarding Bard IVC filters	6149			Email from Dr. Nicholson to co-author of York Hospit	al Study
Email from York Hospital to Dr. Nicholson attaching surgical procedure log Emails between York Hospital and Dr. Nicholson regarding number of Bard filters used at the hospital Email from JAMA to Dr. Nicholson regarding publication of York Hospital Study manuscript Email to Nicholson from Walcott regarding FDA MedWatch Report Email from Delio Cox to Walcott regarding fracture report Email from Delio Cox to Walcott regarding fracture report Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters Email from Dr. Nicholson to FDA regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from York Hospital and Dr. Nicholson regarding HIPAA Emails between York Hospital to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding Pork Hospital Study Email from Dr. Nicholson regarding York Hospital Study Email from Dr. Nicholson regarding York Hospital Study Email from Dr. Nicholson regarding York Hospital Study Email from Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6150			Email from FDA to Dr. Nicholson regarding Bard IVC	filters
number of Bard filters used at the hospital Email from JAMA to Dr. Nicholson regarding publication of York Hospital Study manuscript Email to Nicholson from Walcott regarding FDA MedWatch Report Email from Delio Cox to Walcott regarding fracture report Email from Delio Cox to Walcott regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters Email from Dr. Nicholson to FDA regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding patients in study Email from York Hospital to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson Email from Bard to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Email from NEJM to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson and colleague regarding publication of York Hospital Study	6151			Email from York Hospital to Dr. Nicholson attaching s	urgical
Email from JAMA to Dr. Nicholson regarding publication of York Hospital Study manuscript Email to Nicholson from Walcott regarding FDA MedWatch Report Email from Delio Cox to Walcott regarding fracture report Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters Email from Dr. Nicholson to FDA regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between York Hospital and Dr. Nicholson regarding HIPAA Email from NEJM to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from NEJM to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson and Colleague regarding publication of York Hospital Study	6152			Emails between York Hospital and Dr. Nicholson reganumber of Bard filters used at the hospital	rding
Email to Nicholson from Walcott regarding FDA MedWatch Report Email from Delio Cox to Walcott regarding fracture report Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters Email from Dr. Nicholson to FDA regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from FDA to Dr. Nicholson regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding HIPAA Emails between York Hospital and Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson Email from NEJM to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6153			Email from JAMA to Dr. Nicholson regarding publicat	ion of
Email from Delio Cox to Walcott regarding fracture report Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters Email from Dr. Nicholson to FDA regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from FDA to Dr. Nicholson regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding york Hospital Study Emails between York Hospital and Dr. Nicholson regarding HIPAA Email from York Hospital to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson Email from Bard to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6154			Email to Nicholson from Walcott regarding FDA Med	Watch
Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters Email from Dr. Nicholson to FDA regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from FDA to Dr. Nicholson regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between York Hospital and Dr. Nicholson regarding HIPAA Email from York Hospital to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson Email from NEJM to Dr. Nicholson regarding York Hospital Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from Dr. Nicholson and Dr. Lynch regarding IVC filter patient Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6155				nort
Email from Dr. Nicholson to FDA regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Email from FDA to Dr. Nicholson regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between York Hospital and Dr. Nicholson regarding HIPAA Email from York Hospital to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson Email from Bard to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6156			Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re R	
Email from Bard to Dr. Nicholson regarding York Hospital Study Email from FDA to Dr. Nicholson regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between York Hospital and Dr. Nicholson regarding HIPAA Email from York Hospital to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson Email from Bard to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6157				
Email from FDA to Dr. Nicholson regarding Study Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between York Hospital and Dr. Nicholson regarding HIPAA Email from York Hospital to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson Email from Bard to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6158			Email from Bard to Dr. Nicholson regarding York Hos	pital
Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between York Hospital and Dr. Nicholson regarding HIPAA Email from York Hospital to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson Email from Bard to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6159				
Emails between York Hospital and Dr. Nicholson regarding HIPAA Email from York Hospital to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6160			Email from Bard to Dr. Nicholson regarding York Hosp	oital
Email from York Hospital to Dr. Nicholson regarding patients in study Email from NEJM to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6161			Emails between York Hospital and Dr. Nicholson regar	ding
Email from NEJM to Dr. Nicholson Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6162			Email from York Hospital to Dr. Nicholson regarding p	atients
Email from Bard to Dr. Nicholson regarding York Hospital Study Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6163				
Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6164			Email from Bard to Dr. Nicholson regarding York Hosp	ital
Email from Dr. Nicholson to FDA regarding Study Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6165			Emails between Dr. Nicholson and Dr. Lynch regarding	IVC
Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	6166				
	6167			Emails between Dr. Nicholson and colleague regarding	
Zimin from 1 Dr. to Dr. Micholson regarding Study	6168			Email from FDA to Dr. Nicholson regarding Study	

Exhibit	Marked for ID	Admitted in Evidence	Description	
6169			Email from Dr. Nicholson to FDA regarding Study	
6170			Emails between Dr. Nicholson and the Archives of Inte	rnal
			Medicine regarding publication of York Hospital Study	
6171			Email from Dr. Nicholson to FDA regarding York Hos	pital
			Study	•
6172			Email from Dr. Nicholson to FDA regarding Study	
6173			Note from Dr. Nicholson to an editor attaching table of	his
			study patients	
6174			Draft of Dr. Nicholson article	
6175			Email from Dr. Nicholson to Christopher Tuohy regard	ing
			statistical analysis of York Hospital Study	
6176			Deposition of Carol Vierling, taken May 11, 2016, Exhi	
6177			Deposition of Carol Vierling, taken May 11, 2016, Exhi	bit 212
6178			Deposition of Carol Vierling, taken May 11, 2016, Exhi	bit 226
6179			Deposition of Carol Vierling, taken May 11, 2016, Exhi	bit 227
6180			Deposition of Carol Vierling, taken May 11, 2016, Exhi	bit 236
6181			Deposition of Carol Vierling, taken May 11, 2016, Exhi	bit 240
6182			Deposition of Carol Vierling, taken May 11, 2016, Exhi	bit 244
6183			Deposition of Carol Vierling, taken May 11, 2016, Exhi	bit 245
6184			Deposition of Carol Vierling, taken May 11, 2016, Exhi	bit 247
6185			Deposition of Kay Fuller, taken January 11, 2016, Exhib	oit 140
6186			Deposition of Kay Fuller, taken January 11, 2016, Exhi	bit 153
6187			Deposition of Kay Fuller, taken January 11, 2016, Exhi	bit 161
6188			Deposition of Kay Fuller, taken January 11, 2016, Exhi	bit 164
6189			Deposition of Kay Fuller, taken January 11, 2016, Exhi	bit 168
6190			Deposition of Carol Vierling, taken May 5, 2011, Exhib	it 226
6191			Deposition of Carol Vierling, taken May 5, 2011 Exhibit	it 242
6192			Deposition of Carol Vierling, taken May 5, 2011, Exhib	oit 247
6193			Deposition of Mary Edwards, taken August 19, 2016, Ex 355	khibit
6194			Deposition of Mary Edwards, taken August 19, 2016, Ex 356	chibit
6195			Deposition of Mary Edwards, taken August 19, 2016, Ex 357	hibit
6196			Deposition of Mary Edwards, taken August 19, 2016, Ex 358	hibit
6197			Deposition of Mary Edwards, taken August 19, 2016, Ex 360	hibit
6198			Deposition of Dr. David Ciavarella, taken November 12, Exhibit 21	2013,
6199			Deposition of Dr. David Ciavarella, taken November 12, Exhibit 23	2013,

Exhibit	Marked for ID	Admitted in Evidence	Description
6200			Deposition of Dr. David Ciavarella, taken November 12, 2013, Exhibit 35
6201			Deposition of Dr. David Ciavarella, taken November 12, 2013, Exhibit 39
6202			Deposition of Gin Schulz, taken January 30, 2014, Exhibit 2
6203			Deposition of Gin Schulz, taken January 30, 2014, Exhibit 10
6204			Deposition of Gin Schulz, taken January 30, 2014, Exhibit 11
6205			Deposition of Gin Schulz, taken January 30, 2014, Exhibit 12
6206			Deposition of Gin Schulz, taken January 30, 2014, Exhibit 15
6207			Deposition of Gin Schulz, taken January 30, 2014, Exhibit 17
6208			Deposition of Robert Ferrara, taken April 7, 2017, Exhibit 3
6209			Deposition of Robert Ferrara, taken April 7, 2017, Exhibit 11
6210			Deposition of Sherr-Una Booker, taken on 2/20/2017, Exhibit 1: Plaintiff Profile Form
6211			Deposition of Sherr-Una Booker, taken on 2/20/2017, Exhibit 2: Plaintiff Fact Sheet
6212			Deposition of Sherr-Una Booker, taken on 2/20/2017, Exhibit 3: Supplemental Fact Sheet
6213			Deposition of Sherr-Una Booker, taken on 2/20/2017, Exhibit 4: Supplemental Fact Sheet
6214			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit 1: Curriculum vitae
6215			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A: Medical Chart
6216			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A1: Consultation record dated 1/3/12
6217			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A2:
6218		İ	Retrieval procedure record authored by Dr. Kang dated 7/23/14 Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A3: X-ray report dated 7/3/14
6219			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A4: Consultation note dated 7/23/14 authored by Dr. Heller
6220			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A5: Hospital chart
6221			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A6: TEE record
6222			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A7: Informed consent forms
6223			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A10: Dr. Richard Harvey's operative Report dated 7/28/14
6224]	Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A11: Surgical pathology report
6225		1	Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A12: Discharge summary

Exhibit	Marked for ID	Admitted in Evidence	Description
6226			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A13: Office notes
6227			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A14: Office Notes
6228			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A15: CT scan report
6229			Deposition of Salil Patel, MD, taken on 3/22/2017, Exhibit A16: Office notes 8/8/16
6230			Deposition of Scott Trerotola, M.D., taken 1/20/17, Exhibit 688
6231			Deposition of S. William Stavropoulos, M.D., taken 2/1/2017, Exhibit 827
6232			2011.05.23 deposition of Robert Ritchie Exhibit 1
6233			2011.05.23 deposition of Robert Ritchie Exhibit 2
6234			2011.05.23 deposition of Robert Ritchie Exhibit 3
6235			2011.05.23 deposition of Robert Ritchie Exhibit 4
6236			2011.05.23 deposition of Robert Ritchie Exhibit 5
6237			2011.05.23 deposition of Robert Ritchie Exhibit 6
6238			2011.05.23 deposition of Robert Ritchie Exhibit 7
6239			2011.05.23 deposition of Robert Ritchie Exhibit 8
6240			2011.05.23 deposition of Robert Ritchie Exhibit 9
6241			2011.05.23 deposition of Robert Ritchie Exhibit 10
6242			2011.05.23 deposition of Robert Ritchie Exhibit 11
6243			2011.05.24 deposition of Robert McMeeking Exhibit 1
6244			2011.05.24 deposition of Robert McMeeking Exhibit 2
6245			2011.05.24 deposition of Robert McMeeking Exhibit 3
6246			2011.05.24 deposition of Robert McMeeking Exhibit 4
6247			2011.05.24 deposition of Robert McMeeking Exhibit 5
6248			2011.05.24 deposition of Robert McMeeking Exhibit 6
6249			2011.05.24 deposition of Robert McMeeking Exhibit 7
6250			2012.04.02 deposition of Robert Ritchie Exhibit 01
6251			2012.04.02 deposition of Robert Ritchie Exhibit 02
6252			2012.04.02 deposition of Robert Ritchie Exhibit 03
6253			2012.04.02 deposition of Robert Ritchie Exhibit 04
6254			2012.04.02 deposition of Robert Ritchie Exhibit 05
6255			2012.04.02 deposition of Robert Ritchie Exhibit 06
6256			2012.04.02 deposition of Robert Ritchie Exhibit 07
6257			2012.04.02 deposition of Robert Ritchie Exhibit 08
6258			2012.04.02 deposition of Robert Ritchie Exhibit 09
6259			2012.04.02 deposition of Robert Ritchie Exhibit 10
6260			2012.04.02 deposition of Robert Ritchie Exhibit 11
6261			2014.04.22 McMeeking Depo Exhibit 01
6262			2014.04.22 McMeeking Depo Exhibit 02
6263			2014.04.22 McMeeking Depo Exhibit 03

Exhibit	Marked for ID	Admitted in Evidence	Description	
6264			2014.04.22 McMeeking Depo Exhibit 04	
6265			2014.04.22 McMeeking Depo Exhibit 05	
6266			2014.04.22 McMeeking Depo Exhibit 06	
6267			2014.04.22 McMeeking Depo Exhibit 07	
6268			2014.05.08 Ritchie Depo Exhibit 01	
6269			2014.05.08 Ritchie Depo Exhibit 02	
6270			2014.05.08 Ritchie Depo Exhibit 03	
6271			2014.05.08 Ritchie Depo Exhibit 04	
6272			2014.05.08 Ritchie Depo Exhibit 05	
6273			2014.05.08 Ritchie Depo Exhibit 06	
6274			2014.05.08 Ritchie Depo Exhibit 07	
6275			2014.06.13 Parisian Depo Exhibit 01	
6276			2014.06.13 Parisian Depo Exhibit 02	
6277			2014.06.13 Parisian Depo Exhibit 03	
6278			2014.06.13 Parisian Depo Exhibit 04	
5279			2014.06.13 Parisian Depo Exhibit 05	
5280			2014.06.13 Parisian Depo Exhibit 06	
5281			2014.06.13 Parisian Depo Exhibit 07	
5282			2014.06.13 Parisian Depo Exhibit 08	
5283			2014.06.13 Parisian Depo Exhibit 09	
5284			2014.06.13 Parisian Depo Exhibit 10	
5285			2014.06.13 Parisian Depo Exhibit 11	
5286			2014.06.13 Parisian Depo Exhibit 12	
5287			2014.06.13 Parisian Depo Exhibit 13	
5288			2014.06.13 Parisian Depo Exhibit 14	
289		-	2014.06.13 Parisian Depo Exhibit 15	
290			2014.06.13 Parisian Depo Exhibit 16	
291			2014.06.13 Parisian Depo Exhibit 17	
292			2014.06.13 Parisian Depo Exhibit 18	
293			2014.09.25 Parisian Depo Exhibit 01	
294			2014.09.25 Parisian Depo Exhibit 02	
295			2014.09.25 Parisian Depo Exhibit 03	
296			2014.09.25 Parisian Depo Exhibit 04	
297			2014.09.25 Parisian Depo Exhibit 05	
298			2014.12.18 Parisian Depo - CD	
299			2014.12.18 Parisian Depo Exhibit 01	
300			2014.12.18 Parisian Depo Exhibit 02	
301			2014.12.18 Parisian Depo Exhibit 03	
302			2014.12.18 Parisian Depo Exhibit 04	
303			2014.12.18 Parisian Depo Exhibit 05	
304			2014.12.18 Parisian Depo Exhibit 06	
305			2014.12.18 Parisian Depo Exhibit 07	
306			2014.12.18 Parisian Depo Exhibit 08	

Exhibit	Marked for ID	Admitted in Evidence	Description
6307			2014.12.18 Parisian Depo Exhibit 09
6308			2014.12.18 Parisian Depo Exhibit 10
6309			2014.12.18 Parisian Depo Exhibit 11
6310			2014.12.18 Parisian Depo Exhibit 12
6311			2014.12.18 Parisian Depo Exhibit 13
6312			2014.12.18 Parisian Depo Exhibit 14
6313			2014.12.18 Parisian Depo Exhibit 15
6314			2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert
			Deposition Exhibit 01
6315			2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert
			Deposition Exhibit 02
6316			2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert
			Deposition Exhibit 03
6317			2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert
			Deposition Exhibit 04
6318			2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert
			Deposition Exhibit 05
6319			2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert
			Deposition Exhibit 06
6320			2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert
			Deposition Exhibit 07
6321			2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert
			Deposition Exhibit 08
6322			2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert
			Deposition Exhibit 09
6323			2015.05.01 Robert Ritchie Deposition Exhibit 01
6324			2015.05.01 Robert Ritchie Deposition Exhibit 02
6325			2015.05.01 Robert Ritchie Deposition Exhibit 03
6326			2015.05.01 Robert Ritchie Deposition Exhibit 04
6327			2015.05.01 Robert Ritchie Deposition Exhibit 05
6328			2015.05.05 Suzanne Parisian Deposition Exhibit 01
6329			2015.05.05 Suzanne Parisian Deposition Exhibit 02
6330			2015.05.05 Suzanne Parisian Deposition Exhibit 03
6331			2015.05.05 Suzanne Parisian Deposition Exhibit 04
6332			2015.05.05 Suzanne Parisian Deposition Exhibit 05
6333			2015.05.05 Suzanne Parisian Deposition Exhibit 06
6334			2015.05.05 Suzanne Parisian Deposition Exhibit 07
6335			2015.05.05 Suzanne Parisian Deposition Exhibit 08
6336			2015.05.05 Suzanne Parisian Deposition Exhibit 09
6337			2015.05.05 Suzanne Parisian Deposition Exhibit 10
6338			2015.05.05 Suzanne Parisian Deposition Exhibit 11
6339			2015.05.05 Suzanne Parisian Deposition Exhibit 12
6340			2015.05.05 Suzanne Parisian Deposition Exhibit 13

Exhibit	Marked for ID	Admitted in Evidence	Description	
6341			2015.05.05 Suzanne Parisian Deposition Exhibit 14	
6342			2016.07.21 Derek Muehrcke Exhibit 01	
6343			2016.07.21 Derek Muehrcke Exhibit 02	
6344			2016.07.21 Derek Muehrcke Exhibit 03	
6345			2016.07.21 Derek Muehrcke Exhibit 04	
6346			2016.07.21 Derek Muehrcke Exhibit 05	
6347			2016.07.21 Derek Muehrcke Exhibit 06	
6348			2016.07.21 Derek Muehrcke Exhibit 07	
6349			2016.07.21 Derek Muehrcke Exhibit 08	
6350			2016.07.21 Derek Muehrcke Exhibit 09	
6351			2016.07.21 Derek Muehrcke Exhibit 10	
6352			2016.07.21 Derek Muehrcke Exhibit 11	
6353			2016.07.21 Derek Muehrcke Exhibit 12	
6354			2016.07.21 Derek Muehrcke Exhibit 13	
6355			2016.07.21 Derek Muehrcke Exhibit 14	
6356			2016.07.21 Derek Muehrcke Exhibit 15	
6357			2016.07.21 Derek Muehrcke Exhibit 16	
6358			2016.07.21 Derek Muehrcke Exhibit 17	
6359			2016.07.21 Derek Muehrcke Exhibit 18	-
6360			2016.07.21 Derek Muehrcke Exhibit 19	
6361			2016.07.21 Derek Muehrcke Exhibit 20	
6362			2016.07.26 Rebecca Betensky Exhibit 01	
6363			2016.07.26 Rebecca Betensky Exhibit 02	
6364			2016.07.26 Rebecca Betensky Exhibit 03	
6365			2016.07.26 Rebecca Betensky Exhibit 04	
6366			2016.07.26 Rebecca Betensky Exhibit 05	
6367			2016.07.26 Rebecca Betensky Exhibit 06	
6368			2016.08.17 Mark Eisenberg Exhibit 01	
6369			2016.08.17 Mark Eisenberg Exhibit 02	
6370			2016.08.17 Mark Eisenberg Exhibit 03	
6371			2016.08.17 Mark Eisenberg Exhibit 04	
6372			2016.08.17 Mark Eisenberg Exhibit 05	
6373			2016.08.17 Mark Eisenberg Exhibit 06	
6374			2016.08.17 Mark Eisenberg Exhibit 07	
6375			2017.01.31 Wilson, Mark Exhibit 795	
6376			2017.01.31 Wilson, Mark Exhibit 796	
6377			2017.01.31 Wilson, Mark Exhibit 797	
6378			2017.01.31 Wilson, Mark Exhibit 798	
6379			2017.01.31 Wilson, Mark Exhibit 800	
6380			2017.01.31 Wilson, Mark Exhibit 801	
6381			2017.01.31 Wilson, Mark Exhibit 802	
6382			2017.01.31 Wilson, Mark Exhibit 803	
6383			2017.06.09 Robert Ritchie Exhibit 01	

Exhibit	Marked for ID	Admitted in Evidence	Description	
6384			2017.06.09 Robert Ritchie Exhibit 02	
6385			2017.06.09 Robert Ritchie Exhibit 03	
6386			2017.06.09 Robert Ritchie Exhibit 04	
6387			2017.06.09 Robert Ritchie Exhibit 05	
6388			2017.06.09 Robert Ritchie Exhibit 06	
6389			2017.06.09 Robert Ritchie Exhibit 07	
6390			2017.06.09 Robert Ritchie Exhibit 08	
6391			2017.06.09 Robert Ritchie Exhibit 09	
6392			2017.06.09 Robert Ritchie Exhibit 10	
6393			2017.06.09 Robert Ritchie Exhibit 11	
6394			2017.06.17 Kinney, MD, Thomas B Exhibit 01	
6395			2017.06.17 Kinney, MD, Thomas B Exhibit 02	
6396			2017.06.17 Kinney, MD, Thomas B Exhibit 03	
6397			2017.06.17 Kinney, MD, Thomas B Exhibit 04	
6398			2017.06.17 Kinney, MD, Thomas B Exhibit 05	
6399			2017.06.17 Kinney, MD, Thomas B Exhibit 06	
6400			2017.06.17 Kinney, MD, Thomas B Exhibit 07	
6401			2017.06.17 Kinney, MD, Thomas B Exhibit 08	
6402		·	2017.06.17 Kinney, MD, Thomas B Exhibit 09	
6403			2017.06.17 Kinney, MD, Thomas B Exhibit 10	
6404			2017.06.17 Kinney, MD, Thomas B Exhibit 11	
6405			2017.06.17 Kinney, MD, Thomas B Exhibit 11r	
6406			2017.06.17 Kinney, MD, Thomas B Exhibit 12	
6407			2017.06.17 Kinney, MD, Thomas B Exhibit 13	
6408			2017.06.17 Kinney, MD, Thomas B Exhibit 14	
6409			2017.06.17 Kinney, MD, Thomas B Exhibit 15	
6410			2017.06.17 Kinney, MD, Thomas B Exhibit 16	
6411			2017.06.17 Kinney, MD, Thomas B Exhibit 17	
6412			2017.06.17 Kinney, MD, Thomas B Exhibit 18	
6413			2017.06.17 Kinney, MD, Thomas B Exhibit 19	
6414			2017.06.17 Kinney, MD, Thomas B Exhibit 20	
6415			2017.06.17 Kinney, MD, Thomas B Exhibit 21	
6416			2017.06.17 Kinney, MD, Thomas B Exhibit 22	
6417			2017.06.21- Filter MDL- David A Garcia Exhibit 02	
6418			2017.06.21- Filter MDL- David A Garcia Exhibit 01	
6419			2017.06.21- Filter MDL- David A Garcia Exhibit 03	
6420			2017.06.21- Filter MDL- David A Garcia Exhibit 04	
6421			2017.06.21- Filter MDL- David A Garcia Exhibit 05	
6422			2017.06.21- Filter MDL- David A Garcia Exhibit 06	
6423		2	2017.06.21- Filter MDL- David A Garcia Exhibit 07	
6424			2017.06.21- Filter MDL- David A Garcia Exhibit 08	
6425		2	2017.06.21- Filter MDL- David A Garcia Exhibit 09	
6426		2	2017.06.21- Filter MDL- David A Garcia Exhibit 10	

Exhibit	Marked for ID	Admitted in Evidence	Description	
6427			2017.06.21- Filter MDL- David A Garcia Exhibit 11	
6428			2017.06.21- Filter MDL- David A Garcia Exhibit 12	
6429			2017.06.21 Suzanne Parisian, MD Exhibit 01	
6430			2017.06.21 Suzanne Parisian, MD Exhibit 02	
6431			2017.06.21 Suzanne Parisian, MD Exhibit 03	
6432			2017.06.21 Suzanne Parisian, MD Exhibit 04	
6433			2017.06.21 Suzanne Parisian, MD Exhibit 05	
6434			2017.06.21 Suzanne Parisian, MD Exhibit 06	
6435			2017.06.21 Suzanne Parisian, MD Exhibit 07	
6436			2017.06.21 Suzanne Parisian, MD Exhibit 08	
6437			2017.07.06 Mark Eisenberg, MD Exhibit 01	
6438			2017.07.06 Mark Eisenberg, MD Exhibit 02	
6439			2017.07.06 Mark Eisenberg, MD Exhibit 03	
6440			2017.07.06 Mark Eisenberg, MD Exhibit 04	
6441			2017.07.06 Mark Eisenberg, MD Exhibit 05	
6442			2017.07.06 Mark Eisenberg, MD Exhibit 06	
6443			2017.07.06 Mark Eisenberg, MD Exhibit 07	18.00
6444			2017.07.06 Mark Eisenberg, MD Exhibit 08	
6445			2017.07.06 Mark Eisenberg, MD Exhibit 09	
6446			2017.07.06 Mark Eisenberg, MD Exhibit 10	
6447			2017.07.06 Mark Eisenberg, MD Exhibit 11	
6448			2017.07.06 Mark Eisenberg, MD Exhibit 12	
6449			2017.07.06 Mark Eisenberg, MD Exhibit 13	
6450			2017.07.06 Robert McMeeking, PhD Exhibit 01	
6451			2017.07.06 Robert McMeeking, PhD Exhibit 02	
6452			2017.07.06 Robert McMeeking, PhD Exhibit 03	
6453			2017.07.06 Robert McMeeking, PhD Exhibit 04	
6454			2017.07.06 Robert McMeeking, PhD Exhibit 05	
6455			2017.07.06 Robert McMeeking, PhD Exhibit 05a	
6456			2017.07.06 Robert McMeeking, PhD Exhibit 06	
6457			2017.07.06 Robert McMeeking, PhD Exhibit 07	
6458			2017.07.06 Robert McMeeking, PhD Exhibit 07a	
6459			2017.07.06 Robert McMeeking, PhD Exhibit 07b	
6460			2017.07.06 Robert McMeeking, PhD Exhibit 08	
6461			2017.07.06 Robert McMeeking, PhD Exhibit 08a	
6462			2017.07.06 Robert McMeeking, PhD Exhibit 08b	
6463			2017.07.06 Robert McMeeking, PhD Exhibit 09	
6464			2017.07.06 Robert McMeeking, PhD Exhibit 09a	
6465			2017.07.06 Robert McMeeking, PhD Exhibit 09b	
6466			2017.07.06 Robert McMeeking, PhD Exhibit 10	
6467			2017.07.06 Robert McMeeking, PhD Exhibit 10a	
6468			2017.07.06 Robert McMeeking, PhD Exhibit 10b	
6469			2017.07.06 Robert McMeeking, PhD Exhibit 11	

Exhibit	Marked for ID	Admitted in Evidence	Description	
6470			2017.07.06 Robert McMeeking, PhD Exhibit 11a	****
6471			2017.07.06 Robert McMeeking, PhD Exhibit 11b	
6472			2017.07.06 Robert McMeeking, PhD Exhibit 12	
6473			2017.07.06 Robert McMeeking, PhD Exhibit 13	
6474			2017.07.06 Robert McMeeking, PhD Exhibit 14	
6475			2017.07.06 Robert McMeeking, PhD Exhibit 15	
6476			2017.07.06 Robert McMeeking, PhD Exhibit 16	
6477			2017.07.06 Robert McMeeking, PhD Exhibit 17	
6478			2017.07.06 Robert McMeeking, PhD Exhibit 18	7.1
6479			2017.07.07 Roberts, MD, Anne Exhibit 01	
6480			2017.07.07 Roberts, MD, Anne Exhibit 02	
6481			2017.07.07 Roberts, MD, Anne Exhibit 03	
6482			2017.07.07 Roberts, MD, Anne Exhibit 04	
6483			2017.07.07 Roberts, MD, Anne Exhibit 05	
6484			2017.07.07 Roberts, MD, Anne Exhibit 06	
6485			2017.07.07 Roberts, MD, Anne Exhibit 07	
6486			2017.07.07 Roberts, MD, Anne Exhibit 08	
6487			2017.07.07 Roberts, MD, Anne Exhibit 09	
6488			2017.07.07 Roberts, MD, Anne Exhibit 10	
6489			2017.07.07 Roberts, MD, Anne Exhibit 11	
6490			2017.07.07 Roberts, MD, Anne Exhibit 12	
6491			2017.07.07 Roberts, MD, Anne Exhibit 13	
6492			2017.07.07 Roberts, MD, Anne Exhibit 14	
6493			2017.07.07 Roberts, MD, Anne Exhibit 15	
6494			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 01	
6495			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 02	
6496			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 03	
6497			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 04	
6498			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 05	
6499			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 06	
6500			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 07	
6501			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 08	
6502			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 09	
6503			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 10	
6504			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 11	
6505			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 12	
6506			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 13	
6507			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 14	
6508			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 15	
6509			2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 16	
6510			2017.07.24 Derek Muehrcke Exhibit 01	
6511			2017.07.24 Derek Muehrcke Exhibit 02	
6512		2	2017.07.24 Derek Muehrcke Exhibit 03	

Exhibit	Marked for ID	Admitted in Evidence	Description	
6513			2017.07.24 Derek Muehrcke Exhibit 04	
6514			2017.07.24 Derek Muehrcke Exhibit 05	
6515			2017.07.24 Derek Muehrcke Exhibit 06	
6516			2017.07.24 Derek Muehrcke Exhibit 07	
6517			2017.07.24 Derek Muehrcke Exhibit 08	
6518			2017.07.24 Derek Muehrcke Exhibit 34	
6519			2017.07.24 Derek Muehrcke Exhibit 35	
6520			2017.07.24 Derek Muehrcke Exhibit 36	
6521			2017.07.24 Derek Muehrcke Exhibit 37	
6522			2017.07.24 Derek Muehrcke Exhibit 38	
6523			2017.07.24 Derek Muehrcke Exhibit 39	
6524			2017.07.26 Sims, James Matthew Exhibit 04	
6525			2017.07.31 David A Kessler, MD Exhibit 01	
6526			2017.07.31 David A Kessler, MD Exhibit 02	
6527			2017.07.31 David A Kessler, MD Exhibit 03	
6528			2017.07.31 David A Kessler, MD Exhibit 04	
6529			2017.07.31 David A Kessler, MD Exhibit 05	
6530			2017.07.31 David A Kessler, MD Exhibit 06	
6531			2017.07.31 David A Kessler, MD Exhibit 07	
6532			2017.07.31 David A Kessler, MD Exhibit 08	
6533			2017.07.31 David A Kessler, MD Exhibit 09	
6534			2017.07.31 David A Kessler, MD Exhibit 10	
6535			2017.07.31 David A Kessler, MD Exhibit 11	
6536			2017.07.31 David A Kessler, MD Exhibit 12	
6537			2017.07.31 David A Kessler, MD Exhibit 13	
6538			2017.08.04 Robert Ritchie Exhibit 6007	
6539			2017.08.04 Robert Ritchie Exhibit 6008	
6540			2017.08.04 Robert Ritchie Exhibit 6009	
6541		. [2017.08.04 Robert Ritchie Exhibit 6010	
6542			2017.08.04 Robert Ritchie Exhibit 6011	
6543			2017.08.04 Robert Ritchie Exhibit 6012	
6544			2017.08.04 Robert Ritchie Exhibit 6013	
6545			2017.08.04 Robert Ritchie Exhibit 6014	
6546			2017.08.07 Darren Hurst, MD Exhibit 16	
6547			2017.08.07 Darren Hurst, MD Exhibit 17	
6548			2017.08.07 Darren Hurst, MD Exhibit 18	
6549			2017.08.07 Darren Hurst, MD Exhibit 19	
6550			2017.08.07 Darren Hurst, MD Exhibit 20	
6551		2	2017.08.07 Darren Hurst, MD Exhibit 21	
6552			2017.08.07 Darren Hurst, MD Exhibit 22	
6553		2	2017.08.07 Darren Hurst, MD Exhibit 23	+
6554		2	2017.08.07 Darren Hurst, MD Exhibit 24	
6555		2	2017.08.07 Darren Hurst, MD Exhibit 25	_

Exhibit	Marked for ID	Admitted in Evidence	Description	
6556			2017.08.07 Darren Hurst, MD Exhibit 26	
6557			2017.08.16 White, Lora Exhibit 01	
6558			2017.08.16 White, Lora Exhibit 02	
6559			2017.08.16 White, Lora Exhibit 03	
6560			2017.08.16 White, Lora Exhibit 04	
6561			2017.08.16 White, Lora Exhibit 05	
6562			2017.08.16 White, Lora Exhibit 06	
6563			2017.08.16 White, Lora Exhibit 07	
6564			2017.08.16 White, Lora Exhibit 08	
6565			2017.08.16 White, Lora Exhibit 09	
6566			2017.08.16 White, Lora Exhibit 10	
6567			2017.08.16 White, Lora Exhibit 11	
6568			2011.03.21 Deposition of William Nicholson, Exhibit 01.pdf	
6569			2011.03.21 Deposition of William Nicholson, Exhibit 02.pdf	
6570			2011.03.21 Deposition of William Nicholson, Exhibit 03.pdf	
6571			2011.03.21 Deposition of William Nicholson, Exhibit 04.pdf	
6572			2011.03.21 Deposition of William Nicholson, Exhibit 05.pdf	
6573			2011.03.21 Deposition of William Nicholson, Exhibit 06.pdf	
6574			2011.03.21 Deposition of William Nicholson, Exhibit 07.pdf	
6575			2011.03.21 Deposition of William Nicholson, Exhibit 08.pdf	
6576			2011.03.21 Deposition of William Nicholson, Exhibit 09.pdf	-
6577			2011.03.21 Deposition of William Nicholson, Exhibit 10.pdf	\dashv
6578			2011.03.21 Deposition of William Nicholson, Exhibit 11.pdf	\dashv
6579			2011.03.21 Deposition of William Nicholson, Exhibit 12.pdf	
6580			2011.03.21 Deposition of William Nicholson, Exhibit 13.pdf	
6581			2011.03.21 Deposition of William Nicholson, Exhibit 14.pdf	\neg
6582			2011.03.21 Deposition of William Nicholson, Exhibit 15.pdf	\dashv
6583			2011.03.21 Deposition of William Nicholson, Exhibit 16.pdf	\dashv
6584			2011.03.21 Deposition of William Nicholson, Exhibit 17.pdf	
6585			2011.03.21 Deposition of William Nicholson, Exhibit 18.pdf	
6586			2011.03.21 Deposition of William Nicholson, Exhibit 19.pdf	
6587			2011.03.21 Deposition of William Nicholson, Exhibit 20.pdf	\neg
6588			2011.03.21 Deposition of William Nicholson, Exhibit 21.pdf	
6589			2011.03.21 Deposition of William Nicholson, Exhibit 22.pdf	
6590			2011.03.21 Deposition of William Nicholson, Exhibit 23.pdf	
6591			2011.03.21 Deposition of William Nicholson, Exhibit 25.pdf	٦
6592			2011.03.21 Deposition of William Nicholson, Exhibit 26.pdf	\exists
6593			2011.03.21 Deposition of William Nicholson, Exhibit 27.pdf	\exists
6594			2011.03.21 Deposition of William Nicholson, Exhibit 28.pdf	7
6595			2011.03.21 Deposition of William Nicholson, Exhibit 29.pdf	\exists
6596			2011.03.21 Deposition of William Nicholson, Exhibit 30.pdf	\exists
6597			2011.03.21 Deposition of William Nicholson, Exhibit 31.pdf	
6598			2011.03.21 Deposition of William Nicholson, Exhibit 32.pdf	\neg

Exhibit	Marked for ID	Admitted in Evidence	Description	
6599			2011.03.21 Deposition of William Nicholson, Exhibit	33 ndf
6600			2011.03.21 Deposition of William Nicholson, Exhibit	34 ndf
6601			2011.03.21 Deposition of William Nicholson, Exhibit	35.pdf
6602			2011.03.21 Deposition of William Nicholson, Exhibit	36.pdf
6603			2011.03.21 Deposition of William Nicholson, Exhibit	37 pdf
6604			2011.03.21 Deposition of William Nicholson, Exhibit	38 ndf
6605			2011.03.21 Deposition of William Nicholson, Exhibit	30.pdf
6606			2011.03.21 Deposition of William Nicholson, Exhibit	40 pdf
6607			2011.03.21 Deposition of William Nicholson, Exhibit	41 ndf
6608			2011.03.21 Deposition of William Nicholson, Exhibit	42 pdf
6609			2011.03.21 Deposition of William Nicholson, Exhibit	43 pdf
6610			2011.03.21 Deposition of William Nicholson, Exhibit	44.pdf
6611			2011.03.21 Deposition of William Nicholson, Exhibit	45 pdf
6612			2011.03.21 Deposition of William Nicholson, Exhibit	46 pdf
6613			2011.03.21 Deposition of William Nicholson, Exhibit	47 pdf
6614			2011.03.21 Deposition of William Nicholson, Exhibit	18 ndf
6615			2011.10.04 Nicholson Defendant Exhibit 1.pdf	40.pui
6616			2011.10.04 Nicholson Plaintiff Exhibit 1.pdf	
6617			2011.10.04 Nicholson Plaintiff Exhibit 2.pdf	
6618			2011.04.28 Delio-Cox Exhibit 01.pdf	
6619			2011.04.28 Delio-Cox Exhibit 02.pdf	
6620			2011.04.28 Delio-Cox Exhibit 03.pdf	
6621		,	2011.04.28 Delio-Cox Exhibit 04.pdf	
6622			2011.04.28 Delio-Cox Exhibit 05.pdf	
6623			2011.04.28 Delio-Cox Exhibit 06.pdf	
6624			2011.04.28 Delio-Cox Exhibit 07.pdf	
6625			2011.04.28 Delio-Cox Exhibit 08.pdf	
6626			2011.04.28 Delio-Cox Exhibit 09.pdf	
6627			2011.04.28 Delio-Cox Exhibit 10.pdf	
6628			2011.04.28 Delio-Cox Exhibit 11.pdf	
6629			2011.04.28 Delio-Cox Exhibit 12.pdf	
6630			2011.04.28 Delio-Cox Exhibit 13.pdf	
6631			Exhibit 1 of Kush Desai Deposition, taken 6/6/2017.	
6632			Exhibit 2 of Kush Desai Deposition, taken 6/6/2017.	
6633			Exhibit 3 of Kush Desai Deposition, taken 6/6/2017.	
6634			Exhibit 4 of Kush Desai Deposition, taken 6/6/2017.	
6635			Exhibit 8 of Kush Desai Deposition, taken 6/6/2017.	
6636		l	Exhibit 9 of Kush Desai Deposition, taken 6/6/2017.	
6637		I	Exhibit 10 of Kush Desai Deposition, taken 6/6/2017.	
6638		I	Exhibit 11 of Kush Desai Deposition, taken 6/6/2017.	
6639		I	Exhibit 12 of Kush Desai Deposition, taken 6/6/2017.	
6640		E	Exhibit 13 of Kush Desai Deposition, taken 6/6/2017.	
6641			Exhibit 14 of Kush Desai Deposition, taken 6/6/2017.	

Exhibit	Marked for ID	Admitted in Evidence	Description
6642			Deposition of Natalie Wong, taken 10/18/2016, Exhibit 537
6643		3-00-18	Hospital Admission History and Physical: Lincoln Medical Center
6644			Chest x-ray
6645			CT Scan: Chest
6646			Discharge Summary: Lincoln Medical Center
6647			Admission History & Physical: New York Methodist Hospital
6648			Echocardiogram
6649			Filter Product Sticker
6650			Hematology Consult: DVT/Recurrent PE
6651			Vascular Attending Progress Note
6652		3-02-18	Consent: IVC filter placement
6653			Filter placement report
6654			Fluoroscopy Report & Abdominal spot film done during filter placement
6655			Radiation Oncology Follow up note
6656		3-22-18	ER Visit: Lincoln Medical Center
6657		0010	CT Scan: Abdomen/pelvis
6658			Discharge Summary: Lincoln Medical Center
6659			CT scan: Abdomen/Pelvis
6660		3-27-18	Admission History & Physical: New York Methodist Hospital
6661			Hematology/Oncology Admit Note: New York Methodist Hospital
6662			CT Scan: Abdomen/Pelvis
6663			Doppler flow study
6664			Hematology/Oncology Progress Note
6665			Discharge Summary: New York Methodist Hospital
6666			Occupational Health Service: Lincoln Medical Center
6667		3-02-18	ER Visit: Lincoln Medical Center
6668		3-27-18	Lumbosacral Spine X-ray
6669		3-22-18	CT scan: Abdomen/pelvis
6670			ER Visit: Lincoln Medical center
6671		-	Comprehensive Assessment by Social Work
6672			CT Scan: Cervical Spine
6673			ER Note/Discharge: Lincoln Medical Center
6674			ER Visit: Lincoln Medical center
6675			Chest x-ray
6676			Admission History and Physical: Lincoln Medical Center
6677			Consult: Depression
6678			Progress Notes by Attending Physician (Dr. Garg)
6679			Discharge Summary: Lincoln Medical Center
6680			Nursing Discharge Summary Note: Lincoln Medical Center
6681		3-33-18	ER Visit: Gwinnett Medical Center

Exhibit	Marked for ID	Admitted in Evidence	Description
6682			Doppler flow study
6683		3-27-18	ER Visit: Gwinnett Medical Center
6684			Chest x-ray
6685			Office visit: North Chattahoochee Family Physicians
6686			CT Scan: Abdomen/Pelvis
6687			New Patient Consult: Cervical Cancer
6688			Chest x-ray
6689			Consult MD: Abdominal hernia
6690			Patient Intake Form: Gwinnet Medical Group: Cardiology)
6691			Pre-Op evaluation: Gwinnet Medical Center
6692			Stress Myocardial Perfusion scan
6693		3-22-18	ER Visit: Eastside Medical Center
6694		7000	CT Scan: Abdomen/Pelvis (2 separate readings)
6695			Chest x-ray
6696		3-22-18	ER Visit: Piedmont Hospital: Henry County
6697		100 8	ER Visit: Fledmont Hospital: Henry County ER Visit: Eastside Medical Center
6698			Chest x-ray
6699		0.02.51	ER Visit: Gwinnett Medical center
6700		3-22-18	CT scan: Abdomen/Pelvis
6701			
6702			Charter (Ald Jane 1)
6703			Chest x-ray/Abdominal
6704			Consult: Dr. David Langford (Cardiothoracic Surgeon)
6705			Filter retrieval procedure & Consent
6706	,		Filter retrieval procedure & Consent
			Post Procedure Nurse's Notes
6707			Consult: Chest pain (Dr. Heller)
6708			TTE
6709			Progress Note: Dr. Kang
6710		3-28-18	CT Angiogram of the heart
6711			TEE & consent
6712			TEE & consent
6713			Consultation: Medical Management
6714			Carotid Doppler study-bilateral
6715			Chest X-ray(s)
6716			Handwritten Progress Notes
6717			Consult: Dr. Richard Harvey
6718			Surgical procedure: Minimally invasive tricuspid valve repair & Consent
6719			Surgical procedure: Minimally invasive tricuspid valve repair & Consent
6720			Handwritten Cardiovascular post-operative note
6721			Pathology Report
6722			TEE

Exhibit	Marked for ID	Admitted in Evidence	Description
6723			Discharge Summary: Gwinnett Medical Center
6724			Letter to Dr. Patel from Dr. Harvey
6725			Office Visit: Cardiovascular and Thoracic Surgery
6726			Chest x-ray
6727			Ultrasound: Abdomen
6728			Office Visit: Cardiovascular and Thoracic Surgery
6729			Addendum ER Visit: Gwinnett Medical Center Chest x-ray/CT
			scan: Chest
6730			Addendum ER Visit: Gwinnett Medical Center Chest x-ray/CT
			scan: Chest
6731			Addendum ER Visit: Gwinnett Medical Center Chest x-ray/CT
			scan: Chest
6732			ER Visit: New York Methodist Hospital CT Scan:
			Abdomen/pelvis
6733			ER Visit: New York Methodist Hospital CT Scan:
			Abdomen/pelvis
6734			CT Angiogram; Chest
6735			Chest x-ray
6736			Admitting History & Physical: Gwinnett Medical Center
6737			Discharge Summary: Gwinnett Medical Center
6738			CT Scan: Abdomen
6739			ER Visit: Gwinnett Medical Center
6740			Office Visit: Vine Medical Associates
6741		3-77-18	ER Visit: Piedmont Hospital-Atlanta
6742			CT Scan: Chest
6743			Admission History & Physical: Piedmont Hospital-Atlanta
6744			Echocardiogram
6745		3-88-8	Discharge Summary: Piedmont Hospital-Atlanta
6746			Chest X-ray
6747			Office Visit: Vine Medical Associates
6748		3-22-18	ER Visit: Gwinnett Medical Center
6749			Chest x-ray
6750			CT Angiogram: Chest
6751		3-22-18	Office visit: Gwinnett Medical Group: Cardiology
6752		7	TTE
6753			Office Visit: University GYN Oncology & Colposcopy
6754			Letter to Sherr Una Booker
6755			CT Scan: Abdomen/Pelvis
6756			ER Visit
6757		/ /	Consult: Dr. Patel
6758			Chest x-ray
6759			Duplex venous flow studies
6760			Admission History & Physical

Exhibit	Marked for ID	Admitted in Evidence	Description
6761			Consult: Gastroenterology-Sanjay Parikh, M.D.
6762			Physician Progress Notes
6763			CT Scan: Abdomen and Pelvis
6764			Discharge Summary
6765			Office Visit: Atlanta Gastroenterology Associates
6766			Office Visit: Atlanta Gastroenterology Associates
6767			Office Visit: Atlanta Gastroenterology Associates
6768		3-22-18	Office Visit: Gwinnett Medical Group: Cardiology
6769			Office Visit: Vine Medical Associates
6770		3-22-18	ER Visit
6771			Office Visit: Vine Medical Associates
6772			Office Visit: University GYN Oncology & Colposcopy
6773			Office Note: University GYN Oncology
6774			Eastside Urgent Care Visit
6775			Chest X-ray
6776			ER Visit
6777	i		Ultrasound: Left lower extremity
6778		3-22-18	Office Visit: Gwinnett Consultants in Cardiology
6779			Transthoracic Echocardiogram (TTE)
6780		2-22-18	Gwinnett Consultants in Cardiology: Letter(s)
6781		70	Gwinnett Consultants in Cardiology: Cardiac monitoring report
6782			Office Visit: WellStar Breast Surgery of North Fulton
6783			ER Visit
6784			Lab: Sedimentation Rate
6785			CT Scan: Head
6786			Office Visit: Vine Medical Associates
6787			CT Scan: Abdomen/Pelvis
6788			Ultrasound lower extremity venous duplex
6789			Ultrasound lower extremity arterial duplex
6790			Office Visit: Vine Medical Associates
6791			Office Communications Dr. Patel's office
6792			Advanced Urology Institute of GA
6793			Atlanta Gastro Associates
6794			Brooklyn OB/GYN Care
6795			Cardiothoracic Surgeons - Harvey, MD
6796			Cardiovascular & Thoracic Surgeons
6797			Eastside Medical Center
6798			Emory Johns Creek Hospital
6799			Georgia Cancer Specialists
6800			GMC
6801			Gwinnett Consultants in Cardiology
6802			Gwinnett Consultants in Cardiology
6803			Gwinnett Consultants in Cardiology

Exhibit	Marked for ID	Admitted in Evidence	Description
6804			Gwinnett Medical Center and Physicians Bills
6805			Lincoln Medical & Mental Health Center
6806			Metro Atlanta Ambulance
6807			Metro Atlanta Ambulance (bill)
6808			North Chattahoochee Family Physicians
6809			North Metro Radiology Billing
6810			North Metro Radiology Billing
6811			North Metro Radiology Billing
6812			Northside Radiology
6813			NY Methodist
6814			Piedmont Atlanta Hospital
6815			Piedmont Healthcare bills
6816			Piedmont Henry
6817			University Gynecologic Oncology
6818			Vine Medical Associates
6819			Vine Medical Associates bills
6820			Vine Medical Billing
6821			Wellstar North Fulton
6822		3-28-18	Emory Eastside Medical Center
6823		3-28-8	Gwinnett Medical Center
6824			Gwinnett Medical Center
6825		3-27-18	Lincoln Medical Center
6826		3 2818	Northside Hospital
6827		308-2018	NY Methodist Hospital
6828			Piedmont Hospital
6829			Piedmont Henry Hospital
6830			Wellstar North Fulton Radiology
6831			Home Depot (The)
6832			Social Security Administration
6833			Spark Wireless
6834			Uber Technologies (GA), Inc. c/o CT Corporation Systems
6835			Should you worry about the radiation from CT scans?
			https://www.washingtonpost.com/national/health-science/how-
			much-to-worry-about-the-radiation-from-ct-
			scans/2016/01/04/8dfb80cc-8a30-11e5-be39-
			0034bb576eeestory.html?utmterm=.67f42f94c11d Accessed on
			February 20, 2017.
6836			2016 Revised ACR-SIR-SPR Practice Parameter for the
			Performance of Inferior Vena Cava (IVC) Filter Placement for
			the Prevention of Pulmonary Embolism.
			https://www.acr.org/~/media/a569be8f18ae4cfaa2868b6e0984d
			bd8.pdf Accessed January 16, 2017.

Exhibit	Marked for ID	Admitted in Evidence	Description	
6837			Aarabi B, Harrop JS, Tator CH, Alexander M, Dettori JR,	
			Grossman RG, Fehlings MG, Mirvis SE, Shanmuganathan H	ζ
			Zacherl KM, Burau KD, Frankowski RF, Toups E, Shaffrey	· CI
			Guest JD, Harkema SJ, Habashi NM, Andrews P, Johnson M	
			Rosner MK. Predictors of Pulmonary Complications in Blur	
			Traumatic Spinal Cord Injury. J Neurosurg Spine. 2012	
			Sep;17(1 Suppl):38-45. doi: 10.3171/2012.4.AOSPINE1295	í
6838			Abtahian F, Hawkins BM, Ryan DP. Inferior vena cava filte	r
			usage, complications, and retrieval rate in cancer patients. A	
			Med 2014; 127:1111-7.	
6839			ACR Appropriateness Criteria® radiologic management of	
			inferior vena cava filters. Available at:	
			http://guidelines.gov/content.aspx?id=15730#Section420.	
6840			ACR SIR, Practice Parameter for the Performance of Inferio	r
			Vena Cava (IVC) Filter Placement for the Prevention of	•
			Pulmonary Embolism (2014)	
6841			ACR-SIR Practice guideline on informed consent for image-	
			guided procedures 2011	
			https://www.sirweb.org/globalassets/aasociety-of-	
			interventional-radiology-home-page/practice-	
			resources/standards_pdfs/final_acr_doc7109ed01.pdf	
6842		d	ACR-SIR-SPR Practice Parameter for the Performance of	
		3-28-18	Inferior Vena Cava (IVC) Filter Placement for the Prevention	n of
			Pulmonary Embolism. Revised 2016.	
6843			ACR-SIR-SPR Practice Parameter on Informed Consent for	
			Image-Guided Procedures. Revised 2016. https://www.acr.or	·g/-
			/media/ACR/Files/Practice-Parameters/InformedConsent-	
			ImagGuided.pdf	
6844			Adair JD, Harvey KP, Mahmood A. Inferior vena cava filter	
			migration to right ventricle with destruction of tricuspid valve	e: a
			case report. J Trauma. 2008 Feb;64(2):509-11. doi:	ĺ
			10.1097/TA.0b013e318058251c.	
6845			Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson	n
			M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz	JI:
			AMPLIFY Investigators. Oral Apixaban for the Treatment of	
			Acute Thromboembolism. N Engl J Med. 2013 Aug	
			29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 20	13
6046			Jul 1.	
6846			Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnso	n
			M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT	
			Investigators. Apixaban for Extended Treatment of Venous	
			Thromboembolism. N Engl J Med. 2013 Feb 21;368(8) 699-	
			708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8.	ĺ

Exhibit	Marked for ID	Admitted in Evidence	Description
6847			Ahmad I, Yeddula K, Wicky S, Kalva SP. Clinical sequelae of thrombus in an inferior vena cava filter. Cardiovasc Intervent Radiol. 2010 Apr;33(2):285-9. doi: 10.1007/s00270-009-9664-x. Epub 2009 Aug 18.
6848			Alam M, Levine TB. Echocardiographic features of embolized inferior venacaval filter to the right ventricle: a case report. Angiology. 1993 Apr;44(4):338-40.
6849			Albrecht RM, Garwe T, Carter SM, Maurer AJ. Retrievable inferior vena cava filters in trauma patients: factor that influence removal rate and an argument for institutional protocols. Am J Surg 2012; 203:297-302.
6850			Albright HL. Thrombophlebitis: The Problem of Treatment. N Engl J Med. 1947 Jun 19;236(25):928-33. doi: 10.1056/NEJM194706192362502.
6851			Allen CJ, Murray CR, Meizoso JP, Ginzburg E, Schulman CI, Lineen EB, Namias N, Proctor KG. Surveillance and Early Management of Deep Vein Thrombosis Decreases Rate of Pulmonary Embolism in High-Risk Trauma Patients. J Am Coll Surg. 2016 Jan;222(1):65-72. doi: 10.1016/j.jamcollsurg.2015.10.014. Epub 2015 Nov 4.
6852			Allen TL, Carter JL, Morris BJ, Harker CP, Stevens MH. Retrievable vena cava filters in trauma patients for high-risk prophylaxis and prevention of pulmonary embolism. Am J Surg 2005 Jun;189(6):656-61.
6853			Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE. Mortality in patients treated for pulmonary embolism. JAMA 1976;236(13):1477–1480.
6854			American Venous Forum. Upcoming IVC Filter Data From the American Venous Registry [not a peer-reviewed article]
6855			Amole AO, Kathuria MK, Ozkan OS, Gill AS, Ozkan EO. Lumbar artery laceration with retroperitoneal hematoma after placement of a G-2 inferior vena cava filter. Cardiovasc Intervent Radiol. 2008 Nov-Dec;31(6):1257-9. doi: 10.1007/s00270-008-9365-x. Epub 2008 Jun 10.
6856			An T, Moon E, Bullen J, Kapoor B, Wu A, Sands M, Wang W. Prevalence and Clinical Consequences of Fracture and Fragment Migration of the Bard G2 Filter: Imaging and Clinical Follow-up in 684 Implantations. J Vasc Interv Radiol. 2014 Jun;25(6):941-8. doi: 10.1016/j.jvir.2014.01.035. Epub Mar 18.
6857			Anderson FA Jr, Spencer FA. Risk Factors for Venous Thromboembolism. Circulation. 2003 Jun 17;107(23 Suppl 1):I9-16.

Exhibit	Marked for ID	Admitted in Evidence	Description
6858			Anderson FA Jr1, Hirsh J, White K, Fitzgerald RH Jr; Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest 124 (Suppl): S349-S356, 2003
6859			Anderson FA, Jr, Wheeler HB, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933–8.
6860			Andreoli JM, Lewandowski RJ, Vogelzang RL, Ryu RK. Comparison of complication rates associated with permanent and retrievable inferior vena cava filters: a review of the MAUDE database. J Vasc Interv Radiol. 2014 Aug;25(8):1181-5. doi: 10.1016/j.jvir.2014.04.016. Epub 2014 Jun 11.
6861			Andreoli JM, Thornburg BG, Hickey RM. Inferior Vena Cava Filter Related Thrombus Deep Vein Thrombosis Data and Management. Semin Intervent Radiol. 2016 Jun;33(2): 101-4. doi: 10.1055/s-0036-1581087.
6862			Angel LF, Tapson V, Galgon RE, Restrepo MI, Kaufman J. Systematic Review of the Use of Retrievable Inferior Vena Cava Filters. J Vasc Interv Radiol. 2011 Nov;22(11):1522-1530.e3. doi: 10.1016/j.jvir.2011.08.024.
6863			Antevil JL, Sise MJ, Sack DI, Sasadeusz KJ, Swanson SM, Rivera L, Lome BR, Weingarten KE, Kaminski SS. Retrievable Vena Cava Filters for Preventing Pulmonary Embolism in Trauma Patients: A Cautionary Tale. J Trauma. 2006 Jan;60(1):35-40.
6864			Araki T, Ishihara C. Images in cardiovascular medicine. Retroperitoneal Hematoma After Inferior Vena Cava Filter Insertion. Circulation. 2007 Sep 11;116(11):e345.
6865			Arjomand H, Surabhi S, Wolf NM. Right ventricular foreign body: percutaneous transvenous retrieval of a Greenfield filter from the right ventriclea case report. Angiology, 2003. 54(1): 109-13.
6866			Aryafar H, Kinney TB. Optional inferior vena cava filters in the trauma patient. Semin Intervent Radiol. 2010 Mar;27(1):68-80. doi: 10.1055/s-0030-1247890.
6867			Asch MR. Initial experience in humans with a new retrievable inferior vena cava filter. Radiology. 2002 Dec;225(3):835-44.
6868			Assifi MM, Bagameri G, Dimuzio PJ, Eisenberg JA. Management of infected caval filter with simultaneous aortic pseudoaneurysm and retroperitoneal perforation: a case report and literature review. Vascular. 2012 Aug;20(4):225-8. doi: 10.1258/vasc.2011.cr0310. Epub 2012 Jun 11.

Exhibit	Marked for ID	Admitted in Evidence	Description	
6869			Athanasoulis CA, Kaufman JA, Halpern EF, Waltman Geller SC, Fan CM. Inferior vena caval filters: review year single-center clinical experience. Radiology. 2000 Jul;216(1):54-66.	of a 26-
6870			Attar S, Boyd D, Layne E, McLaughlin J, Mansberger Cowley RA. Alterations in coagulation in coagulation fibrinolytic systems following trauma. J Trauma 1969; 965.	and
6871			Avgerinos ED, Bath J, Stevens J, McDaniel B, Marone Dillavou E, Cho JS, Makaroun MS, Chaer RA. Technic patient-related characteristics associated with challengi retrieval of inferior vena cava filters. Eur J Vasc Endov 2013 Sep;46(3):353-9. doi: 10.1016/j.ejvs.2013.06.007 2013 Jul 5.	cal and ng asc Surg.
6872			Aw-Zoretic J, Collins JD. Considerations for Imaging t Inferior Vena Cava (IVC) with without IVC Filters. Ser Intervent Radiol. 2016 Jun;33(2):109-21. doi: 10.1055/ 1583207.	min
6873			Bach JR, Zaneuski R, Lee H. Cardiac arrhythmias from malpositioned Greenfield filter in a traumatic quadriple J Phys Med Rehabil. 1990 Oct;69(5):251-3.	a gic. Am
6874			Balas EA. Information Systems Can Prevent Errors and Improve Quality. J Am Med Inform Assoc. 2001 Jul-Aug;8(4):398-9.	
6875			Ballew KA, Philbrick JT, Becker DM. Vena cava filter Clin Chest Med. 1995 Jun;16(2):295-305.	devices.
6876			Bandle J, Shackford SR, Sise CB, Knudson MM; CLO Group. Variability is the Standard: The management of Thromboembolic Disease Following Trauma. J Trauma Care Surg. 2014 Jan;76(1):213-6. doi: 10.1097/TA.0b013e3182aa2fa9.	Venous
6877			Bard Denali Vena Cava Filter. Femoral Vein Approach. Instructions for Use. http://www.bardpv.com/wp-content/uploads/2014/02/DenaliBAW5410500-US-FEM Accessed on January 20, 2017.	
6878			Bard Eclipse Vena Cava Filter. Femoral Vein Approach Instructions for Use. http://www.bardpv.com/wp-content/uploads/2014/02/EclipseVenaCavaFilterFemIFU Accessed on January 20, 2017.	
6879			Bard G2 Filter System. Femoral Vein Approach. Instruction Use. http://www.bardpv.com/filterfacts/pdf/ifus/G2-BAW5250500-R2.pdf Accessed September 1, 2016.	tions Fem-

Exhibit	Marked for ID	Admitted in Evidence	Description	
6880			Bariatric Surgery Guidelines, Medical Guidelines for Oractice Guidelines for the Perioperative Nutritional, Nand Nonsurgical Support of the Bariatric Patient - 201	Metabolic,
6881			Barral FG. Vena cava filters: why, when, what and hor Cardiovasc Surg (Torino). 2008 Feb;49(1):35-49.	w? J
6882			Barritt DW, Jordan SC. Anticoagulant drugs in the trea pulmonary embolism. A controlled trial. Lancet 1960;1(7138):1309–1312.	atment of
6883			Bauer G. The introduction of heparin therapy in cases thrombosis. Circulation 1959;19(1):108–109.	of early
6884			Becattini C, Agnelli G. Acute pulmonary embolism: ri stratification in the emergency department. Intern Eme 2007;2(2):119–129.	sk rg Med
6885			Becker DM, Philbrick JT, Selby JB. Inferior Vena Cav Indications, safety, effectiveness. Arch Intern Med. 199 Oct;152(10):1985-94.	a Filters. 92
6886			Bélénotti P, Sarlon-Bartoli G, Bartoli MA, Benyamine Thevenin B, Muller C, Serratrice J, Magnan PE, Weille Vena cava filter migration: an unappreciated complicat About four cases and review of the literature. Ann Vasc 2011 Nov;25(8):1141.e9-14. doi: 10.1016/j.avsg.2011.	er PJ. ion. c Surg.
6887			Benenati, Society of Interventional Radiology letter re: Public Health Notification - Removing Retrievable Infe Vena Cava Filters: Initial Communication	FDA
6888			Benenati, Society of Interventional Radiology Respond Blood Clot Device (IVC Filter) Advisory	s to FDA
6889			Berczi V, Bottomley JR, Thomas SM, Taneja S, Gaines Cleveland TJ. Long-term retrievability of IVC filters: slabandon permanent devices? Cardiovasc Intervent Radio Sep-Oct;30(5):820-7. Epub 2007 Sep 1.	hould we
6890			Bikdeli B, Ross JS, Krumholz HM. Data Desert for Infe Vena Caval Filters: Limited Evidence, Supervision, and Research. JAMA Cardiol. 2017 Jan 1;2(1):3-4. doi: 10.1001/jamacardio.2016.3764.	rior
6891			Billett H.H., Jacobs L.G., Madsen E.M., Giannattasio E Mahesh S., Cohen H.W. Efficacy of inferior vena cava anticoagulated patients. J Thromb Haemost. 2007;5:184	filters in
6892		1	Binkert CA, Drooz AT, Caridi JG, Sands MJ, Bjarnasor Lynch FC, Rilling WS, Zambuto DA, Stavropoulos SW Venbrux AC, Kaufman JA. Technical success and safety retrieval of the G2 filter in a prospective, multicenter stu Vasc Interv Radiol. 2009 Nov;20(11):1449-53. doi: 10.1016/j.jvir.2009.08.007.	n H, , v of

Exhibit	Marked for ID	Admitted in Evidence	Description	
6893			Binkert CA, Sasadeusz K, Stavropoulos SW. Retrieva	hilitu of
			the Recovery Vena Cava Filter after Dwell Times Lor	onity of
			180 Days. J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):2	1901 111a11
6894			Birkmeyer NJ, Finks JF, English WJ, Carlin AM, Hav	199-302.
			Genaw JA, Wood MH, Share DA, Birkmeyer JD; Mic	higon
			Bariatric Surgery Collaborative. Risks and Benefits of	nigan
			Prophylactic Inferior Vena Cava Filters in Patients Un	danasims
			Bariatric Surgery. J Hosp Med. 2013 Apr;8(4):173-7.	uergomg
			10.1002/jhm.2013. Epub 2013 Feb 8.	HO1.
6895			Birkmeyer NJ, Share D, Baser O, Carlin AM, Finks JF	D4
			CM, Genaw JA, Birkmeyer JD; Michigan Bariatric Su	, Pesta
			Collaborative. Preoperative placement of inferior vena	rgery
			filters and outcomes after gastric bypass surgery. Ann	cava
			2010 Aug;252(2):313-8. doi: 10.1097/SLA.0b013e318	Surg.
6896			Bjarnason H, Yedlicka JW Jr, Hunter DW, Castañeda-	1e61e4f.
			WR, Amplatz K. In vitro metal fatigue testing of inferi	Zuñiga
			cava filters. Invest Radiol. 1994 Sep;29(9):817-21.	or vena
6897			Rlaszyk H. Wollon DC. Within AV. Dir.	
			Blaszyk H, Wollan PC, Witkiewicz AK, Björnsson J. I	Death
			from pulmonary thromboembolism in severe obesity: la	ack of
			association with established genetic and clinical risk factorishms. Arch. 1999, June 434(6):520, 32	ctors.
6898			Virchows Arch. 1999 Jun;434(6):529-32. Rlebea J. Wilson B. Washill B. M. A.	
			Blebea J, Wilson R, Waybill P, Neumyer MM, Blebea.	JS,
			Anderson KM, Atnip RG. Deep Vein Thrombosis After	•
			Percutaneous Insertion of Vena Caval Filters. J Vasc St Nov;30(5):821-8.	ırg. 1999
6899				
			Bochenek KM, Aruny JE, Tal MG. Right Atrial Migrational of a Court of the Talling of the Court o	on and
			percutaneous retrieval of a Gunther Tulip inferior vena	cava
6900			filter. J Vasc Interv Radiol. 2003 Sep;14(9 Pt 1):1207-9	
			Bos A, Van Ha T, van Beek D, Ginsburg M, Zangan S,	
			Navuluri R, Lorenz J, Funaki B. Strut Penetration: Loca	1
			Complications, Breakthrough Pulmonary Embolism, and	d
			Retrieval Failure in Patients with Celect Vena Cava Filt	ers. J
			Vasc Interv Radiol. 2015 Jan;26(1):101-6. doi:	
6901			10.1016/j.jvir.2014.09.010. Epub 2014 Oct 29.	
		1	Bos AS, Tullius T, Patel M, Leef JA, Navuluri R, Loren	z JM,
			Van Ha TG. Indwelling and Retrieval Complications of	Denali
			and Celect Infrarenal Vena Cava Filters. J Vasc Interv R	adiol.
5902		4	2016 Jul;27(7):1021-6. doi: 10.1016/j.jvir.2016.03.034.	
			Brathwaite CE, Mure AJ, O'Malley KF, Spence RK, Ros	s SE.
		1	Complications of Anticoagulation for Pulmonary Embol	ism in
5903			Low Risk Trauma Patients. Chest. 1993 Sep;104(3):718-	20.
			Braun MA, Collins MB, Sarrafizadeh M, Koslow AR.	
		P	ercutaneous retrieval of tandem right atrial Greenfield f	ilters.
		A	JR Am J Roentgenol. 1991 Jul;157(1):199.	

Exhibit	Marked for ID	Admitted in Evidence	Description	
6904			Brenner DJ, Hall EJ. Computed tomography – an incre-	asino
			source of radiation exposure. N Engl J Med 2007; 357:	2277-84
6905			Brotman DJ, Shihab HM, Prakasa KR, Kebede S, Haut	ER
			Sharma R, Shermock K, Chelladurai Y, Singh S, Segal	JB
		4	Pharmacologic and Mechanical Strategies for Preventing	າວ.
			Venous Thromboembolism After Bariatric Surgery A	- 6
			Systematic Review and Meta-analysis. JAMA Surg. 20	13
			Jul;148(7):675-86. doi: 10.1001/jamasurg.2013.72.	15
6906			Brown AP, Miller MJ, Smith TP. Caval Penetration with	h
			Retroperitoneal Hemorrhage Following Placement of an	n Inferior
			Vena Cava (IVC) Filter. Semin Intervent Radiol. 2007	ii iiiiciioi
			Sep;24(3):312-5. doi: 10.1055/s-2007-985741.	
6907			Brown SL, Bright RA, Tavris DR. Medical Device	
			Epidemiology and Surveillance – Patient Safety is the B	Rattam
			Line. Expert Rev Med Devices. 2004 Sep;1(1):1-2.	ottom
6908			Buckley O, DeVore A, Ersoy H, Sobieszczyk P, Auger	· W
			Kwong R, Rybicki F, Goldhaber S. Embolism after Infe	rior
			Vena Cava Filter Mesh Fragmentation, Letter to the Edi	tor
			November 2010 JVIR, Vol. 21, Number 11, 1782-3, DC)I·
			10.1016/j.jvir.2010.07.021.)1.
6909			Bull PG, Mendel H, Schlegl A. Günther vena caval filte	p.
			clinical appraisal. J Vasc Interv Radiol. 1992 May;3(2):	395_0
6910			Büller HR, Davidson BL, Decousus H, Gallus A, Gent M	M
			Piovella F, Prins MH, Raskob G, Segers AE, Cariou R,	v 1,
			Leeuwenkamp O, Lensing AW; Matisse Investigators.	
			Fondaparinux or enoxaparin for the initial treatment of	
			symptomatic deep venous thrombosis. Ann Intern Med	2004
			Jun 1;140(11):867-73.	2001
6911			Burge AJ, Freeman KD, Klapper PJ, Haramati LB. Incre	eased
			diagnosis of pulmonary embolism without a correspondi	no
			decline in mortality during the CT era. Clin Radiol	6
			2008;63(4):381–386.	
6912			Bustamante M, Abascal F, Garcia-Valtuille R, González	-Tutor
		77.	A, Gómez JM. Sudden death in a patient caused by migra	ation of
			an Antheor vena cava filter to the heart. J Vasc Interv Ra	idiol.
			1998. 9(3): 521-2.	, ,
6913			Cain PG. Comment on Treatment of venous diseasethe	
			innovators. J Vasc Surg. 1995 Sep;22(3):341-3.	1
6914			Cantwell CP, Pennypacker J, Singh H, Scorza LB, Wayb	ill PN
			Lynch FC. Comparison of the recovery and G2 filter as	
		1	retrievable inferior vena cava filters. J Vasc Interv Radio	ol. 2009
		;	Sep;20(9):1193-9. doi: 10.1016/j.jvir.2009.05.037. Epub	2009
			Jul 29.	

Exhibit	Marked for ID	Admitted in Evidence	Description
6915			Caplin DM, Nikolic B, Kalva SP, Ganguli S, Saad WE, Zuckerman DA. Quality Improvement Guidelines for the Performance of Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism. J Vasc Interv Radiol. 2011
6016			Nov;22(11):1499-506. doi: 10.1016/j.jvir.2011.07.012. Epub 2011 Sep 3.
6916			Cappelli F, Vignini S, Baldereschi GJ. ALN inferior vena cava filter upside down rotation with chest caval migration in an asymptomatic patient. J Invasive Cardiol. 2010 Aug;22(8):E153-5.
6917			Carabasi RA 3rd, Moritz MJ, Jarrell BE. Complications encountered with the use of the Greenfield filter. Am J Surg. 1987 Aug;154(2):163-8.
6918			Carlin AM, Tyburski JG, Wilson RF, Steffes C. Prophylactic and therapeutic inferior vena cava filters to prevent pulmonary emboli in trauma patients. Arch Surg. 2002 May;137(5):521-5; discussion 525-7.
6919			Carman TL, Alahmad A. Update on vena cava filters. Curr Treat Options Cardiovasc Med. 2008 Apr;10(2):101-11.
6920			Castaneda F, Herrera M, Cragg AH, Salamonowitz E, Lund G, Castaneda-Zuniga WR, Amplatz K. Migration of a Kimray-Greenfield filter to the right ventricle. Radiology. 1983 Dec;149(3):690.
6921			Center for Devices and Radiological Health. Food and Drug Administration. The MAUDE - Manufacturer and User Facility Device Experience Web Homepage. Available from: 142. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/s earch.CFM.
6922			Centers for Disease Control and Prevention. Principles of Epidemiology in Public Health Practice, Third Edition An Introduction to Applied Epidemiology and Biostatistics https://www.cdc.gov/ophss/csels/dsepd/ss1978/lesson3/section2 html accessed on March 6, 2017.
5923) T	Chana-Rodríguez F, Mañanes RP,Rojo-Manaute J, Haro JAC, Vaquero-Martín J. Methods and Guidelines for Venous Thromboembolism Prevention in Polytrauma Patients with Pelvic and Acetabular Fractures. Open Orthop J. 2015; 9: 313–320.
5924		C T	Charalel RA, Durack JC, Mao J, Ross JS, Meltzer AJ, Sedrakyan A. Statewide Inferior Vena Cava Filter Placement, Complications, and Retrievals: Epidemiology and Recent Frends. Med Care. 2018 Mar;56(3):260-265. doi: 0.1097/MLR.0000000000000867.

Exhibit	Marked for ID	Admitted in Evidence	Description
6925			Charles HW, Black M, Kovacs S, Gohari A, Arampulikan J,
			McCann JW, Clark TW, Bashar M, Steiger D. G2 Inferior Vena
			Cava Filter: Retrievability and Safety. J Vasc Interv Radiol.
			2009 Aug;20(8):1046-51. doi: 10.1016/j.jvir.2009.03.046. Epub
(00)			2009 Jun 28.
6926			Charlton-Ouw KM, Leake SS, Sola CN, Sandhu HK, Albarado
			R, Holcomb JB, Miller CC 3rd, Safi HJ, Azizzadeh A
			Technical and financial feasibility of an inferior year gava filter
			retrieval program at a level one trauma center. Ann Vasc Surg
			2015 Jan;29(1):84-9. doi: 10.1016/j.avsg.2014.05.018 Epub
6007			2014 Jun 12.
6927			Chen D, Apple DF Jr, Hudson LM, Bode R. Medical
	j		Complications During Acute Rehabilitation Following Spinal
			Cord Injury – Current Experience of the Model Systems Arch
6000			Phys Med Rehabil. 1999 Nov;80(11):1397-401.
6928			Cherry RA, Nichols PA, Snavely TM, David MT, Lynch FC
			Prophylactic inferior vena cava filters: do they make a
			difference in trauma patients? J Trauma. 2008 Sep;65(3):544-8.
			doi: 10.1097/TA.0b013e31817f980f.
6929			Cheung MC, Asch MR, Gandhi S, Kingdom JC. Temporary
			Inferior Vena Cava Filter Use in Pregnancy. J Thromb
			Haemost. 2005 May;3(5):1096-7.
6930			Chitwood WR Jr, Chiang KS, Williams JM, Zeri RS, Semer
			DA. Embolectomy of a Bird's Nest vena cava filter. Ann Thorac
			Surg. 1994 Dec;58(6):1766-8.
6931			Cipolla J, Weger NS, Sharma R, Schrag SP, Sarani B, Truitt M,
			Lorenzo M, Sims CA, Kim PK, Torigian D, Temple-Lykens B,
			Sicoutris CP, Stawicki SP. Complications of vena cava filters:
			A comprehensive clinical review. OPUS 12 Scientist 2008 Vol.
			2, No. 2.
6932			CIRA, CIRA Statement on IVC Filter Safety Concern Noted by
			Health Canada
6933			CLOTS, Effectiveness of intermittent pneumatic compression in
		1	reduction of risk of DVT
5934		(Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH,
		-	Tomkowski W, Turpie AG, Egberts JF, Lensing AW;
			ARTEMIS Investigators. Efficacy and safety of fondaparinux
		l f	for the prevention of venous thromboembolism in older acute
		r	medical patients: randomised placebo controlled trial. BMJ.
		2	2006 Feb 11;332(7537):325-9. Epub 2006 Jan 26.

Exhibit	Marked for ID	Admitted in Evidence	Description
6935			Connolly PH, Balachandran VP, Trost D, Bush HL Jr. Open
		-	Surgical Inferior Vena Cava Filter Retrieval for Caval
			Perforation and a Novel Technique for minimal cavotomy filter
			extraction. J Vasc Surg. 2012 Jul;56(1):256-9; discussion 259.
			doi: 10.1016/j.jvs.2011.12.065. Epub 2012 Apr 12.
6936			Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren L
			Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J. Wang S.
			Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener
			HC, Joyner CD, Wallentin L; RE-LY Steering Committee and
			Investigators. Dabigatran versus Warfarin in Patients with Atrial
			Fibrillation. N Engl J Med. 2009 Sep 17:361(12):1139-51 doi:
			10.1056/NEJMoa0905561. Epub 2009 Aug 30.
6937			Cook AD, Gross BW, Osler TM, Rittenhouse KJ, Bradburn EH.
			Shackford SR, Rogers FB. Vena Cava Filter Use in Trauma and
			Rates of Pulmonary Embolism, 2003-2015. JAMA Surg. 2017
6020			Aug 1;152(8):724-732. doi: 10.1001/jamasurg.2017.1018.
6938			Corriere, M.A., et al., Vena cava filters and inferior vena cava
6000			thrombosis. J Vasc Surg, 2007. 45(4): 789-94.
6939			Cura, M., Computed tomography evaluation of inferior vena
(0.40			cava Bard G2 filters. (Meeting Abstract). 2010: S3.
6940			Cuschieri, Inflammation and the Host Response to Injury a
			Large Scale Collaborative Project: Patient-Oriented Research
			Core Standard Operating Procedure for Clinical Care X.
			Guidelines for Venous Thromboembolism Prophylaxis in the
(041			Trauma Patient
6941			Cynamon J, Bakal CW, Epstein SB, Gabelman G. Percutaneous
			removal of a titanium Greenfield filter. AJR Am J Roentgenol.
6042			1992 Oct;159(4):777-8.
6942			Damascelli B, Ticha V, Patelli G, et al. Use of a retrievable
			vena cava filter with low-intensity anticoagulation for
			prevention of pulmonary embolism in patients with cancer: an
			observational study in 106 cases. J Vasc Interv Radiol 2011:
6943			22:1312-9.
0943			Dardik A, Campbell KA, Yeo CJ, Lipsett PA. Vena cava filter
			ensnarement and delayed migration: an unusual series of cases
6944			J Vasc Surg. 1997 Nov;26(5):869-74.
U7 44			Das M, Panter L, Wynn GJ, Taylor RM, Connor N, Mills JD,
			Kirchhof P, Gupta D. Primary Care Atrial Fibrillation Service
			Outcomes from Consultant-Led Anticoagulation Assessment
			Clinics in the Primary Care Setting in the UK, BMJ Open, 2015
			Dec 9;5(12):e009267. doi: 10.1136/bmjopen-2015-009267.

Exhibit	Marked for ID	Admitted in Evidence	Description	
6945			Davies MG, Hart JP, El-Sayed HF. Efficacy of prophy inferior vena caval filters in prevention of pulmonary e in the absence of deep venous thrombosis. J Vasc Surg Lymphat Disord. 2016 Jan;4(1):127-130.e1. doi:	mbolism
6946			10.1016/j.jvsv.2015.05.008. Epub 2015 Jul 16 Davison BD, Grassi CJ. TrapEase Inferior Vena Cava Placed via the Basilic Arm Vein: A New Antecubital A	Filter Access. J
6947			Vasc Interv Radiol. 2002 Jan;13(1):107-9. Dazley JM, Wain R, Vellinga RM, Cohen B, Agulnick Prophylactic Inferior Vena Cava Filters Prevent Pulmo Embolisms in High- Risk Patients Undergoing Major S Surgery. J Spinal Disord Tech. 2012 Jun;25(4):190-5.	MA. nary pinal
6948			10.1097/BSD.0b013e31821532bd. de Gonzalez AB, Mahesh M, Kim K-P; et al. Projected risks from computed tomographic scans performed in t United States in 2007. Arch Intern Med. 2009; 169(22)	cancer he
6949			de Villiers L, Mackenzie S, Gibbs H, Leggett D, Neels Harper J., Initial Australian Experience with the Recov. Inferior Vena Cava Filter in Patients with Increased Risthromboembolic disease. J Med Imaging Radiat Oncol. Apr;52(2):124-9. doi: 10.1111/j.1440-1673.2008.01929	M, ery sk of 2008
6950			De Waele JJ, De Pauw M, Van Belleghem Y, Van Noo Diagnosis of myocardial perforation by a Greenfield fil by transesophageal echocardiography. J Am Soc Echoc 2002 Apr;15(4):374-5.	ten G., ter made
6951			Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Simonneau G. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with prodeep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl 1998;338:409-415.	Y, ximal
6952			Defraigne JO, Vahdat O, Lacroix H, Limet R. Proximal migration of vena caval filters: report of two cases with operative retrieval. Ann Vasc Surg. 1995 Nov;9(6):571-	
6953			Deitelzweig S.B., Johnson B.H., Lin J., Schulman K.L.; Prevalence of clinical venous thromboembolism in the Ucurrent trends and future projections. Am J Hematol. 2011;86:217-220.	
6954			Dennis JW, Menawat S, Von Thron J, Fallon WF Jr, Vin GO, Laneve LM, Jagger C, Frykberg ER. Efficacy of Dovenous Thrombosis Prophylaxis in Trauma Patients and Identification of High-Risk Groups. J Trauma. 1993 Jul;35(1):132-8; discussion 138-9.	eep

Exhibit	Marked for ID	Admitted in Evidence	Description	
6955			Desai KR, Errea M, Ryu RK, Lewandowski RJ. Extra Cases in Inferior Vena Cava Filter Retrieval. Semin Ir Radiol. 2016 Jun;33(2):149-56. doi: 10.1055/s-0036-1	itervent
6956			Desai KR, Lewandowski RJ, Salem R, Mouli SK, Kar Laws JL, Ryu RK. Retrieval of Inferior Vena Cava Fil Prolonged Dwell Time: A Single-Center Experience in Retrieval Procedures. JAMA Intern Med. 2015 Sep;175(9):1572-4. doi: 10.1001/jamainternmed.2015	p JK, Iters With n 648
6957			Desai SS, Naddaf A, Pan J, Hood D, Hodgson KJ. Imp Consensus Statements and Reimbursement on Vena C Utilization. J Vasc Surg. 2016 Aug;64(2):425-429. doi 10.1016/j.jvs.2016.01.046. Epub 2016 Mar 4.	act of ava Filter
6958			Desai TR, Morcos OC, Lind BB, Schindler N, Caprini D, Warner D, Gupta N. Complications of indwelling reversus permanent inferior vena cava filters. J Vasc Sur Lymphat Disord. 2014 Apr;2(2):166-73. doi: 10.1016/j.jvsv.2013.10.050. Epub 2014 Jan 16.	trievable
6959			Desai KR, Pandhi MB, Seedial SM, Errea MF, Salem I RK, Lewandowski RJ. Retrievable IVC Filters: Compr Review of Device-related Complications and Advanced Retrieval Techniques. Radiographics. 2017 Jul-Aug;37 1245. doi: 10.1148/rg.2017160167.	ehensive d
6960			Desjardins B, Kamath SH, Williams D. Fragmentation, embolization, and left ventricular perforation of a recoviliter. J Vasc Interv Radiol. 2010 Aug;21(8):1293-6. do 10.1016/j.jvir.2010.04.019. Epub 2010 Jul 3.	erv
6961			Deso SE, Idakoji IA, Muelly MC, Kuo WT. Creation of and Android Mobile Application for Inferior Vena Cava Filters. Semin Intervent Radiol. 2016 Jun;33(2):137-43. 10.1055/s-0036-1583206.	a (IVC)
6962			Deso SE, Idakoji IA, Kuo WT. Evidence-Based Evalua Inferior Vena Cava Filter Complications Based on Filte Semin Intervent Radiol. 2016 Jun;33(2):93-100. doi: 10 0036-1583208.	r Type.
6963			DeVivo MJ, Krause JS, Lammertse DP. Recent Trends Mortality and Causes of Death Among Persons with Sp. Cord Injury. Arch Phys Med Rehabil. 1999 Nov;80(11)	inal
6964			DeYoung E, Minocha J. Inferior Vena Cava Filters: Gui Best Practice, and Expanding Indications. Semin Interve Radiol. 2016 Jun;33(2):65-70. doi: 10.1055/s-0036-158	idelines. ent
6965			Dhand S, Stulberg SD, Puri L, Karp J, Ryu RK, Lewand RJ. The Role of Potentially Retrievable Inferior Vena Ca Filters in High-Risk Patients Undergoing Joint Arthropla Clin Diagn Res. 2015 Dec;9(12):TC01-3.	lowski ava

Exhibit	Marked for ID	Admitted in Evidence	Description
6966			Dimick, J.B., D.O. Staiger and J.D. Birkmeyer, Ranking
			hospitals on surgical mortality: the importance of reliability
			adjustment. Health Serv Res, 2010. 45(6 Pt 1): 1614-29.
6967			Dinglasan LA, Oh JC, Schmitt JE, Trerotola SO, Shlansky-
			Goldberg RD, Stavropoulos SW.Radiology. Complicated
			inferior vena cava filter retrievals: associated factors identified
			at preretrieval CT. 2013 Jan;266(1):347-54. doi:
			10.1148/radiol.12120372. Epub 2012 Oct 9.
6968			Dinglasan LA, Trerotola SO, Shlansky-Goldberg RD,
			Mondschein J, Stavropoulos SW. Removal of Fractured Inferior
			Vena Cava Filters: Feasibility and Outcomes. J Vasc Interv
	i		Radiol. 2012 Feb;23(2):181-7. doi: 10.1016/j.jvir.2011.10.023.
		İ	Epub 2011 Dec 16.
6969			Doe C, Ryu RK. Anatomic and Technical Considerations:
			Inferior Vena Cava Filter Placement. Semin Intervent Radiol.
			2016 Jun;33(2):88-92. doi: 10.1055/s-0036-1581089.
6970			Dorsey, Migrated Kimray-Greenfield filter lodged in the right
			ventricle: surgical removal and transatrial reinsertion
6971			Dossett, Unwarranted National Variation in the Use of
0)/1			Prophylactic Inferior Vena Cava Filters After Trauma: An
			analysis of the National Trauma Databank
6972			Dowell, Celect Inferior Vena Cava Wall Strut Perforation
			Begets Additional Strut Perforation
6973			Dreyer, Inferior vena cava filter migration to the right ventricle:
			a case report and review of filter migration and misdeployment
6974			Duffett L, Carrier M. Inferior vena cava filters. J Thromb
			Haemost. 2017 Jan;15(1):3-12. doi: 10.1111/jth.13564. Epub
			2016 Dec 26.
6975			Duffett LD, Gándara E, Cheung A, Bose G, Forster AJ, Wells
			PS. Outcomes of patients requiring insertion of an inferior vena
			cava filter: a retrospective observational study. Blood Coagul
			Fibrinolysis, 2014. 25(3): 266-71.
5976			Duggirala HJ, Herz ND, Caños DA, Sullivan RA, Schaaf R,
			Pinnow E, Marinac-Dabic D. Disproportionality analysis for
			signal detection of implantable cardioverter-defibrillator-related
			adverse events in the Food and Drug Administration Medical
	ļ		Device Reporting System. Pharmacoepidemiol Drug Saf. 2012
			Jan;21(1):87-93. doi: 10.1002/pds.2261. Epub 2011 Nov 18.
5977			Duperier, Acute Complications Associated with Greenfield
			Filter Insertion in High-Risk Trauma Patients

Exhibit	Marked for ID	Admitted in Evidence	Description	
6978			Durack JC, Westphalen AC, Kekulawela S, Bhanu SB, A	Avrin
			DE, Gordon RL, Kerlan RK. Perforation of the IVC, Rul	e
			Rather Than Exception, After Longer Indwelling Times f	for the
			Gunther Tulip and Celect Retrievable Filters. Cardiovasc	:
			Intervent Radiol. 2012 Apr;35(2):299-308. doi:	
			10.1007/s00270-011-0151-9. Epub 2011 Mar 30.	
6979			Duszak Jr R, Parker L, Levin DC, Rao VM. Placement ar	nd
			removal of inferior vena cava filters: national trends in th	ie.
			Medicare population. Am Coll Radiol 2011; 8 (7) 483-48	9
6980			Eifler AC, Lewandowski RJ, Gupta R, Karp J, Salem R, I	Lee I
			Ryu RK. Optional or Permanent: Clinical Factors that Op	timize
			Inferior Vena Cava Filter Utilization. J Vasc Interv Radio	olimniz.c
1			2013 Jan;24(1):35-40. doi: 10.1016/j.jvir.2012.09.021. Ep	n. Suh
			2012 Nov 22.	Jub
6981			EINSTEIN Investigators, Bauersachs R, Berkowitz SD, B	
			B, Buller HR, Decousus H, Gallus AS, Lensing AW, Miss	selwitz
			F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells	D D
			Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piove	ı, ellə E
			Schellong S. Oral rivaroxaban for symptomatic venous	chai,
			thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2	2400
			510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.	. 1
6982			EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensi	in
			AW, Decousus H, Jacobson BF, Minar E, Chlumsky J,	111
		İ	Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SI	,
			Bounameaux H, Davidson BL, Misselwitz F, Gallus A\$,	<i>)</i> ,
			Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the	he
			treatment of symptomatic pulmonary embolism. N Engl J	Med
			2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa11135	772
			Epub 2012 Mar 26.	772.
6983			Emaminia A, Fedoruk LM, Hagspiel KD, Bozlar U, Kron	II
			Inferior vena cava filter migration to the heart. Ann Thorac	iL.
			Surg. 2008 Nov;86(5):1664-5. doi:	
			10.1016/j.athoracsur.2008.04.063.	
6984			Engmann E, Asch MR. Clinical experience with the antecu	hital
			Simon nitinol IVC filter. J Vasc Interv Radiol. 1998 Sep-	ionai
			Oct;9(5):774-8.	İ
5985			Eriksson, Rivaroxaban versus enoxaparin for	
			thromboprophylaxis after hip arthroplasty	
5986			Errea M, Lewandowski R, Salem R, Karp J, Desai K. Devi	CO
			specific adverse event rates in retrievable inferior vena cava	0
			filters: a systematic review and meta-analysis. Abstract 205	a
			JVIR Scientific Session, March 7, 2017, S90-S91.	<i>)</i> .
5987			Esparez, Fibrin Cap Disruption: An Adjunctive Technique	for
			Inferior Vena Cava Filter Retrieval	101

Exhibit	Marked for ID	Admitted in Evidence	Description	
6988			Ezekowitz, Comparison of Dabigatran and Warfarin i	n Dotionts
			with Atrial Fibrillation and Valvular Heart Disease	n ranems
6989			Falck-Ytter, Prevention of VTE in orthopedic surgery	natiente
6990			Fan, K., et al., High-Performance Signal Detection for	r Adverse
			Drug Events using MapReduce Paradigm. AMIA Ann	III Symn
6001			Proc, 2010. 2010: 902-6	
6991	j		FDA Safety - Inferior Vena Cava (IVC) Filters: Initial	
			Communication: Risk of Adverse Events with Long T	erm Use
6000			08/09/2010.	
6992			FDA Safety Communications, Removing Retrievable	Inferior
			Vena Cava Filters. 05/06/2014, http://wayback.archive	_
			1t.org//993/20170722215731/https://www.fda.gov/Me	dicalDevi
6002			ces/Safety/AlertsandNotices/ucm396377.htm	
6993			FDA Safety Communications, Removing Retrievable	nferior
			vena Cava Filters: Initial Communication	
			08/09/2010.http://www.fda.gov/MedicalDevices/Safet	v/Alertsa
(004			ndNotices/ucm221676.htm	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6994			FDA, Device Post Market Surveillance.	
			http://www.fda.gov/MedicalDevices/Safety/CDRHPos	tmarketS
(005			urveillance/default.ht m Accessed on January 20, 2017	
6995			FDA, MAUDE: Manufacturer and user facility device	
	1		experience. Available at:	
			http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfm	aude/sear
(00)			cn.cim	
6996			FDA, National Evaluation System for health Technolog	
			nttp://www.fda.gov/AboutFDA/CentersOffices/Officeo	fMedical
			Products and Tobacco /CDRH/CDRHReports/ucm 3019	12.htm
5997			Accessed on January 20, 2017.	
1997			Fedullo PF, Roberts A. Placement of vena cava filters a	nd their
			complications. UpToDate 2017.	
			https://www.uptodate.com/contents/placement-of-vena-	cava-
5998			filters-and-their-complications	
1990]	Feezor RJ, Huber TS, Welborn MB 3rd, Schell SR. Duc	denal
		į į	perforation with an interior vena cava filter- an unusual	cause of
999			abdominal pain. J Vasc Surg. 2002 May:35(5):1010-2	
1999		1	reigal DW, Gardner SN, McClellan M. Ensuring Safe a	nd
		1	Effective Medical Devices. N Engl J Med. 2003 Jan	
000			6;348(3):191-2.	
			Gerguson EJ, Lurie F, Brown M. Low Retrieval Rates of	
		1	emporary Inferior Vena Cava Filters in Trauma Patient	s. Am
001			ourg. 2015 Apr;81(4):428-9.	
		F	erreiro C, Abad-Cervero JF, Lopez-Pino MA. Fracture	and
	į	n	nigration of an Antheor vena cava filter. J Vasc Intery R	adiol.
		<u> </u>	996 Jan-Feb;7(1):149-50.	

Exhibit	Marked for ID	Admitted in Evidence	Description	
7002			Ferris EJ, McCowan TC, Carver DK, McFarland DR.	
			Percutaneous inferior vena caval filters: follow-up of	reven
			designs in 320 patients. Radiology. 1993 Sep;188(3):8	851 ₋₆
7003			Fotiadis NI, Sabharwal T, Dourado R, Fikrat S, Adam	Δ
			Technical error during deployment leads to vena cava	filton
			migration and massive pulmonary embolism. Cardiov	mer
	İ		Intervent Radiol. 2008 Jul;31 Suppl 2:S174-6. Epub 2	007 4112
			29.	007 Aug
7004			Frezza EE, Wachtel MS. A Simple Venous Thromboe	mala a 1:
			Prophylaxis Protocol for Patients Undergoing Bariatric	German
			Obesity (Silver Spring). 2006 Nov;14(11):1961-5.	c Surgery.
7005			Friedell ML, Goldenkranz RJ, Parsonnet V, Alpert J, I) CDV
			Brener BJ, Aueron FM. Migration of a Greenfield filte	Brief DK,
			pulmonary artery: a case report. J Vasc Surg. 1986	r to the
			Jun;3(6):929-31.	
7006			Friese J, Leake B, Fleming CJ, Woodrum, DA, Bjarna	* *
			Misra S, McKusick MA, McPhail I, Stockland A. Incr	son H,
			hospital mortality in patients with pe/DVT and IVC fil	eased in-
			Abstract No. 53. JVIR Scientific Session, S26	ter.
7007			Frisbie JH, Sharma GV, Brahma P, Hess MJ, Hayes JA	
			Recurrent Pulmonary Embolism and Duly	\
			Recurrent Pulmonary Embolism and Pulmonary Hyper in Chronic Tetraplacia, Spinal Card, 2005, O. 4.42(10)	tension
7008			in Chronic Tetraplegia. Spinal Cord. 2005 Oct;43(10):6	525-30.
			Frisbie JH, Sharma GV. The Prevalence of Pulmonary	
			Embolism in Chronically Paralyzed Subjects: A Review	v of
			Available Evidence. Spinal Cord. 2012 Jun; 50(6):400-3	3. doi:
7009			10.1038/sc.2011.154. Epub 2011 Dec 13.	
			Funaki B, Funaki C. Embolization of High Flow Arteri	ovenous
			Malformation. Semin Intervent Radiol. 2016 Jun;33(2): doi: 10.1055/s-0036-1582125.	157-60.
7010			Funaki, B. Filter migration to right heart. Semin Interve	
			Radiol 2007 Sept 24(2):256 60 dai: 10.1055/ 2007 og	nt
7011			Radiol. 2007 Sep;24(3):356-60. doi: 10.1055/s-2007-98	5751.
			Furtado CD, Aguirre DA, Sirlin CB, et al. Whole-body	CT
		,	screening: spectrum of findings and recommendations i	n 1192
012			patients. Radiology 2005; 237(2):385-94.	
			Galanaud JP, Laroche JP, Righini M. The history and hi	storical
		, i	reatments of deep vein thrombosis. J Thromb Haemost.	2013
013			Mar;11(3):402-11. doi: 10.1111/jth.12127.	
			Galhotra S, Amesur NB, Zajko AB, Simmons RL. Migr	ation of
		l T	he Gunther Tulip inferior vena cava filter to the chest. J	Vasc
		1	nterv Radiol. 2007 Dec;18(12):1581-5.	

Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current	Exhibit	Marked for	Admitted in	Description
Vemulapalli P, Gibbs K, Suggs WD. Long-Term Outdome of Inferior Vena Cava Filter Placement in Patients Undergoing Gastric Bypass. Ann Vasc Surg. 2010 Oct;24(7):946-9. doi: 10.1016/j.avsg.2010.05.004. Gargiulo NJ 3rd, Veith FJ, Lipsitz EC, Suggs WD, Ohki T, Goodman E. Experience with inferior vena cava filter placement in patients undergoing open gastric bypass procedures. J Vasc Surg. 2006 Dec;44(6):1301-5. Epub 2006 Oct 20. Gaspard SF, Gaspard DJ. Retrievable Inferior Vena Cava Filter. Are Rarely Removed. Am Surg. 2009 May;75(5):426-8. Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg. 2011; 54:348-88. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec. 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Lowdose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Berggvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thrombolysis. 2007;34:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Set finking the One-Filter-f	7014	ID	Evidence	
Inferior Vena Cava Filter Placement in Patients Undergoing Gastric Bypass. Ann Vasc Surg. 2010 Oct;24(7):946-9. doi: 10.1016/j.avsg.2010.05.004. Gargiulo NJ 3rd, Veith FJ, Lipsitz EC, Suggs WD, Ohki T, Goodman E. Experience with inferior vena cava filter placement in patients undergoing open gastric bypass procedures. J Vasc Surg. 2006 Dec;44(6):1301-5. Epub 2006 Oct 20. 7016 Gaspard SF, Gaspard DJ, Retrievable Inferior Vena Cava Filter Are Rarely Removed. Am Surg. 2009 May;75(5):426-8. Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:348-88. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low- dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Berggvist D, Lassen MR, Colvell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F, Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7.	7014			Gargiulo NJ 3rd, O'Connor DJ, Veith FJ, Lipsitz EC,
Gastric Bypass. Ann Vasc Surg. 2010 Oct;24(7):946-9. doi: 10.1016/j.avsg.2010.05.004. Gargiulo NJ 3rd, Veith FJ, Lipsitz EC, Suggs WD, Ohki T, Goodman E. Experience with inferior vena cava filter placement in patients undergoing open gastric bypass procedures. J Vasc Surg. 2006 Dec;44(6):1301-5. Epub 2006 Oct 20. Gaspard SF, Gaspard DJ. Retrievable Inferior Vena Cava Filter Are Rarely Removed. Am Surg. 2009 May;75(5):426-8. Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:34S-88. Gerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7.				Vemulapalli P, Gibbs K, Suggs WD. Long-Term Outcome of
10.1016/j.avsg.2010.05.004.				Interior Vena Cava Filter Placement in Patients Undergoing
Gargiulo NJ 3rd, Veith FJ, Lipsitz EC, Suggs WD, Ohki T, Goodman E. Experience with inferior vena cava filter placement in patients undergoing open gastric bypass procedures. J Vasc Surg. 2006 Dec;44(6):1301-5. Epub 2006 Oct 20. Gaspard SF, Gaspard DJ. Retrievable Inferior Vena Cava Filter Are Rarely Removed. Am Surg. 2009 May;75(5):426-8. Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:348-8S. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low- dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqwist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C, Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thrombo Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7.				Gastric Bypass. Ann Vasc Surg. 2010 Oct;24(7):946-9. doi:
Goodman E. Experience with inferior vena cava filter placement in patients undergoing open gastric bypass procedures. J Vasc Surg. 2006 Dec;44(6):1301-5. Epub 2006 Oct 20. Gaspard SF, Gaspard DJ. Retrievable Inferior Vena Cava Filter Are Rarely Removed. Am Surg. 2009 May;75(5):426-8. Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:348-88. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stem JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7.	7015			10.1016/j.avsg.2010.05.004.
placement in patients undergoing open gastric bypass procedures. J Vasc Surg. 2006 Dec;44(6):1301-5. Epub 2006 Oct 20. Gaspard SF, Gaspard DJ. Retrievable Inferior Vena Cava Filter Are Rarely Removed. Am Surg. 2009 May;75(5):426-8. Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:348-88. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep:122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current	/015			Gargiulo NJ 3rd, Veith FJ, Lipsitz EC, Suggs WD, Ohki T,
procedures. J Vasc Surg. 2006 Dec;44(6):1301-5. Epub 2006 Oct 20. 7016 Gaspard SF, Gaspard DJ. Retrievable Inferior Vena Cava Filter. Are Rarely Removed. Am Surg. 2009 May;75(5):426-8. Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:348-88. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				Goodman E. Experience with inferior vena cava filter
Oct 20. Gaspard SF, Gaspard DJ. Retrievable Inferior Vena Cava Filter Are Rarely Removed. Am Surg. 2009 May;75(5):426-8. Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:345-88. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrivable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current for the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the content of the				placement in patients undergoing open gastric bypass
Gaspard SF, Gaspard DJ. Retrievable Inferior Vena Cava Filter Are Rarely Removed. Am Surg. 2009 May;75(5):426-8. Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:34S-8S. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WHI. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7.				procedures. J Vasc Surg. 2006 Dec;44(6):1301-5. Epub 2006
Are Rarely Removed. Am Surg. 2009 May;75(5):426-8. Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:34S-88. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al.: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH I. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrivable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7.	7016			
Are Rarely Removed. Am Surg. 2009 May;75(5):426-8. Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:34S-8S. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current	7016			Gaspard SF, Gaspard DJ. Retrievable Inferior Vena Cava Filters
Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:34S-8S. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WHI. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				Are Rarely Removed. Am Surg. 2009 May;75(5):426-8.
retrieval rates of femporary inferior vena cava filters. J Vasc Surg 2011; 54:345-85. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Lowdose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current	7017			Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving
Surg 2011; 54:34S-8S. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospectiv Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Lowdose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				retrieval rates of temporary inferior vena cava filters. J Vasc
Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low- dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				Surg 2011; 54:34S-8S.
Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Low- dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current	7018			Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospective
Engl J Med. 1994 Dec 15;331(24):1601-6. Geerts WH, Jay RM, Code KI, et al: A Comparison of Lowdose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				Study of Venous Thromboembolism After Major Trauma, N
Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				Engl J Med. 1994 Dec 15;331(24):1601-6.
dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH I. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current	7019			Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-
Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				dose Heparin with Low-molecular Weight Heparin as
Trauma. N. Eng. J. Med. 1996; 335: 701-707. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				Prophylaxis against Venous Thromboembolism after Major
Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				Trauma. N. Eng. J. Med. 1996; 335: 701-707.
Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1. Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582 123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current	7020			Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR
Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH I, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				Colwell CW, Ray JG. Prevention of Venous
Antithrombotic and Thrombolytic Therapy. Geerts WH 1, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current			!	Thromboembolism, The Seventh ACCP Conference on
GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				Antithrombotic and Thrombolytic Therapy, Geerts WH1 Pineo
Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray IG
Cava filter. J Cardiothorac Vasc Anesth, 2009. 23(3): 381-3. Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current	7021			Gelzinis, T., et al., Intracardiac migration of retrievable yena
Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				cava filter. J Cardiothorac Vasc Anesth, 2009, 23(3): 381-3
five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current	7022			Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W K. A.
neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				five-year, retrospective, comparison review of survival in
and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				neurosurgical patients diagnosed with venous thromboembolism
anticoagulants. J Thromb Thrombolysis. 2007;24:247-254. Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				and treated with either inferior yena caya filters or
Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				
Vena Cava Filters: Rethinking the One-Filter-for-All Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current	7023		(Ghatan CE, Ryu RK, Permanent versus Retrievable Inferior
to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current				Vena Cava Filters: Rethinking the One-Filter-for-All Approach
Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current			1	to Mechanical Thromboembolic Prophylaxis Semin Intervent
Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current]	Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123
filters: so far so weak. Chest. 2002 Sep;122(3):963-7. Giroux M-F. Ask the experts: what is your practice's current	7024		(Girard P, Stern JB, Parent F. Medical literature and year cave
Giroux M-F. Ask the experts: what is your practice's current			l f	filters: so far so weak. Chest. 2002 Sep. 122(3):963-7
IVC filter retailers I what is your practice's current	7025		(Giroux M-F. Ask the experts: what is your practice's aurent
1 IV THE FEITHER PROTOCOL and in which cases do you devicte			I	VC filter retrieval protocol, and in which cases do you deviate
from it? Endovascular Today October 2015, pp. 53-58.			f	rom it? Endovascular Today October 2015, pp. 52.50

Exhibit	Marked for ID	Admitted in Evidence	Description	
7026			Giugliano RP, Ruff CT, Braunwald E, Murphy SA, W	iviott SD,
			Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Šp	inar J,
			Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M,	Grip LT,
			Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM	
			ENGAGE AF-TIMI 48 Investigators. Edoxaban versu	s warfarin
			in patients with atrial fibrillation. N Engl J Med. 2013	Nov
			28;369(22):2093-104. doi: 10.1056/NEJMoa1310907.	Epub
7027			Godat LN, Kobayashi L, Chang D, Coimbra R: Can W	/ F
			Stop Worrying About Venous Thromboembolism After	e Ever
			Trauma?1 Trauma 2015; 78: 475-481.	er
7028			Goei AD, Josephs SC, Kinney TB, Ray CE Jr, Sacks I	\
			Improving the tracking and removal of retrievable infe).
			cava filters. Semin Intervent Radiol. 2011 Mar;28(1):1	rior vena
			doi: 10.1055/s-0031-1273946.	18-27.
7029			Goldhaber SZ, et al: A prospective study of risk factor	a for
			pulmonary em holism in women. JAMA 277:642-645,	1007
7030			Gómez-Outes A, Terleira-Fernández AI, Lecumberri R	Suároz
			Gea ML, Vargas-Castrillón E. Direct oral anticoagulan	ts in the
			treatment of acute venous thromboembolism: a system	atic
			review and meta-analysis. Thromb Res. 2014 Oct;134(4).774_
			82. doi: 10.1016/j.thromres.2014.06.020. Epub 2014 Ju	116
7031			Gosin JS, Graham AM, Ciocca RG, Hammond JS. Effi	cacy of
			Prophylactic Vena Cava Filters in High-Risk Trauma P	atients
			Ann Vasc Surg. 1997 Jan;11(1):100-5.	
7032			Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arc	elus JI.
·			Heit JA, Samama CM. Prevention of VTE in nonorthor	edic
			surgical patients: Antithrombotic Therapy and Preventi	on of
			Thrombosis, 9th ed: American College of Chest Physic	ians
			Evidence-Based Clinical Practice Guidelines, Chest. 20	12
7022			Feb;141(2 Suppl):e227S-e277S. doi: 10.1378/chest.11-	2297.
7033			Grande WJ, Trerotola SO, Reilly PM. et al. Experience	with the
			Recovery Filter as a Retrievable Inferior Vena Cava Fil	ter. J
7034			Vasc Interv Radiol. 2005;16:1189 – 1193.	
7034			Granger CB, Alexander JH, McMurray JJ, Lopes RD, F	Iylek
			EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezu	m A,
			Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G,	Garcia
			D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosil	lo AG,
]]	Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis F	BS,
		1	Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FV	W, Zhu
		J	J, Wallentin L; ARISTOTLE Committees and Investiga	tors.
			Apixaban versus warfarin in patients with atrial fibrillat	ion. N
			Engl J Med. 2011 Sep 15;365(11):981-92. doi:	
			10.1056/NEJMoa1107039. Epub 2011 Aug 27.	

Exhibit	Marked for ID	Admitted in Evidence	Description	
7035			Granke K, Abraham FM, McDowell DE. Vena cava f	iltar
			disruption and central migration due to accidental gui	dewire
			manipulation: a case report. Ann Vasc Surg. 1996 Jan	:10(1):49-
			53.	
7036			Grassi CJ, Goldhaber SZ. Interruption of the inferior	vena cava
			for prevention of pulmonary embolism: transvenous f	llter
5005		***************************************	devices. Herz. 1989 Jun;14(3):182-91.	
7037			Grassi CJ, Matsumoto AH, Teitelbaum GP. Vena Cav	al
			Occlusion after Simon Nitinol Filter Placement: Identi	fication
			with MR Imaging in Patients with Malignanacy. J Vas	c Interv
7020			Radiol. 1992 Aug;3(3):535-9.	
7038			Grassi CJ, Swan TL, Cardella JF, Meranze SG, Oglev	ie SB,
			Omary RA, Roberts AC, Sacks D, Silverstein MI, Toy	vbin RB,
			Lewis CA. Quality	
			improvement guidelines for percutaneous permanent in	nferior
			vena cava filter placement for the prevention of pulmo	nary
7039			embolism. J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S	271-5.
7039			Grassi CJ. Inferior Vena Caval Filters Analysis of Five	
į			Currently Available Devices. AJR Am J Roentgenol. 1	991
7040			Apr;156(4):813-21.	
7040			Greenfield LJ, Cho KJ, Proctor M, Bonn J, Bookstein.	IJ,
			Castaneda-Zuniga WR, Cutler B, Ferris EJ, Keller F, M	1cCowan
			T, et al. Results of a multicenter study of the modified	hook
7041			titanium Greenfield filter. J Vasc Surg. 1991 Sep;14(3)	:253-7.
/ / / /			Greenfield LJ, Cho KJ, Tauscher JR. Evolution of Hoo	k Design
			for Fixation of the Titanium Greenfield Filter. J Vasc S	urg.
7042			1990 Sep;12(3):345-53.	
			Greenfield LJ, Proctor MC, Cho KJ, Cutler BS, Ferris I	EJ,
			McFarland D, Sobel M, Tisnado J. Extended Evaluation Titanium Greenfield Vena Caval Filter. J Vasc Surg. 19	n of the
			Sep;20(3):458-64; discussion 464-5.	194
7043			Greenfield LJ, Proctor MC. The Percutaneous Greenfie	1.1.00
			Outcomes and Practice Patterns. J Vasc Surg. 2000	ld Filter-
		-	Nov;32(5):888-93.	
7044			Greenfield LJ, Proctor MC. Twenty Year Clinical Expe	
		,	with Greenfield Filter. 1995; Cardiovasc. Surg. 3:199-2	nence
7045			Greenfield LJ, Zocco J, Wilk J, Schroeder TM, Elkins F	03.
			Clinical experience with the Kim-Ray Greenfield vena	eaval
		1	filter. Ann Surg. 1977 Jun; 185(6): 692-8.	avai
7046		(Greenfield LJ. Historical Reminiscence: Origin of the	
			Greenfield Filter. Am Surg. 2010 Dec;76(12):1319-20.	

Exhibit	Marked for ID	Admitted in Evidence	Description
7047			Groom H, Hopkins DP, Pabst LJ, Murphy Morgan J, Patel M,
			Calonge N, Coyle R, Dombkowski K, Groom AV, Kurilo MB,
			Rasulnia B, Shefer A, Town C, Wortley PM, Zucker J
			Community Preventive Services Task Force. Immunization
			Information Systems to Increase Vaccination Rates – A
			Community Guide Systematic Review. J Public Health Manag
			Pract. 2015 May-Jun;21(3):227-48. doi:
			10.1097/PHH.0000000000000069.
7048			Guidance for the Industry - Good Pharmacovigilance Practices
			and Pharmacoepidemiologic assessment, March 2005
			https://www.fda.gov/downloads/Drugs/GuidanceComplianceRe
			gulatoryInformation/Guidances/UCM071696.pdf
7049			Guyatt GH, Akl EA, Crowther M, Gutterman DD,
			Schuünemann HJ, American College of Chest Physicians
			Antithrombotic Therapy and Prevention of Thrombosis Panel.
			Executive summary: Antithrombotic Therapy and Prevention of
			Thrombosis, 9th ed: American College of Chest Physicians
			Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb.
7050			141 (2 Suppl):7S-47S.
7050			Guyatt GH, et al: Approach to outcome measurement in the
			prevention of thrombosis in surgical and medical patients:
			antithrombotic therapy and prevention of thrombosis, 9th Ed.:
			American College of Chest Physicians Evidence-Based Clinical
7051			Practice Guidelines. Chest 141 (Suppl):31855S-3194S, 2012.
7051			Haddadian, B., et al., Sudden cardiac death caused by migration
			of a TrapEase inferior vena cava filter: case report and review
7052			of the literature. Clin Cardiol, 2008. 31(2): 84-7
1032			Hahn D. Retrievable Filter Update: The Denali Vena Cava
7053			Filter Semin Intervent Radiol. 2015;32(4): 379–383.
1033			Halkett GK, Jiwa M, Lobb EA. Patients' Perspectives on the
			Role of Their General Practitioner After Receiving an
			Advanced Cancer Diagnosis. Eur J Cancer Care (Engl). 2015
7054			Sep;24(5):662-72. doi: 10.1111/ecc.12224. Epub 2014 Aug 6.
7034			Halmi, Preoperative placement of retrievable inferior vena cava
7055			filters in bariatric surgery
, 033			Hammond, Audit of the use of IVC filters in the UK: experience
7056			from three centres over 12 years Harries SP, Wells IP, Pophettem CA, Lorg town 6-11
			Harries SR, Wells IP, Roobottom CA. Long-term follow-up of the antheor inferior vena cava filter. Clin Radiol. 1998
			May;53(5):350-2.
7057			
			Hauben, M., Signal detection in the pharmaceutical industry: integrating clinical and computational approaches. Drug Saf,
			mogramig chinear and computational approaches. Drug Saf.

Exhibit	Marked for	Admitted in	Description	
7050	ID	Evidence	•	
7058			Haut ER, Garcia LJ, Shihab HM, Brotman DJ, Stevens	KA,
			Sharma R, Chelladurai Y, Akande TO, Shermock KM,	Kebede
			S, Segal JB, Singh S. The effectiveness of prophylactic	inferior
			vena cava filters in trauma patients: a systematic review	and
			meta-analysis. JAMA Surg. 2014 Feb;149(2):194-202	doi:
7050			10.1001/jamasurg.2013.3970.	
7059			Headrick JR Jr, Barker DE, Pate LM, Horne K, Russell	WL,
			Burns RP. The Role of Ultrasonography and Inferior Ve	ena Cava
			Filter Placement in High-Risk Trauma Patients. Am Sur	rg. 1997
70.50			Jan;63(1):1-8.	<i>O</i>
7060			Health Canada, Inferior Vena Cava Filters - Risk of Ser	ious
			Complications	
7061			Heit JA, et al: The epidemiology of venous thromboemb	nolism
			in the community. Thrombi Haemost 86:452-463, 2001.	00113111
7062			Helling TS, Kaswan S, Miller SL. Practice patterns in th	e use of
			retrievable inferior vena cava filters in a trauma populati	ion: Δ
			single-center experience. J Trauma 2009; 67:1293-6.	ion. A
7063			Hemmila MR, Osborne NH, Henke PK, Kepros JP, Pate	LSG
			Cain-Nielsen AH, Birkmeyer NJ. Prophylactic Inferior V	aou, 'ena
			Cava Filter Placement Does Not Result in a Survival Ber	ona nafit for l
			Trauma Patients. Ann Surg. 2015 Oct;262(4):577-85. do	:.
			10.1097/SLA.0000000000001434.	1.
7064			Ho KM, Tan JA, Burrell M, Rao S, Misur P. Venous	
İ			Thrombotic, Thromboembolic, and Mechanical Complic	entions
			After Retrievable Inferior Vena Cava Filters for Major T	roume
			Br J Anaesth. 2015 Jan;114(1):63-9. doi: 10.1093/bja/aet	1105
			Epub 2014 Jun 30.	1193.
7065			Hoff WS, Hoey BA, Wainwright GA, Reed JF, Ball DS,	
			Ringold M, Grossman MD. Early Experience with Retrie	vyo blo
			Inferior Vena Cava Filters in High-Risk Trauma Patients.	vable
			Coll Surg. 2004 Dec;199(6):869-74.	. J Am
7066			Hoffer, E.K., et al., Safety and efficacy of the Gunther Tu	-1:
			retrievable vena cava filter: midterm outcomes. Cardiova	шр
			Intervent Radiol, 2013. 36(4): 998-1005	sc
7067			Hokusai-VTE Investigators, Büller HR, Décousus H, Gro	
			MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE,	osso
			Schellong SM, Schwocho L, Segers A, Shi M, Verhamme	. D
			Wells P. Edoxaban versus warfarin for the treatment of	εP,
			symptomatic venous thromboembolism. N Engl J Med. 20	013
			Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638.	013
			2013 Aug 31.	Epub

Exhibit	Marked for ID	Admitted in Evidence	Description
7068			Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin
			versus dabigatran or rivaroxaban for thromboprophylaxis after
			hip or knee arthroplasty: Results of separate pooled analyses of
			phase III multicenter randomized trials. Circ Cardiovasc Qual
			Outcomes. 2010 Nov;3(6):652-60. doi:
			10.1161/CIRCOUTCOMES.110.957712. Epub 2010 Oct 5.
7069			Hull JE, Han J, Giessel GM. Retrieval of the recovery filter
			after arm perforation, fracture, and migration to the right
			ventricle. J Vasc Interv Radiol. 2008 Jul;19(7):1107-11. doi:
			10.1016/j.jvir.2008.03.011. Epub 2008 May 2. Review.
7070			Hull JE, Robertson SW. Bard Recovery filter: evaluation and
			management of vena cava limb perforation, fracture, and
			migration. J Vasc Interv Radiol. 2009 Jan;20(1):52-60 doi:
			10.1016/j.jvir.2008.09.032. Epub 2008 Nov 21.
7071			Iliescu B, Haskal ZJ. Advanced Techniques for Removal of
			Retrievable Inferior Vena Cava Filters. Cardiovasc Intervent
			Radiol. 2012 Aug;35(4):741-50. doi: 10.1007/s00270-011-
			0205-z. Epub 2011 Jun 15.
7072			Image Wisely. http://www.imagewisely.org Accessed on
			February 20, 2017.
7073			IMS Health. IMS Health Hospital Supply Index. Available
			from:
			http://www.imshealth.com/deployedfiles/imshealth/Global/Nort
			h%20America/United%20 States/Medical Device US/IMS
			Hospital Supply Index.pdf.
7074			Inuzuka, K., et al., Hemorrhagic shock with delayed
			retroperitoneal hemorrhage after deployment of an inferior vena
			cava filter: report of a case. Surg Today, 2007. 37(7): 618-21.
7075			Irwin E, Byrnes M, Schultz S, et al. A systematic method for
			follow-up improves removal rates for retrievable inferior vena
			cava filters in a trauma patient population. J Trauma 2010;
			69:866-9.
7076			Izutani, H., et al., Migration of an inferior vena cava filter to the
			right ventricle and literature review. Can J Cardiol, 2004. 20(2):
			233-5.
7077			Jaff M.R., McMurtry M.S., Archer S.L., Management of
		:	massive and submassive pulmonary embolism, iliofemoral deep
		1	vein thrombosis, and chronic thromboembolic pulmonary
			hypertension: a scientific statement from the American Heart
1070			Association. Circulation. 2011;123:1788-1830.
078			laff MR, Kaufman J. A measured approach to vena cava filter
			use – respect rather than regret. JAMA Cardiol. 2017; 2(1):5-6.

Exhibit	Marked for ID	Admitted in Evidence	Description	
7079			James KV, Sobolewski AP, Lohr JM, Welling RE. Tricus	spid
			insufficiency after intracardiac migration of a Greenfield	
			case report and review of the literature. J Vasc Surg. 1996	6
			Sep;24(3):494-8.	_
7080			Jassar AS, Nicotera SP, Levin N, Vernick WJ, Szeto WY	
			Inferior vena cava filter migration to the right ventricle. J	
			Surg. 2011 Mar;26(2):170-2. doi: 10.1111/j.1540-	ouru
			8191.2010.01194.x. Epub 2011 Feb 8.	
7081			Jia Z, Fuller TA, McKinney JM, Paz-Fumagalli R, Frey G	т
			Sella DM, Van Ha T, Wang W. Utility of Retrievable Inf	ferior
			Vena Cava Filters: A Systematic Literature Review and	CITOI
			Analysis of the Reasons for Nonretrieval of Filters with	
			Temporary Indications. Cardiovasc Intervent Radiol. 2018	8 Ian
			22. doi: 10.1007/s00270-018-1880-9. [Epub ahead of prin	o san H
7082			Jia Z, Wu A, Tam M et al. Caval Penetration by Inferior V	Zena
			Cava Filters: A Systematic Literature Review of Clinical	VCIIA
			Significance and Management. Circulation. 2015;132:944	L-52
7083			Joels CS, Sing RF, Heniford BT. Complications of Inferio	r JZ.
			Vena Cava Filters. Am Surg. 2003 Aug;69(8):654-9.	<i>7</i> 1
7084			Johnson MS. Vena cava filter fracture: unplanned obsolese	cence
			J Vasc Interv Radiol. 2012 Feb;23(2):196-8. doi:	cence.
			10.1016/j.jvir.2011.12.004.	
7085			Jones T, Ugalde V, Franks P, Zhou H, White RH. Venous	
			Thromboembolism After Spinal Cord Injury: Incidence, T	ime
			Course, and Associated Risk Factors in 16,240 Adults and	I I
			Children. Arch Phys Med Rehabil. 2005 Dec;86(12):2240-	-7
7086			Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl I	FA
			Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Mui	rad
			MH. Prevention of VTE in nonsurgical patients: Antithron	nhotic
			Therapy and Prevention of Thrombosis, 9th ed: American	1100116
			College of Chest Physicians Evidence-Based Clinical Prac	etice
			Guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-e226S. d	loi.
			10.1378/chest.11-2296.	
7087			Kakkar V.V., Howe C.T., Flanc C., Clarke M.B.; Natural	
			history of postoperative deep-vein thrombosis. Lancet.	
			1969;2:230-232.	
7088			Kalva SP, Athanasoulis CA, Fan CM, Curvelo M, Geller S	SC
			Greenfield AJ, Waltman AC, Wisky S. Recovery Vena Cav	va
			Filter: Experience in 96 Patients. Cardiovasc Intervent Rad	liol
			(2006) 29:559-564.	.101

Exhibit	Marked for ID	Admitted in Evidence	Description
7089	1.0	Evidence	Kalva SP, Chlapoutaki C, Wicky S, Greenfield AJ, Waltman
			AC, Athanasoulis CA. Suprarenal Inferior Vena Cava Filters: A
			20 Year Single Center Experience. J Vasc Interv Radiol. 2008
			Jul;19(7):1041-7. doi: 10.1016/j.jvir.2008.03.026. Epub 2008
			May 27.
7090			Kamath SD, McMahon BJ.Update on Anticoagulation: What
			the Interventional Radiologist Needs to Know. Semin Intervent
			Radiol. 2016 Jun;33(2):122-31. doi: 10.1055/s-0036-1582124.
7091			Kardys CM, Stoner MC, Manwaring ML, Barker M, Macdonald
			KG, Pender JR, Chapman WH 3rd. Safety and efficacy of
		i	intravascular ultrasound-guided inferior vena cava filter in super
			obese bariatric patients. Surg Obes Relat Dis. 2008 Jan-
5000			Feb;4(1):50-4. Epub 2007 Dec 11.
7092			Kardys CM, Stoner MC, Manwaring ML, Bogey WM, Parker
			FM, Powell S. The Use of Intravascular Ultrasound Imaging to
			Improve Use of Inferior Vena Cava Filters in a High-Risk
			Bariatric Population. J Vasc Surg. 2007 Dec;46(6):1248-52.
7093			Epub 2007 Oct 24.
1093			Karmy-Jones R, Jurkovich GJ, Velmahos GC, Burdick T,
			Spaniolas K, Todd SR, McNally M, Jacoby RC, Link D,
			Janczyk RJ, Ivascu FA, McCann M, Obeid F, Hoff WS,
			McQuay N Jr, Tieu BH, Schreiber MA, Nirula R, Brasel K,
			Dunn JA, Gambrell D, Huckfeldt R, Harper J, Schaffer KB,
			Tominaga GT, Vinces FY, Sperling D, Hoyt D, Coimbra R, Rosengart MR, Forsythe R, Cothren C, Moore EE, Haut ER,
			Hayanga AJ, Hird L, White C, Grossman J, Nagy K, Livaudais
			W, Wood R, Zengerink I, Kortbeek JB. Practice patterns and
			outcomes of retrievable vena cava filters in trauma patients: an
			AAST multicenter study. J Trauma. 2007 Jan;62(1):17-24;
			discussion 24-5.
7094			Karp JK, Desai KR, Salem R, et al. A dedicated inferior vena
			cava filter service line: how to optimize your practice. Semin
			Intervent Radiol 2016; 33:105-8.
7095			Katsamouris AA, Waltman AC, Delichatsios MA, Athanasoulis
			CA. Inferior vena cava filters: in vitro comparison of clot
			trapping and flow dynamics. Radiology. 1988 Feb;166(2):361-
7006			6.
7096			Kaufman JA, Kinney TB, Streiff MB, Sing RF, Proctor MC,
			Becker D, Cipolle M, Comerota AJ, Millward SF, Rogers FB,
] }	Sacks D, Venbrux AC. Guidelines for the use
			of retrievable and convertible vena cava filters: report from the
			Society of Interventional Radiology multidisciplinary consensus
			conference. J Vasc Interv Radiol. 2006 Mar;17(3):449-59.

Exhibit	Marked for ID	Admitted in Evidence	Description
7097			Kaufman JA, Rundback JH, Kee ST, Geerts W, Gillespie D, Kahn SR, Kearon C, Rectenwald J, Rogers FB, Stavropoulos SW, Streiff M, Vedantham S, Venbrux A. Development of a Research Agenda for Inferior Vena Cava Filters: Proceedings from a Multidisciplinary Research Consensus Panel. J Vasc Interv Radiol. 2009 Jun;20(6):697-707. doi: 10.1016/j.jvir.2009.03.007.
7098			Kaufman JA. Optional Vena Cava Filters: What, Why, and When. Vascular. 2007 Sep-Oct;15(5):304-13.
7099			Kazmers A, Jacobs LA, Perkins AJ. Pulmonary embolism in Veterans Affairs Medical Centers: is vena cava interruption underutilized? Am Surg. 1999; 65:1171-5.
7100			Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JR, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-52.
7101			Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic Therapy for Venous Thromboembolism Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):454S-545S. doi: 10.1378/chest.08-0658.
7102			Kearon C., Akl E.A., Comerota A.J., American College of Chest Physicians Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e419S-e494S.
7103			Keeling WB, Haines K, Stone PA, Armstrong PA, Murr MM, Shames ML. Current Indications for Preoperative Inferior Vena Cava Filter Insertion in Patients Undergoing Surgery for Morbid Obesity. Obes Surg. 2005 Aug;15(7):1009-12.
7104			Keller EJ, Vogelzang RL.Providing Context: Medical Device Litigation and Inferior Vena Cava Filters. Semin Intervent Radiol. 2016 Jun;33(2):132-6. doi: 10.1055/s-0036-1581086.
7105			Khansarinia S, Dennis JW, Veldenz HC, Butcher JL, Hartland L. Prophylactic Greenfield Filter Placement in Selected High-Risk Trauma Patients. J Vasc Surg. 1995 Sep;22(3):231-5; discussion 235-6.
7106			Kiefer RM, Pandey N, Trerotola SO, Nadolski GJ, Stavropoulos SW. The Value of Rotational Venography Versus Anterio Posterior Venography in 100 Consectutive IVC Filter Retrievals. Cardiovasc Intervent Radiol. 2016 Mar;39(3):394-9. doi: 10.1007/s00270-015-1183-3. Epub 2015 Jul 29.

Exhibit	Marked for ID	Admitted in Evidence	Description
7107			Kiguchi MM, Dillavou ED. IVC filters: challenges and future
			directions. Adv Vasc Med 2014; 2014:1-6.
7108			Kim H, Sarg I, Jang JH: Outcomes of Retrievable Inferiro Vena
			Cava Filters in Patients with Deep Vein Thrombosis and
			Transient Contraindication for Anticoagulation. 2015; Ann. Of
			Surgical Treatment and Research; 89(1):30-36.
7109			Kim, H.S., et al., A comparison of clinical outcomes with
			retrievable and permanent inferior vena cava filters. J Vasc
			Interv Radiol, 2008. 19(3): 393-9.
7110	İ		Kinney TB, Rose SC, Valji K, Oglevie SB, Roberts AC. Does
			Cervical Spinal Cord Injury Induce a Higher Incidence of
			Complications after prophylactic Greenfield inferior vena cava
			filter usage? J Vasc Interv Radiol. 1996 Nov-Dec;7(6):907-15.
7111	1		Kinney TB. Primum non nocere. J Vasc Interv Radiol. 2012
			Dec;23(12):1564-5. doi: 10.1016/j.jvir.2012.10.003.
7112			Kinney TB. Update on inferior vena cava filters. J Vasc Interv
			Radiol. 2003 Apr;14(4):425-40.
7113			Kitchens CS, Konkle BA and Kessler CM. Consultative
			Hemostasis and Thrombosis, 3rd Edition.
7114			Knudson MM, Ikossi DG. Thromboembolism After Trauma.
			Curr Opin Crit Care. 2004 Dec;10(6):539-48.
7115			Ko SH, Reynolds BR, Nicholas DH, et al. Institutional protocol
			improves retrievable inferior vena cava filter recovery rate.
			Surgery 2009; 146:809-16.
7116			KrauthD et al: Safety and efficacy of long-term oral
			anticoagulation in cancer patients. Cancer 59:983-985, 1987.
7117			Kuo W, Robertson S. Bard Denali Inferior Vena Cava Filter
			Fracture and Embolization Resulting in Cardiac Tamponade: A
			Device Failure Analysis. J Vasc Interv Radiol. 2015
-110			Jan;26(1):111-5.e1. doi: 10.1016/j.jvir.2014.08.001.
7118			Kuo WT, Cupp JS, Louie JD, Sze DY, Kothary N, Hwang GL,
			Hofmann L. Retrieval of permanently-embedded IVC filters and
			description of the laser-assisted sheath technique: Radiographic-
			histopathologic correlation (Abstract No. 4). Journal of
			Vascular and Interventional Radiology, Feb. 2010, Volume 21.
7110			Issue 2, Suppl., Page S4.
7119			Kuo WT, Cupp JS. The Excimer Laser Sheath Technique for
]	Embedded Inferior Vena Cava Filter Removal. J Vasc Interv
		[]	Radiol. 2010 Dec;21(12):1896-9. doi:
7120			10.1016/j.jvir.2010.08.013. Epub 2010 Nov 3.
7120		1	Kuo WT, Odegaard JI, Rosenberg JK, Hofmann LV. Laser
		1	Assisted Removal of Embedded Vena Cava Filters: A 5 Year
		I	First in Human Study. Chest. 2017 Feb;151(2):417-424. doi:
			0.1016/j.chest.2016.09.029. Epub 2016 Oct 8.

Exhibit	Marked for ID	Admitted in Evidence	Description
7121			Kuo WT, Robertson SW, Odegaard JI, Hofmann LV. Complex retrieval of fractured, embedded, and penetrating inferior vena cava filters: a prospective study with histologic and electron microscopic analysis. J Vasc Interv Radiol. 2013 May;24(5):622-630.e1; quiz 631. doi: 10.1016/j.jvir.2013.01.008. Epub 2013 Mar 21.
7122			Kuo WT, Tong RT, Hwang GL, Louie JD, Lebowitz EA, Sze DY, Hofmann LV. High-risk retrieval of adherent and chronically implanted IVC filters: techniques for removal and management of thrombotic complications. J Vasc Interv Radiol. 2009 Dec;20(12):1548-56. doi: 10.1016/j.jvir.2009.08.024. Epub 2009 Oct 27.
7123			Kuo, W.T. and Robertson, S.W. Bard Denali inferior vena cava filter fracture and embolization resulting in cardiac tamponade: a device failure analysis. J Vasc Interv Radiol. 2015; 26: 111–115.
7124			Kuo, W.T., C.T. Loh and D.Y. Sze, Emergency retrieval of a G2 filter after complete migration into the right ventricle. J Vasc Interv Radiol, 2007. 18(9): 1177-82.
7125			Kuy S, Dua A, Lee CJ, Patel B, Desai SS, Dua A, Szabo A, Patel PJ. National Trends in Utilization of Inferior Vena Cava Filters in the United States, 2000-2009. J Vasc Surg Venous Lymphat Disord. 2014 Jan;2(1):15-20. doi: 10.1016/j.jvsv.2013.08.007. Epub 2013 Dec 12.
7126			Laborda A, Sierre S, Malvè M, De Blas I, Ioakeim I, Kuo WT, De Gregorio MA. Influence of Breathing Movements and Valsalva Maneuver on Vena Caval Dynamics. World J Radiol. 2014 Oct 28;6(10):833-9. doi: 10.4329/wjr.v6.i10.833.
7127			Lampert R. Managing with Pacemakers and Implantable Cardioverter Defibrillators. Circulation. 2013 Oct 1;128(14):1576-85. doi: 10.1161/CIRCULATIONAHA.113.001555.
7128			Lang W, Schweiger H, Hofmann-Preiss K. Results of Long-Term Venacavography Study After Placement of a Greenfield Vena Caval Filter. J Cardiovasc Surg (Torino). 1992 Sep-Oct;33(5):573-8.
7129			Langan EM 3rd, Miller RS, Casey WJ 3rd, Carsten CG 3rd, Graham RM, Taylor SM. Prophylactic Inferior Vena Cava Filters in Trauma Patients at High Risk: Follow-up Examination and Risk/Benefit Assessment. J Vasc Surg. 1999 Sep;30(3):484-88.
7130			Laplante JS, Contractor FM, Kiproff PM, Khoury MB. Migration of the Simon nitinol vena cava filter to the chest. AJR Am J Roentgenol 1993; 160(2):385-6.

Exhibit	Marked for ID	Admitted in Evidence	Description	
7131		Evidence	Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, LM; ADVANCE-3 Investigators. Apixaban versus En for Thromboprophylaxis after Hip Replacement. N En 2010 Dec 23;363(26):2487-98. doi: 10.1056/NEJMoa	oxaparin gl J Med.
7132			Lavan 0, Rimon U, Simon D, et al: The use of optiona vena cava filters of type Optease in trauma patients—type of filter in a single medical center. 2015 Thromb. 135:873-876.	l inferior a single
7133			Laws JL, Lewandowski RJ, Ryu RK, Desai KR. Retries Inferior Vena Cava Filters: Technical Considerations. Intervent Radiol. 2016 Jun;33(2):144-8. doi: 10.1055/s1582119.	Semin
7134			Leach TA, Pastena JA, Swan KG, Tikellis JI, Blackwo Odom JW. Surgical Prophylaxis for Pulmonary Embol Surg. 1994 Apr;60(4):292-5.	od JM, ism. Am
7135			Leask RL, Johnston KW, Ojha M. In Vitro Hemodynan Evaluation of a Simon Nitinol Vena Cava Filter: Possil Explanation of IVC Occlusion. J Vasc Interv Radiol. 20 May;12(5):613-8.	ole
7136			Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M Randomized Comparison of Low-Molecular-Weight H versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with (CLOT) Investigators. Low-molecular-weight heparing coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Me Jul 10;349(2):146-53.	1; eparin of Cancer versus a
7137			Lee MJ, Valenti D, deGregorio MA, et al. The CIRSE retrievable IVC filter registry: retrieval success rates in Cardiovasc Intervent Radiol 2015; 38:1502-7.	practice.
7138			Leeper WR, Murphy PB, Vogt KN, et al: Are Retrieval Cava Filters Placed in Trauma Patients Really Retrieval J. Trauma Emergency Surg. 2016; 42:459-464.	le Vena ole. Eur.
7139			LeFevre ML; U.S. Preventive Services Task Force. Scree for Abdominal Aortic Aneurysm – US Preventative Ser Task Force Recommendation Statement. Ann Intern Med Aug 19;161(4):281-90. doi: 10.7326/M14-1204.	vices
7140			Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vait Goldhaber SZ; PREVENT Medical Thromboprophylaxi Group. Randomized, placebo-controlled trial of daltepathe prevention of venous thromboembolism in acutely il medical patients. Circulation. 2004 Aug 17;110(7):874-12004 Aug 2.	s Study rin for l

Exhibit	Marked for ID	Admitted in Evidence	Description	
7141			Lessne ML, Sing RF. Counterpoint: Do the Benefits C the Risks for Most Patients Under Consideration for Ir Vena Cava Filters? No. Chest. 2016 Dec;150(6):1182-doi: 10.1016/j.chest.2016.08.1477. Epub 2016 Oct 20.	iferior
7142			Lewandowski, R.J., et al., Abstract No. 54: A prospect of 467 IVC filter placements: is there a difference betwoptional and permanent filters? J Vasc Interv Radiol, 2 23(3): S25	veen
7143			Li W, Gorecki P, Semaan E, Briggs W, Tortolani AJ, I M. Concurrent prophylactic placement of inferior vena filter in gastric bypass and adjustable banding operation Bariatric Outcomes Longitudinal Database. J Vasc Sur Jun;55(6):1690-5. doi: 10.1016/j.jvs.2011.12.056. Epul Feb 22.	cava ns in the g. 2012
7144			Li W, Gorecki P, Semaan E, Briggs W, Tortolani AJ, I M. Concurrent prophylactic placement of inferior vena filter in gastric bypass and adjustable banding operation Bariatric Outcomes Longitudinal Database. J Vasc Surg Jun;55(6):1690-5. doi: 10.1016/j.jvs.2011.12.056. Epub Feb 22.	cava ns in the g. 2012
7145			Linkins LA, Dans AL, Moores LK, Bona R, Davidson Schulman S, Crowther M. Treatment and prevention of induced thrombocytopenia: Antithrombotic Therapy an Prevention of Thrombosis, 9th ed: American College of Physicians Evidence-Based Clinical Practice Guideline 2012 Feb;141(2 Suppl):e495S-e530S. doi: 10.1378/che. 2303. Review. Erratum in: Chest. 2015 Dec;148(6):152	heparin- d Chest s. Chest.
7146			Lloyd GL, Singh MJ, Messing EM. An Unusual Cause Enhancing Retroperitoneal Mass. Urology. 2012 Apr;79 2. doi: 10.1016/j.urology.2011.06.042. Epub 2011 Sep 2	of an 9(4):e61-
7147			Lynch FC, Kekulawela S. Removal of the G2 Filter: Differences between Implantation Times Greater and Le 180 Days. J Vasc Interv Radiol. 2009 Sep;20(9):1200-910.1016/j.jvir.2009.05.039. Epub 2009 Jul 29.	ess than
7148			Lynch FC. A method for following patients with retrieve inferior vena cava filters: results and lessons learned frofirst 1,100 patients. J Vasc Interv Radiol 2011; 22:1507-	m the
7149			Lynch FC. Balloon-assisted Removal of Tilted Inferior Cava Filters with Embedded Tips. J Vasc Interv Radiol. 20: 1210-1214.	Vena

Exhibit	Marked for ID	Admitted in Evidence	Description	
7150			Lyon SM, Riojas GE, Uberoi R, Patel J, Lipp ME, Pla	nt GR De
			Gregorio MA, Günther RW, Voorhees WD, McCann-	Brown
			JA. Short- and Long-term Retrievability of the Celect	Vena
			Cava Filter: Results from a Multi-institutional Registry	v I Vasc
			Interv Radiol. 2009 Nov;20(11):1441-8. doi:	,
			10.1016/j.jvir.2009.07.038.	
7151			Majdalany BS, Khaja MS, Williams DM. Bard Denali	filter
			fractures. J Vasc Interv Radiol. 2016; 27: 1099-1101.	
7152			Malgor RD, Hines GL, Terrana L, Labropoulos N. Per	sistent
			Abdominal Pain Caused by an Inferior Vena Cava Filt	er
	i		Protruding Into the Duodenum and the Aortic Wall. As	nn Vasc
			Surg. 2012 Aug;26(6):858.e3-6. doi:	in vasc
			10.1016/j.avsg.2011.11.038. Epub 2012 May 23.	
7153			Mandelblatt JS, Stout NK, Schechter CB, van den Brod	ek II
			Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz	z D. Lee
			SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikow	ske K
			Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijns	diik FA
			Chisholm G, Huang X, Huang H, Ergun MA, Gangnon	R P
			Sprague BL, Plevritis S, Feuer E, de Koning HJ, Croni	n K A
			Collaborative Modeling of the Benefits and Harms Ass	ociated
			with Different US Breast Cancer Screening Strategies.	Ann
	1		Intern Med. 2016 Feb 16;164(4):215-25. doi: 10.7326/1	M15-
			1536. Epub 2016 Jan 12.	1115
7154			MAUDE Manufacturer and User Facility Device Exper	ience
			U.S. Food & Drug Administration. Accessible via:	
			https://www.accessdatalda.goviscripts/cdrh/cfdocs/cfm	aude/sear
			ch.cfm. Accessed April 4, 2017.	- I - I - I - I - I - I - I - I - I - I
7155			Maxwell RA, Chavarria-Aguilar M, Cockerham WT, L	ewis PI
			Barker DE, Durham RM, Ciraulo DL, Richart CM. Rou	itine
			Prophylactic Vena Cava Filtration Is Not Indicated after	r Acute
			Spinal Cord Injury. J Trauma. 2002 May;52(5):902-6.	
7156			McCowan TC, Ferris EJ, Carver DK, Molpus WM.	
			Complications of the nitinol vena caval filter. J Vasc Int	terv
			Radiol. 1992 May;3(2):401-8.	
7157			McKenney K, Boneva D, Deeter M, Barquist E, Ang D	Kave
			M. Trauma Admission CT as a Road Map for IVC Filte	rs. Int
		;	Surg. 2014 Nov-Dec;99(6):734-8. doi: 10.9738/INTSUI	RG-D-
			13-00192.1.	
7158			McLoney ED, Krishnasamy VP, Castle JC, Yang X, Gu	v G.
		(Complications of Celect, Günther tulip, and Greenfield	inferior
		1	vena cava filters on CT follow-up: a single-institution	
		6	experience. J Vasc Interv Radiol. 2013 Nov;24(11):1723	3-9. doi:
		1	10.1016/j.jvir.2013.07.023. Epub 2013 Sep 13.	,

Exhibit	Marked for ID	Admitted in Evidence	Description	
7159			McMurtry AL, Owings JT, Anderson JT, Battistella F	D
			Gosselin R. Increased Use of Prophylactic Vena Cava	Filters in
			Trauma Patients Failed to Decrease Overall Incidence	of
	i		Pulmonary Embolism. J Am Coll Surg. 1999 Sep; 1890	(3):314-
			20.	
7160			Mehanni, S., M. Higley and R.C. Schenning, Expector	ation of
			an inferior vena cava filter strut. BMJ Case Rep. 2016.	2016.
7161			Melinek J, Livingston E, Cortina G, Fishbein MC. Aut	opsy
			Findings Following Gastric Bypass Surgery for Morbi	d Obesity.
			Arch Pathol Lab Med. 2002 Sep;126(9):1091-5.	
7162			Meyer A, Schönleben F, Heinz M, Lang W. Perforated	Inferior
			Vena Cava Filters as the Cause of Unclear Abdominal	Pain.
			Ann Vasc Surg. 2013 Apr;27(3):354.e9-354.e12. doi:	
5 4.60			10.1016/j.avsg.2012.08.006.	
7163			Michetti CP, Franco E, Coleman J, Bradford A, Tricke	y AW.
			Deep Vein Thrombosis Screening and Risk Factors in	a High-
			Risk Trauma Population. J Surg Res. 2015 Dec;199(2)	545-51.
71.61			doi: 10.1016/j.jss.2015.04.069. Epub 2015 Apr 27.	
7164			Miller KE. Indications for Vena Cava Filters for Recur	rent
71.65			DVT. Am Fam Physician. 2003 Feb 1;67(3):593.	
7165			Miller, C.L. and R.J. Wechsler. CT evaluation of Kimra	ay-
			Greenfield filter complications. AJR Am J Roentgenol,	1986.
7166			147(1): 45-50.	
7166			Millward SF, Grassi CJ, Kinney TB, Kundu S, Becker	GJ,
			Cardella JF, Martin LG, Silberzweig JE, Sacks D. Repo	rting
			standards for inferior vena caval filter placement and pa	tient
			follow-up: supplement for temporary and retrievable/or	tional
			filters. J Vasc Interv Radiol. 2009 Jul;20(7 Suppl):S374	-6. doi:
7167			10.1016/j.jvir.2009.04.009.	
/10/			Millward SF. Temporary and Retrievable Inferior Vena	Cava
			Filters: Current Status. J Vasc Interv Radiol. 1998 May-	·
7168			Jun;9(3):381-7.	
/100			Minocha J, Idakoji I, Riaz A, Karp J, Gupta R, Chrisma	n HB,
			Salem R, Ryu RK, Lewandowski RJ. Improving inferio	r vena
		•	cava filter retrieval rates: impact of a dedicated inferior	vena
			cava filter clinic. J Vasc Interv Radiol. 2010 Dec;21(12)	:1847-
			51. doi: 10.1016/j.jvir.2010.09.003. Epub 2010 Oct 28.	

Exhibit	Marked for ID	Admitted in Evidence	Description
7169			Mismetti P, Laporte S, Pellerin O, Ennezat PV, Couturaud F,
			Elias A, Falvo N, Meneveau N, Quere I, Roy PM, Sanchez O,
			Schmidt J, Seinturier C, Sevestre MA, Beregi JP, Tardy B,
			Lacroix P, Presles E, Leizorovicz A, Decousus H, Barral F,
			Meyer G; PREPIC2 Study Group. Effect of a retrievable
			inferior vena cava filter plus anticoagulation vs anticoagulation
			alone on risk of recurrent pulmonary embolism: a randomized
			clinical trial. JAMA. 2015 Apr 28;313(16):1627-35. doi:
			10.1001/jama.2015.3780.
7170			Mitchell WB, Bonn J. Percutaneous retrieval of a Greenfield
			filter after migration to the left pulmonary artery. J Vasc Interv
			Radiol. 2005 Jul;16(7):1013-7.
7171	, , , , , , , , , , , , , , , , , , , ,		Mitsunaga, M.M. and HC. Yoon, Fracture Rate and Serious
			Complications of Vena Cava Filters. Open Journal of
			Radiology, 2013. 03(02): 85-90
7172			Mohan G, Kasmani R, Okoli K, Elkambergy H. Right atrial
			foreign body: transvenous migration of Greenfield filter.
			Interact Cardiovasc Thorac Surg. 2009 Feb;8(2):245-6. doi:
,			10.1510/icvts.2008.189605. Epub 2008 Nov 17.
7173			Montgomery JP, Kaufman JA. A Critical Review of Available
			Retrievable Inferior Vena Cava Filters and Future Directions.
			Semin Intervent Radiol. 2016 Jun;33(2):79-87. doi: 10.1055/s-
			0036-1582121.
7174			Montgomery JP, Kaufman JA. Inferior Vena Cava Filters:
			Indications, Outcomes, and Evidence. Curr Treat Options
			Cardiovasc Med. 2015 Sep;17(9):401. doi: 10.1007/s11936-
			015-0401-2.
7175			Moore FD, et al: Anticoagulants, venous thromboembolism, and
			the cancer patient. Arch Surg 116:405-407, 1981
7176			Moore R, Dagher FJ, Tavares S, Attar S. Migration of Kim-Ray
			Greenfield Umbrella to the heart. South Med J. 1983
			Jul;76(7):946-7.
7177			Moore, Feliciano, Mattox. Trauma, Fifth Edition
7178			Morales JP, Li X, Irony TZ, Ibrahim NG, Moynahan M,
			Cavanaugh KJ. Decision analysis of retrievable inferior vena
			cava filters in patients with pulmonary embolism. J Vasc Surg
			Venous Lymphat Disord. 2013 Oct;1(4):376-84. doi:
			10.1016/j.jvsv.2013.04.005. Epub 2013 Jul 4.
7179			Morris CS, Cushman M. Perforation of the inferior vena cava
			by a Greenfield filter. Journal of Thrombosis and Haemostasis
			2008; 6:1835-1836.

Exhibit	Marked for ID	Admitted in Evidence	Description
7180			Morris CS, LaRosa J, and VanAman ME. Technically difficult percutaneous Kimray-Greenfield filter insertions. Presented at the 48th annual meeting, Ohio State Radiological Society; 1988 May 13; Toledo, OH.
7181			Morris CS, Rogers FB, Najarian KE, Bhave AD, Shackford SR. Current trends in vena caval filtration with the introduction of a retrievable filter at a level I trauma center. J Trauma 2004; 57:32-36
7182			Muriel A, Jimenez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol 2014; 63:1675-83.
7183			Mutyala, Realistic expectations and candidate selection for entry level vascular technologist in a busy laboratory
7184			Myerburg RJ, Feigal DW Jr, Lindsay BD. Life threatening Malfunction of Implanatable Cardiac Devices. N Engl J Med. 2006 Jun 1;354(22):2309-11. Epub 2006 May 15.
7185			Narayan A, Hong K, Streiff M, Kim HS. (2008). Abstract No. 68: Safety and Efficacy of Retrievable vs Permanent IVC Filters in Oncology Patients – A Case Control Study. Journal of Vascular and Interventional Radiology - J VASC INTERVEN
7186			RADIOL. 19 10.1016/j.jvir.2007.12.076. Nathani N, Barzallo M, Mungee S. Myopericarditis secondary to embolization of fractured inferior vena cava filter limbs. J Invasive Cardiol. 2010 Dec;22(12):E225-8.
7187			National Cancer Institute. https://www.cancer.gov/about-cancer/diagnosis-staging/ct-scans-fact-sheet Accessed on February 20, 2017.
7188			Nazzal M, Abbas J, Nazzal M. A complication of a G2 Bard filter. J Vasc Interv Radiol. 2010 Nov;21(11):1784-5. doi: 10.1016/j.jvir.2010.07.010. Epub 2010 Sep 29.
7189			Nazzal M, Chan E, Nazzal M, Abbas J, Erikson G, Sediqe S, Gohara S. Complications related to inferior vena cava filters: a single-center experience. Ann Vasc Surg. 2010 May;24(4):480-6. doi: 10.1016/j.avsg.2009.07.015. Epub 2009 Nov 8.
7190			NCRP Report No. 160, Ionizing Radiation Exposure of the Population of the United States. http://ncrponline.org/publications/reports/ncrp-report-160/Accessed on March 15, 2017.
7191		1	Nelson HD, Cantor A, Humphrey L, Fu R, Pappas M, Daeges M, Griffin J. Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation [Internet]. Agency for Healthcare Research and Quality (US); 2016 Jan. Report No.: 14-05201-EF-1.

Exhibit	Marked for ID	Admitted in Evidence	Description	
7192		ZVIdence	Nicholson AA, Ettles DF, Paddon AJ, Dyet JF. Long-t	
)			Follow-up of the Bird's Nest IVC Filter. Clin Radiol.	1000
			Nov;54(11):759-64.	1999
7193			Nicholson W, Nicholson WJ, Tolerico P, Taylor B, So	lomon S
			Schryver T, McCullum K, Goldberg H, Mills J, Schule	er R
			Shears L, Siddoway L, Agarwal N, Tuohy C. Prevalen	ce of
			Fracture and Fragment Embolization of Bard Retrieval	hle Vena
			Cava Filters and Clinical Implications Including Cardi	ac vena
	i		Perforation and Tamponade. Arch Intern Med. 2010 N	ac
			8;170(20):1827-31. doi: 10.1001/archinternmed.2010.	316 Enub
			2010 Aug 9.	10. Epub
7194			Nicholson W. Refrain, Recover, Replace. J Vasc Inter	v Radial
			2012; 23:195-196.	v Radioi
7195			Nicholson W. Correction to Article About Prevalence	of.
			Fracture and Fragment Embolization of Bard Retrieval	ile Vena
			Cava Filters. ARCH INTERN MED/VOL 172 (NO. 12) June
			25, 2012.), June
7196			Nissim L, Romano W. Successful Retrieval from Right	
			Ventricular Wall of an Embolized Bard Meridian Filter	
			Fragment. J Vasc Interv Radiol. 2013 Dec;24(12):1933	4 doi:
			10.1016/j.jvir.2013.09.001.	-4. uoi.
7197			Obeid FN, et al: Efficacy of prophylactic inferior vena	cava
			filter placement in bariatric surgery. Sug Obes Relat Di	s 3:606-
			610, 2007.	3 3.000-
7198			Offner PJ, Hawkes A, Madayag R, Seale F, Maines C.	The Role
			of Temporary Inferior Vena Cava Filters in Critically II	
		}	Surgical Patients. Arch Surg. 2003 Jun;138(6):591-4; d	scussion
			594-5.	
7199			Oh J, Stavropoulos SW, Trerotola S, Soulen MC, Shlan	sky-
			Goldberg R, Nemeth A, Mondschein J, Solomon JA. Re	moval
			of retrievable IVC filters with CT findings indicating fil	ter strut
			perforation. Abstract No. 5. Journal of Vascular and	
			Interventional Radiology, February 2010, Volume 21, Is	ssue 2.
			Supplement, Page S4.	
7200			Oh JC, Trerotola SO, Dagli M, Shlansky-Goldberg RD,	Soulen
		-	MC, Itkin M, Mondschein J, Solomon J, Stavropoulos S	W.
			Removal of retrievable inferior vena cava filters with co	mputed
		1	tomography findings indicating tenting or penetration of	the
		i	inferior vena cava wall. J Vasc Interv Radiol. 2011	İ
			Jan;22(1):70-4. doi: 10.1016/j.jvir.2010.09.021. Epub 20	10 Nov
			24.	

Exhibit	Marked for ID	Admitted in Evidence	Description	
7201			Oliva VL, Perreault P, Giroux MF, Bouchard L, Thera	asse E,
			Soulez G. Recovery G2 inferior vena cava filter: techn	nical
			success and safety of retrieval. J Vasc Interv Radiol. 2	008
			Jun;19(6):884-9. doi: 10.1016/j.jvir.2008.02.025. Epu Apr 18.	6 2008
7202			Oliva VL, Soulez G, Therasse E, Giroux M, Perreault	Ρ,
			Bouchard L, Denbow N. Recovery G2 vena cava filter	r
			retrievability study. Scientific Poster, Cardiovascular	and
			Interventional Radiological Society of Europe, P235.	
7203			Olorunsola OG, Kohi MP, Fidelman N, et al. Caval pe	enetration
			by retrievable inferior vena cava filters: a retrospective	•
			comparison of Option and Gu?nther Tulip filters. J Va	sc Interv
7204			Radiol 2013;24:566-571.	
7204			Olorunsola OG, Kohi MP, Fidelman N, Westphalen A	C, Kolli
			PK, Taylor AG, Gordon RL, LaBerge JM, Kerlan RK.	Caval
			Penetration by Retrievable Inferior Vena Cava Filters:	A
			Retrospective Comparison of Option and Gunther Tuli	p Filters.
			J Vasc Interv Radiol. 2013 Apr;24(4):566-71. doi:	
7205			10.1016/j.jvir.2012.12.024. Epub 2013 Feb 23.	
1203			O'Malley KF, Ross SE,: Pulmonary Embolism in Majo	r Trauma
7206			Patients. J Trauma 1990; 30:748-750.	
7200			Osker T, Rogers FB: 1997: Prophylaxis after Major Tra	auma.
7207			Letter to the Editor. N. Eng. J. Med. Pg 586.	
7207			Ota, S., et al., The Gunther-Tulip retrievable IVC filter	clinical
			experience in 118 consecutive patients. Circ J, 2008. 72 92.	2(2): 287-
7208			Overby DW, Kohn GP, Cahan MA, Dixon RG, Stavas	IM Moll
			S, Burke CT, Colton KJ, Farrell TM. Risk-Group Targe	eted
			Inferior Vena Cava Filter Placement in Gastric Bypass	Patients
			Obes Surg. 2009 Apr;19(4):451-5. doi: 10.1007/s11695	-008-
			9794-2. Epub 2009 Jan 6.	000-
7209			Owens CA, Bui JT, Knuttinen MG, Gaba RC, Carrillo	rc
			Hoefling N, Layden-Almer JE. Intracardiac migration of	f
			inferior vena cava filters: review of published data. Che	st. 2009
			Sep;136(3):877-887. doi: 10.1378/chest.09-0153. Epub	2009
7016			Apr 6.	
7210			Owens, C.A., et al., Endovascular retrieval of intracardi	ac
		i	inferior vena cava filters: a review of published technique	ues. J
			Vasc Interv Radiol, 2009. 20(11): 1418-28	

Exhibit	Marked for	Admitted in	Description
	ID	Evidence	Description
7211			Oxford Centre for Evidence-based Medicine
			http://www.cebm.net/oxford-centre-evidence-based-medicine-
			levels-evidence-march-2009/)
			(https://www.ahrq.gov/professionals/clinicians-
			providers/guidelines-recommendations/uspstf/index.html)
7010			accessed on March 6, 2017.
7212			Palestrant AM, Prince M, Simon M. Comparative in vitro
			evaluation of the nitinol inferior vena cava filter. Radiology.
			1982 Nov;145(2):351-5.
7213			Pan Y, Zhao J, Mei J, Shao M, Zhang J, Wu H. Retrievable
			Inferior Vena Cava Filters in Trauma Patients: Prevalence and
			Management of Thrombus Within the Filter. Eur J Vasc
			Endovasc Surg. 2016 Dec;52(6):830-837. doi:
			10.1016/j.ejvs.2016.08.012. Epub 2016 Sep 28.
7214			Pandhi MB, Desai KR, Ryu RK, Lewandowski RJ. The Role of
			Inferior Vena Cava Filters in Cancer Patients. Semin Intervent
			Radiol. 2016 Jun;33(2):71-4. doi: 10.1055/s-0036-1581090.
7215			Parker, N.A., et al., Complication and Retrieval Rates of
			Inferior Vena Cava Filters, a Single-Center Retrospective
7216			Study. Journal of Vascular Surgery, 2016. 64(3): 868-869.
7216			Passman M. Vena Cava Interruption and Pulmonary Embolism.
			In: Rutherford's Vascular Surgery, Cronenwett JL (ed) Elsevier
7017			2014. 816.
7217			Patel A, Cholankeril J. Case of the migrating embolic filter.
7210			Hosp Pract (Off Ed). 1991 Apr 15;26(4):129-32.
7218			Patton JH Jr, Fabian TC, Croce MA, Minard G, Pritchard FE,
			Kudsk KA. Prophylactic Greenfield Filters: Acute
			Complications and Long-Term Follow-up. J Trauma. 1996
7210			Aug;41(2):231-6; discussion 236-7.
7219			Peters, M.N., et al., Inferior vena cava filter migration to the
			right ventricle causing nonsustained ventricular tachycardia.
7220			Tex Heart Inst J, 2013. 40(3): 316-9
7220			Peterson EA, Yenson PR, Liu D, Lee AYY. Predictors of
			attempted inferior vena cava filters retrieval in a tertiary care
7221			centre. Thromb Res 2014; 134:300-4.
1221			Piano G, Ketteler ER, Prachand V, Devalk E, Van Ha TG,
		'	Gewertz BL, Alverdy JC. Safety, feasibility, and outcome of
			retrievable vena cava filters in high-risk surgical patients. J
7222			Vasc Surg. 2007 Apr;45(4):784-8; discussion 788.
1444			Piercecchi, C.W., et al., Cardiac Perforation by Migrated
			Fractured Strut of Inferior Vena Cava Filter Mimicking Acute
			Coronary Syndrome. Heart Lung Circ, 2017. 26(2): e11-e13.

Exhibit	Marked for ID	Admitted in Evidence	Description
7223	110	Evidence	Pierfitte C, Bégaud B, Lagnaoui R, Moore ND. Is Reporting
, 223			Rate a Good Predictor of Risks Associated with Drugs? Br J
			Clin Pharmacol. 1999 Mar;47(3):329-31.
7224			Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-
,,,,,			Effectiveness Analyses of Colorectal Cancer Screening – A
			Systematic Review for the US Preventative Services Task
			Force. Ann Intern Med. 2002 Jul 16;137(2):96-104.
7225			Piotrowski, Is Deep Vein Thrombosis Surveillance Warranted
, 225			in High-Risk Trauma Patients?
7226			Poletti PA, Becker CD, Prina L, Ruijs P, Bounameaux H, Didier
			D, Schneider PA, Terrier F. Long-term results of the Simon
			nitinol inferior vena cava filter. Eur Radiol. 1998;8(2):289-94.
7227			Porcellini, M., et al., Intracardiac migration of nitinol TrapEase
			vena cava filter and paradoxical embolism. Eur J Cardiothorac
			Surg, 2002. 22(3): 460-1.
7228			Prasad V, Rho J, Cifu, A. The Inferior Vena Cava Filter, How
			Could a Medical Device Be So Well Accepted Without Any
			Evidence of Efficacy? JAMA Intern Med. 2013;173(7):493-
			495. doi:10.1001/jamainternmed.2013.2725
7229			Pratt WB, MD, Leake SS, Afaq S, Sandhu HK, Safi HJ,
			Azizzadeh A, Charlton-Ouw KM. Asymptomatic Patients With
			Inferior Vena Cava Filter Penetration Through the Wall May be
			Managed Conservatively. Journal of Vascular Surgery, March
			2017, Volume 65, Issue 3, Pages e7-e8.
7230			PREPIC Study Group. Eight-year follow-up of patients with
			permanent vena cava filters in the prevention of pulmonary
			embolism: the PREPIC (Prevention du Risque d'Embolie
			Pulmonaire par Interruption Cave) randomized study.
			Circulation. 2005 Jul 19;112(3):416-22. Epub 2005 Jul 11.
7231			PRESERVE Trial (Predicting the Safety and Effectiveness of
			Inferior Vena Cava Filters) http://www.preservetrial.com/Study-
			Design accessed on February 26, 2017.
7232			Proctor MC, Cho KJ, Greenfield LJ. In Vivo Evaluation of
			Vena Caval Filters- Can Function Be Linked to Design
			Characteristics? Cardiovasc Intervent Radiol. 2000 Nov-
—			Dec;23(6):460-5.
7233			Proctor MC, Greenfield LJ. Pulmonary embolism: diagnosis,
500.4			incidence and implications. Cardiovasc Surg. 1997; 5:77-81.
7234			Pryor HI 2nd, Singleton A, Lin E, Lin P, Vaziri K. Practice
			Patterns in High-Risk Bariatric Venous Thromboembolism
			Prophylaxis. Surg Endosc. 2013 Mar;27(3):843-8. doi:
			10.1007/s00464-012-2521-z. Epub 2012 Oct 6.

Exhibit	Marked for ID	Admitted in Evidence	Description	
7235	<u> </u>	Evidence	Prystowsky JB, Morasch MD, Eskandari MK, Hungne	ge EC
			Nagle AP. Prospective Analysis of the Incidence of De	SS ES,
			Venous Thrombosis in Bariatric Surgery Patients. Surg	rep
			2005 Oct;138(4):759-63; discussion 763-5.	gery.
7236			Puram B, Maley TJ, White NM, Rotman HH, Miller C	Aguta
			myocardial infarction resulting from a migration of a (
			filter. Chest. 1990 Dec;98(6):1510-1.	reemieid
7237			Purcell, S.T., et al., PS232. Complications Associated	With IVC
			Filters: A large, Single Institution Review. Journal of V	Vascular
			Surgery, 2014. 59(6): 88S	docarar
7238			Putterman D, Niman D, Cohen G. Aortic Pseudoaneur	vsm after
			Penetration by a Simon Nitinol Inferior Vena Cava File	er I
			Vasc Interv Radiol. 2005 Apr;16(4):535-8.	ici. j
7239			Queiroz R, Waldman DL. Transvenous retrieval of a G	reenfield
			filter lodged in the tricuspid valve. Cathet Cardiovasc I	Diagn
			1998 Jul;44(3):310-2.	Jiagii.
7240			Radiation Dose in X-ray and CT Exams.	
			http://www.radiologyinfo.org/en/info.cfm?pg=safety-x	rav
			Accessed on February 20, 2017.	
7241			Raghavan S, Akhtar A, Bastani B. Migration of inferio	r vena
			cava filter into renal hilum. Nephron. 2002 Jun;91(2):3	33-5
7242			Rajasekhan A, Elmariah H, Lottenberg L, et al: Inferior	r Vena
			Cava Filters in Trauma Patients: A National Practice Pa	atterns
			Survey of US Trauma Centers: The American Surgeon	
			80: 1237-1244.	
7243			Rajasekhar A, Crowther MA. ASH evidence-based guid	delines:
			what is the role of inferior vena cava filters in the perio	perative
			prevention of venous thromboembolism in bariatric sur	gerv
			patients? Hematology Am Soc Hematol Educ Program.	
			2009:302-4. doi: 10.1182/asheducation-2009.1.302.	
7244			Rajasekhar A, Lottenberg L, Lottenberg R, Feezor RJ, A	Armen
			SB, Liu H, Efron PA, Crowther M, Ang D. A pilot stud	v on the
			randomization of inferior vena cava filter placement for	venous
			thromboembolism prophylaxis in high-risk trauma patie	nts. J
			Trauma. 2011 Aug;71(2):323-8; discussion 328-9. doi:	
			10.1097/TA.0b013e318226ece1.	
7245			Rajasekhar A, Lottenberg R, Lottenberg L, Liu H, Ang	D.
			Pulmonary embolism prophylaxis with inferior vena cay	va filters
			in trauma patients: a systemic review using the meta-ana	alysis of
			observational studies in epidemiology (MOOSE) guidel	ines. J
		,	Thromb Thrombolysis. 2011; 32(1):40-6.	

Exhibit	Marked for ID	Admitted in Evidence	Description
7246			Rajasekhar A, Streiff MB. Vena cava filters for management of venous thromboembolism: a clinical review. Blood Rev. 2013 Sep;27(5):225-41. doi: 10.1016/j.blre.2013.07.001. Epub 2013
50.15			Aug 7.
7247			Rajasekhar A., Crowther M. Inferior vena caval filter insertion prior to bariatric surgery: a systematic review of the literature. J Thromb Haemost. 2010;8:1266-1270.
7248			Rao KM, Simons AJ, Hare CL, Smulyan H. Migration of a Kimray-Greenfield filter into the pulmonary artery: localization by transesophageal echocardiography. Am Heart J. 1993 Feb;125(2 Pt 1):543-4.
7249			Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a standard care nomogram. A randomized controlled trial. Ann Intern Med 1993;119(9):874–881.
7250			Rasuli P, Mehran R, French G, Turek M, Lalonde KA, Cardinal P. Percutaneous retrieval of a vena cava filter from the right atrium: case report. Can Assoc Radiol J. 2000 Feb;51(1):30-5.
7251			Rasuli P. Inferior vena cava penetration by günther tulip filter? J Vasc Interv Radiol. 2013 May;24(5):752. doi: 10.1016/j.jvir.2013.01.501.
7252			Ray CE Jr, Kaufman JA. Complications of inferior vena cava filters. Abdom Imaging. 1996 Jul-Aug;21(4):368-74.
7253			Ray CE Jr, Mitchell E, Zipser S, Kao EY, Brown CF, Moneta GL. Outcomes with retrievable inferior vena cava filters: a multicenter study. J Vasc Interv Radiol. 2006 Oct;17(10):1595-604.
7254			Redberg R. Continued High Rates of IVC Filter Use After US Food and Drug Safety Warning. JAMA Intern Med. 2017 Sep 1;177(9):1374-1375. doi: 10.1001/jamainternmed.2017.2724.
7255			Redberg, R.F., Medical devices and the FDA approval process: balancing safety and innovation; comment on prevalence of fracture and fragment embolization of bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med, 2010. 170(20): 1831-3
7256			Redberg, Rita F., Comment on 'Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Tamponade, Archives of Internal Medicine 2010; 170(20):1827-1831

Exhibit	Marked for ID	Admitted in Evidence	Description	
7257			Reis SP, Kovoor J, Sutphin PD, Toomay S, Trimmer CA, Reddick M, Kalva SP. Safety and Effectiveness of t Inferior Vena Cava Filter: Intermediate Follow-Up Res Vasc Endovascular Surg. 2016 Aug;50(6):385-90. doi: 10.1177/1538574416666223. Epub 2016 Aug 31.	he Denali sults.
7258			Renno, A., et al., A single center experience with retrie IVC filters. Vascular, 2015. 23(4): 350-7.	vable
7259			Ritchie AJ, Mitchell L, Forty J. Migration of a vena cato the pulmonary artery. Br J Surg. 1995 Feb;82(2):207	
7260			Roberts AC. Inferior Vena Cava Filters, Today's clot fitechnologies offer a variety of options. Endovascular T February 2003.	Itration
7261			Roberts PR. Follow up and optimization of cardiac pac Heart. 2005; 91(9):1229-34.	ing.
7262			Rodriguez JL, Lopez JM, Proctor MC, Conley JL, Gern Marx MV, Taheri PA, Greenfield LJ. Early Placement Prophylactic Vena Cava Filters in Injured Patients at H for Pulmonary Embolism. J Trauma. 1996 May;40(5):7 discussion 802-4.	of igh Risk
7263			Rodriguez LF, Saltiel FS. Long-term follow-up of ectopintracardiac Greenfield filter. Chest. 1993 Aug;104(2):6	
7264			Rogers FB, Cipolle MD, Velmahos G, Luchette F. Prac Management Guidelines for the Prevention of Venous Thromboembolism in Trauma Patients. The EAST Prac Management Guidelines Work Group. J Trauma Acute Surg. 2002, 53:142-164.	tice tice
7265			Rogers FB, Osler TM, Shackford SR: Immediate Pulmo Embolism after Trauma. Trauma 2000; 48:146-148.	nary
7266			Rogers FB, Shackford SR, Horst MA, Miller JA, Wu D Bradburn E, Rogers A, Krasne M. Determining venous thromboembolic risk assessment for patients with traum Trauma Embolic Scoring System. J Trauma Acute Care 2012; 73(2):511-5.	a: The
7267			Rogers FB, Shackford SR, Miller JA, et al. Improved re of prophylactic inferior vena cava filters in trauma patie results of a dedicated filter registry and critical pathway filter removal. J Trauma 2012; 72:381-4.	nts: the
7268			Rogers FB, Shackford SR, Miller JA, Wu D, Rogers A, Gambler A. Improved Recovery of Prophylactic Inferio Cava Filters in Trauma Patients: The Results of a Dedic Filter Registry and Critical Pathway for Filter Removal. Trauma Acute Care Surg. 2012 Feb;72(2):381-4. doi: 10.1097/TA.0b013e3182447811.	r Vena ated

Exhibit	Marked for ID	Admitted in Evidence	Description	
7269			Rogers FB, Shackford SR, Wilson J, Ricci MA, Morris C Prophylactic vena cava filter insertion in severely injured trauma patients: Indications and preliminary results. J Tra 1993; 35:637-641.	
7270			Rogers FB, Strindberg G, Shackford SR, Osler TM, Morr Ricci MA, Najarian KE, D'Agostino R, Pilcher DB. Five-follow-up of prophylactic vena cava filters in high-risk trapatients. Arch Surg 1998; 133:406-411.	-year
7271			Rogers FB, Strindberg G, Shackford SR, Osler TM, Morra Ricci MA, Najarian KE, D'Agostino R, Pilcher DB. Five-Follow-up of Prophylactic Vena Cava Filters in High-Risk Trauma Patients. Arch Surg. 1998 Apr;133(4):406-11; discussion 412.	-year
7272			Rogoff, P.A., et al., Cephalic migration of the bird's nest in vena caval filter: report of two cases. Radiology, 1992. 18 819-22.	nferior 34(3):
7273			Rose SC, Kinney TB, Valji K, Winchell RJ. Placement of Inferior Vena Caval Filters in the Intensive Care Unit. J Valnterv Radiol. 1997 Jan-Feb;8(1 Pt 1):61-4.	asc
7274			Rosenthal D, Kochupura PV, Wellons ED, Burkett AB, Methodius-Rayford WC. Gunther Tulip and Celect IVC Fi in Multiple-Trauma Patients. J Endovasc Ther. 2009 Aug;16(4):494-9. doi: 10.1583/09-2728.1.	ilters
7275			Rosenthal D, McKinsey JF, Levy AM, Lamis PA, Clark M. Use of Greenfield filter in patients with major trauma. Cardiovasc Surg. 1994 Feb;2(1):52-5.	ИD.
7276			Rosenthal D, Wellons ED, Levitt AB, Shuler FW, O'Conn RE, Henderson VJ. Role of prophylactic temporary inferio vena cava filters placed at the ICU bedside under intravasc ultrasound guidance in patients with multiple trauma. J Vas Surg. 2004 Nov;40(5):958-64.	or cular
7277			Rossi, P., et al., Fatal outcome in atrial migration of the Tempofilter. Cardiovasc Intervent Radiol, 1999. 22(3): 227	7 31
7278			Rozin L, Perper JA. Spontaneous Fatal Perforation of Aorta Vena Cava by Mobin-Uddin Umbrella. Am J Forensic Med Pathol. 1989 Jun;10(2):149-51.	a and
7279			Rubenstein L, Chun AK, Chew M, Binkert CA. Loop Snard Technique for Difficult Inferior Vena Cava Filter Retrieval Vasc Interv Radiol. 2007 Oct;18(10):1315-8.	e ls. J
7280			Ryu RK, Desai K, Karp J, et al. A comparison of retrievable Celect versus Option filter. J Vasc Interv Radiol 2015;26:86869.	oility: 65-

Exhibit	Marked for ID	Admitted in Evidence	Description	
7281			Saeed, I., M. Garcia and K. McNicholas, Right ventric migration of a recovery IVC filter's fractured wire with subsequent pericardial tamponade. Cardiovasc Intervel 2006. 29(4): 685-6.	h
7282			Sag AA, Stavas JM, Burke CT, Dixon RG, Marquess JMA. Analysis of Tilt of the Gunther Tulip Filter. J Vas Radiol. 2008 May;19(5):669-76. doi: 10.1016/j.jvir.2008.01.020. Epub 2008 Mar 24.	S, Mauro sc Interv
7283			Sagai HC, Ahn J, Cresla D, et al: Venous Thromboem! Orthopedic Patients: A Survey of OTA Member Practic Patterns and OTA Expert Panel Recommendations: 20 Orthop Trauma 29(10) e355-e362.	ce
7284			Sakuma M, Nakamura M, Nakanishi N, et al. Inferior v filter is a new additional therapeutic option to reduce m from acute pulmonary embolism. Circ J. 2004; 68:816-	ortality
7285			Sangwaiya MJ, Marentis TC, Walker TG, Stecker M, V ST, Kalva SP. Safety and Effectiveness of the Celect Ir Vena Cava Filter: Preliminary Results. J Vasc Interv R 2009 Sep;20(9):1188-92. doi: 10.1016/j.jvir.2009.05.032009 Jul 23.	Wicky Iferior adiol.
7286			Sano M, Unno N, Yamamoto N, Tanaka H, Konno H. I fracture of TrapEase inferior vena cava filters: a long-to follow-up assessment. Arch Intern Med. 2012 Jan 23;172(2):189-91. doi: 10.1001/archinternmed.2011.54 2011 Nov 28.	rm
7287			Sapala JA, Wood MH, Schuhknecht MP, Sapala MA. F Pulmonary Embolism after Bariatric Operations for Mo Obesity: A 24- yr retro analysis. Obes Surg. 2003 Dec;13(6):819-25.	atal
7288			Sarosiek (2016)	
7289			Sarosiek S, Crowther M, Sloan JM. Indications, complicand management of inferior vena cava filters: The expense patients at an academic hospital with a level I traum center. JAMA Intern Med 2013; 173:513-7.	rience in
7290			Sarosiek S, Rybin D, Weinberg J, Burke PA, Kasotakis Sloan JM. Association Between Inferior Vena Cava Filt Insertion in Trauma Patients and In Hospital and Overal Mortality. JAMA Surg. 2017 Jan 1;152(1):75-81. doi: 10.1001/jamasurg.2016.3091.	er
7291			Sathyanarayana R, Tan GX, Van Tonder F, Szikla C, Jh Bard DENALI Inferior Vena Cava Filter Another Arm F J Vasc Interv Radiol. 2016 Nov;27(11):1722-1724. doi: 10.1016/j.jvir.2016.05.025.	amb A.

Exhibit	Marked for	Admitted in	Description	
	ID	Evidence	•	
7292			Satya R, Anderson J, Lievano G, Satya RJ. Inferior Ver	na Cava
'			(IVC) Rupture and Retroperitoneal Hemorrhage Caused	d by IVC
			Filter Migration. J Vasc Interv Radiol. 2009 Aug;20(8):	:1102-4.
7000			doi: 10.1016/j.jvir.2009.05.001.	
7293			Schmidt U, Enderson BL, Chen JP, Maul KI: D-dimer l	levels
			correlate with pathologic thrombosis in trauma patients.	. J
7204			Trauma 1992; 33:312-320.	
7294		i	Schulman S, Kearon C, Kakkar AK, Mismetti P, Schell	ong S,
			Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-C	COVER
			Study Group. Dabigatran versus Warfarin in the Treatm	ent of
			Acute Venous Thromboembolism. N Engl J Med. 2009	Dec
7295			10;361(24):2342-52. doi: 10.1056/NEJMoa0906598.	
1293			Schuster R, Hagedorn JC, Curet MJ, Morton JM. Retrie	vable
			inferior vena cava filters may be safely applied in gastri	c bypass
			surgery. Surg Endosc. 2007 Dec;21(12):2277-9. Epub 2 13.	007 Apr
7296				
1250			Scientific Session 1 IVC Filters, Venous Thromboembo Disease	lic
7297				
1231			Seyfer AR, Saeber AV, Dambrose FA, et al: Coagulation	n
			changes after elective surgery and trauma. Ann. Surg. 193:210-213.	781;
7298			Shackford SR, Cook A, Rogers FB, Littenberg B, Osler	T. The
			Increasing Use of Vena Cava Filters in Adult Trauma Vi	ictims:
			Data From the American College of Surgeons National	Trauma
7200			Data Bank. J Trauma. 2007 Oct;63(4):764-9.	
7299			Shackford SR, Mackersic RC, Holbrook TL, et al: The	
			Epidemiology of Trauma Death: A Population-Based Ar	nalysis.
7200			Arch Surg. 1993;128:571-575.	
7300			Shah AH, Lichliter A, Cura M. Inferior Vena Cava Filter	r
			Removal After Prolonged Dwell Time of 2310 Days. Pro	oc (Bayl
7201			Univ Med Cent). 2016 Jul;29(3):292-4.	
7301			Shamian B, Chamberlain RS. The role for prophylaxis in	nferior
			vena cava filters in patients undergoing bariatric surgery	:
			Replacing Anecdote with Evidence. Am Surg. 2012	1
7302			Dec;78(12):1349-61.	
1302			Shang EK, Nathan DP, Carpenter JP, Fairman RM, Jacks	son
			BM. Delayed Complications of Inferior Vena Cava Filter	rs: Case
			Report and Literature Review. Vasc Endovascular Surg	2011
			Apr;45(3):290-4. doi: 10.1177/1538574410395038. Eput Jan 28.	0 2011
			Juli 20.	i

Exhibit	Marked for ID	Admitted in Evidence	Description
7303			Sharifi M, Bay C, Skrocki L, Lawson D, Mazdeh S. Role of
			IVC filters in endovenous therapy for deep venous thrombosis:
			the FILTER-PEVI (filter implantation to lower thromboembolic
			risk in percutaneous endovenous intervention) trial. Cardiovasc
			Intervent Radiol. 2012 Dec;35(6):1408-13. doi:
			10.1007/s00270-012-0342-z. Epub 2012 Jan 20.
7304			Shaw, C.M., et al., Optional vena cava filter use in the elderly
			population. J Vasc Interv Radiol, 2011. 22(6): 824-8.
7305			Shimizu, M., et al., Retrievable Gunther Tulip filter complicated
			by sepsis and retroperitoneal hemorrhage: successful
			management by filter retrieval. Intern Med, 2005. 44(6): 593-7.
7306			Simon M, Athanasoulis CA, Kim D, Steinberg FL, Porter DH,
			Byse BH, Kleshinski S, Geller S, Orron DE, Waltman AC.
			Simon nitinol inferior vena cava filter: initial clinical
			experience. Work in progress. Radiology. 1989 Jul;172(1):99-
			103.
7307			Simon M, Athanasoulis CA, Kim D, Steinberg FL, Porter DH,
			Byse BH, Kleshinski S, Geller S, Orron DE, Waltman AC.
			Simon nitinol inferior vena cava filter: initial clinical
			experience. Work in progress. Radiology. 1989 Jul;172(1):99-
			103.
7308			Sing RF, Fischer PE. Inferior Vena Cava Filters: Indications
			and Management. Curr Opin Cardiol. 2013 Nov;28(6):625-31.
			doi: 10.1097/HCO.0b013e3283655b97.
7309			Sing RF, Rogers FB, Novitsky YW, Heniford T. Optional vena
			cava filters for patients with high thromboembolic risk:
			questions to be answered. Surgical Innovation 2005; 12:195-
			202.
7310			Singer MA, Wang SL. Modeling blood flow in a tilted inferior
			vena cava filter: does tilt adversely affect hemodynamics? J
			Vasc Interv Radiol. 2011 Feb;22(2):229-35. doi:
			10.1016/j.jvir.2010.09.032. Epub 2011 Jan 6.
7311			Singh S, Haut ER, Brotman DJ, Sharma R, Chelladurai Y,
			Shermock KM, Kebede S, Stevens KA, Prakasa KR, Shihab
	Ī		HM, Akande TO, Zeidan AM, Garcia LJ, Segal JB.
			Pharmacologic and Mechanical Prophylaxis of Venous
			Thromboembolism Among Special Populations [Internet].
			Agency for Healthcare Research and Quality (US); 2013 May.
7210		2 (2)	Report No.: 13-EHC082-1.
7312		5-08/18	SIR Guidelines for IVC filters

Exhibit	Marked for ID	Admitted in Evidence	Description	
7313	111/	Evidence	Smith A Adrehtee D Elithern D Commis A L 1	1 37
1313			Smith A, Adrahtas D, Elitharp D, Gasparis A, Labropo Tassiopoulos A. Changes in the Rate of Prophylactic	uios N,
			Cava Filter Insertion at a University Hospital. Phlebolo	v ena
			Jul;31(6):403-8. doi: 10.1177/0268355515592769. Epu	gy. 2016
			Jun 19.	10 2015
7314			Smith BA, Vena Caval Filters. Emerg Med Clin North	Δ
			1994 Aug;12(3):645-56.	Am.
7315			Smouse B, Johar A. Is Market Growth of Vena Cava F	ilters
			Justified? A review of indications, use, and market ana	lysis.
			Endoscopy Today, Feb. 2010.	
7316			Smouse HB, Rosenthal D, Thuong VH, Knox MF, Dix	on RG.
			Voorhees WD 3rd, McCann-Brown JA. Long-term Ret	rieval
			Success Rate Profile for the Gunther Tulip Vena Cava	Filter. J
			Vasc Interv Radiol. 2009 Jul;20(7):871-7; quiz 878. do	i:
			10.1016/j.jvir.2009.03.033. Epub 2009 May 28.	
7317			Smouse HB, Trost D, Rectenwald JE, Arko FR, Kaufm	an JA,
			Plant G, Atkins MD, Razavi MK, Uberoi R. One	
			QuestionHow Have Your Protocols for IVC Filter Pla	cement,
			Monitoring, and Retrieval Changed in the Past Several	
			Endovascular Today, July 2012. [not a peer-reviewed a	rticle]
7318			Society of Interventional Radiology Responds to FDA	Blood
53.1 0			Clot Device (IVC Filter) Advisory	
7319			Society of Interventional Radiology Responds to FDA I	Blood
7220			Clot Device (IVC Filter) Advisory, 08/12/2010.	
7320			Spencer FA, Bates SM, Goldbert RJ. A population-base	d study
		100	of inferior vena cava filters in patients with acute venou	ıs
7221			thromboembolism. Arch Intern Med 2010; 170:1456-62	
7321			Spinal Cord Injury Thromboprophylaxis Investigators,	
			Prevention of Venous Thromboelism in the Acute Treat	
	į		Phase after Spincal Cord Injury: A Randomized, Multic	enter
			Trial Comparing Low-Dose Heparin Plus Intermittent	
			Pneumatic Compression with Enoxaparin. J Trauma. 20	03
7222			Jun;54(6):1116-24; discussion 1125-6.	
7322			Stavropoulos SW, Dixon RG, Burke CT, Stavas JM, Sh	ah A,
			Shlansky-Goldberg RD, Trerotola SO. Embedded inferi	or vena
			cava filter removal: use of endobronchial forceps. J Vas	c Interv
			Radiol. 2008 Sep;19(9):1297-301. doi:	
7323			10.1016/j.jvir.2008.04.012. Epub 2008 Jun 2.	
, 525			Stavropoulos, S.W., Chen, J.X., Sing, R.F. et al. Analysi	is of the
			final DENALI trial data: a prospective, multicenter stud	y of the
			DENALI inferior vena cava filter. J Vasc Interv Radiol.	2016;
			27: 1531–1538.	

Exhibit	Marked for ID	Admitted in Evidence	Description
7324			Stavropoulos, S.W., et al., Retrieval of Tip-embedded Inferior Vena Cava Filters by Using the Endobronchial Forceps Technique: Experience at a Single Institution. Radiology, 2015. 275(3): 900-7.
7325			Stavropoulos, S.W., et al., The DENALI Trial: an interim analysis of a prospective, multicenter study of the Denali retrievable inferior vena cava filter. J Vasc Interv Radiol, 2014. 25(10): 1497-505, 1505 e1.
7326			Steele JR, Wallace MJ, Hovsepian DM, James BC, Kundu S, Miller DL, Rose SC, Sacks D, Shah SS, Cardella JF. Guidelines for Establishing a Quality Improvement Program in Interventional Radiology. J Vasc Interv Radiol. 2010 May;21(5):617-25. doi: 10.1016/j.jvir.2010.01.010. Epub 2010 Mar 17.
7327			Stein PD, Alnas M, Skaf E, Kayali F, Siddiqui T, Olson RE, Patel K. Outcome and Complications of Retrievable Inferior Vena Cava Filters. Am J Cardiol. 2004 Oct 15;94(8):1090-3.
7328			Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 2004; 164:1541-1545.
7329			Stein PD, Matta F, Huges MJ. Inferior Vena Cava Filters in Stable Patients with Acute Pulmonary Embolism Who Receive Thrombolytic Therapy. Am J Med. 2018 Jan;131(1):97-9.
7330			Stein PD, Matta F, Jull RD. Increasing use of vena cava filters for prevention of pulmonary embolism. Am J Med 2011; 124:655-61.
7331			Stein PD, Matta F, Keyes DC, Willyerd G. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med 2012; 125:478-84.
7332			Stein PD, Matta F, Lawrence FR, Huges MJ. Inferior Vena Cava Filters in Patients with Acute Pulmonary Embolism and Cancer. Am J Med. EPub 2017 Nov10.
7333			Stein PD, Matta F, Lawrence FR, Huges MJ. Usefulness of Inferior Vena Cava Filters in Unstable Patients With Acute Pulmonary Embolism and Patients Who Underwent Pulmonary Embolectomy. Am J Cardio. 2018 Jan;121(4):495-00.
7334			Stein PD, Matta F, Sabra MJ. Case fatality rate with vena cava filters in hospitalized stable patients with cancer and pulmonary embolism. Am J Med. 2013; 126:819-24.
7335			Stein PD, Matta F. Vena cava filters in unstable elderly patients with acute pulmonary embolism. Am J Med 2014; 127:222-5.
7336			Stösslein F, Altmann E. A rare complication with an Antheor cava filter. Cardiovasc Intervent Radiol. 1998 Mar-Apr;21(2):165-7.

Exhibit	Marked for ID	Admitted in Evidence	Description
7337			Streib EW, Wagner JW. Complications of vascular access
			procedures in patients with vena cava filters. J Trauma. 2000
			Sep;49(3):553-7; discussion 557-8.
7338			Streiff MB. Vena Caval Filters: A Comprehensive Review.
			Blood. 2000 Jun 15;95(12):3669-77.
7339			Sudheendra D, Giroux MF, Johnson MS, Murphy E, Garcia,
			MJ. Ask the Experts: What is your practice's current IVC filter
			retrieval protocol, and in which cases do you deviate from it?
			[not a peer-reviewed article]
7340			Sutphin PD, Reis SP, McKune A, et al. Improving inferior vena
			cava filter retrieval rates with the define, measure, analyze,
			improve, control methodology. J Vasc Interv Radiol 2015;
			26:491-8.
7341			Swami, U., G. Annunziata and I. Fulger, Experience with vena
			cava filters at a large community hospital and level-I trauma
			center: indications, complications, and compliance barriers. Clin
			Appl Thromb Hemost, 2014. 20(5): 546-52
7342			Sweeney TJ, Van Aman ME. Deployment Problems with the
·			Titanium Greenfield Filter. J Vasc Interv Radiol. 1993 Sep-
			Oct;4(5):691-4.
7343			Sweet PH III, Armstrong T, Chen J, Masliah E, Witucki P. Fatal
			pulmonary embolism update: 10 years of autopsy experience at
			an academic medical center. JRSM Short Rep. 2013;
			4(9):2042533313489824.
7344			?wi?tkowska B, Szeszenia-D?browska N, Wilczy?ska U.
			Medical Monitoring of Asbestos-Exposed Workers –
			Experience from Poland. Bull World Health Organ. 2016 Aug
			1;94(8):599-604. doi: 10.2471/BLT.15.159426. Epub 2016 Jun
			2.
7345			Taksler GB, Keshner M, Fagerlin A, Hajizadeh N, Braithwaite
			RS. Personalized Estimates of Benefit from Preventative Care
			Guidelines – A Proof of Concept. Ann Intern Med. 2013 Aug
			6;159(3):161-8. doi: 10.7326/0003-4819-159-3-201308060-
			00005.
7346			Tam MD, Spain J, Lieber M, Geisinger M, Sands MJ, Wang W.
			Fracture and distant migration of the Bard Recovery filter: a
			retrospective review of 363 implantations for potentially life-
			threatening complications. J Vasc Interv Radiol. 2012
			Feb;23(2):199-205.e1. doi: 10.1016/j.jvir.2011.10.017. Epub
			2011 Dec 20.

The etc, causes of Death in the Early and Late Stages of	Exhibit	Marked for ID	Admitted in Evidence	Description
Attempted Retrieval in 107 Patients. Abstract No. 2. Journal of Vascular and Intervental Radiology, February 2010Volume 21, Issue 2, Supplement, Page S3. Tan XL, Tam C, Mckellar R, Nandurkar H, Bazargan A. Out of sight, out of mind: an audit of inferior vena cava filter insertion and clinical follow up in an Australian institution and literature review. Intern Med J 2013; 43(4):365-72. Tanner L, FDA clot device advisory tells of patients' risks. The San Diego Union-Tribune, August 9, 2010. Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.ys.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85. Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology. (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.	7347			Tam MD, Zhu X, McLennan G, Sands MJ, W. Wang.
Attempted Retrieval in 107 Patients. Abstract No. 2. Journal of Vascular and Intervental Radiology, February 2010Volume 21, Issue 2, Supplement, Page S3. Tan XL, Tam C, Mckellar R, Nandurkar H, Bazargan A. Out of sight, out of mind: an audit of inferior vena cava filter insertion and clinical follow up in an Australian institution and literature review. Intern Med J 2013; 43(4):365-72. Tanner L, FDA clot device advisory tells of patients' risks. The San Diego Union-Tribune, August 9, 2010. Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.ys.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85. Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology. (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.				Complications of the Bard Recovery Filter and Their Effect on
Issue 2, Supplement, Page S3. Tan XL, Tam C, Mckellar R, Nandurkar H, Bazargan A. Out of sight, out of mind: an audit of inferior vena cava filter insertion and clinical follow up in an Australian institution and literature review. Intern Med J 2013; 43(4):365-72. Tanner L, FDA clot device advisory tells of patients' risks. The San Diego Union-Tribune, August 9, 2010. Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Vascular Surgery have initiated the PRESERVE study Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):524-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Starvopoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of				Attempted Retrieval in 107 Patients. Abstract No. 2. Journal of
Tan XL, Tam C, Mckellar R, Nandurkar H, Bazargan A. Out of sight, out of mind: an audit of inferior vena cava filter insertion and clinical follow up in an Australian institution and literature review. Intern Med J 2013; 43(4):365-72. Tanner L, FDA clot device advisory tells of patients' risks. The San Dicgo Union-Tribune, August 9, 2010. Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech yena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.				Vascular and Intervental Radiology, February 2010Volume 21,
sight, out of mind: an audit of inferior vena cava filter insertion and clinical follow up in an Australian institution and literature review. Intern Med J 2013; 43(4):365-72. Tanner L, FDA clot device advisory tells of patients' risks. The San Diego Union-Tribune, August 9, 2010. Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and Management of Acute Pulmonary Embolism the Task Force for the Diagnosis of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.	72.40			Issue 2, Supplement, Page S3.
and clinical follow up in an Australian institution and literature review. Intern Med J 2013; 43(4):365-72. Tanner L, FDA clot device advisory tells of patients' risks. The San Diego Union-Tribune, August 9, 2010. Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	/348			Tan XL, Tam C, Mckellar R, Nandurkar H, Bazargan A. Out of
review. Intern Med J 2013; 43(4):365-72. Tanner L, FDA clot device advisory tells of patients' risks. The San Diego Union-Tribune, August 9, 2010. Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor PC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.				sight, out of mind: an audit of inferior vena cava filter insertion
Tanner L, FDA clot device advisory tells of patients' risks. The San Diego Union-Tribune, August 9, 2010. Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Acute Pulmonary embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.				and clinical follow up in an Australian institution and literature
San Diego Union-Tribune, August 9, 2010.	72.40			
Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche- Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	/349	į		Tanner L, FDA clot device advisory tells of patients' risks. The
Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.	72.50			San Diego Union-Tribune, August 9, 2010.
Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.	/350			Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-
tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of				Nagle G. Temporary inferior vena cava filter indications,
doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30. Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G, AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.				retrieval rates, and follow up management at a multicenter
Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.				tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437.
detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	7251			doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30.
interactions in adverse event reports. J Am Med Inform Assoc, 2012, 19(1): 79-85 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276-2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	/331			latonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal
7352 Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of				detection algorithm for identifying hidden drug-drug
Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.				interactions in adverse event reports. J Am Med Inform Assoc,
cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.	7252			
Radiol. 1991 Nov;2(4):435-40. The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	1332			Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena
The Guide to Clinical Preventative Services. US Preventative Services Task Force. The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of				cava filter: experience and early follow-up. J Vasc Interv
The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.	7353			Radiol. 1991 Nov;2(4):435-40.
The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	7333			The Guide to Clinical Preventative Services. US Preventative
Vascular Surgery have initiated the PRESERVE study Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	7354			
Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	7331			Vegevier Symposis bear initiated the PREGERAGE
chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	7355			Theorem P. Petel N. L. F. L. H. P. L. C. A. P. P. C. A. P. P. P. C. A. P. P. P. C. A. P. P. P. P. P. P. P. P. P. P. P. P. P.
Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5. Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	7555			about pain in a supersurvividadi S. A. A. R. teaching file:
Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of				Am I Poontropol 2007 Samilance and 1924 5
the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	7356			Tophiol: A Paris A IV
of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	7550			the Diagnosis and Managarata CA at B. I. Task Force for
diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of				of the European Society of Cardialan Collaboration
Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of				diagnosis and management of south rules. It is
Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of				Task Force for the Diagnosis and Management of A
(ESC) Eur Heart J 2008;29(18):2276–2315. Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of				Pulmonary Embolism of the European Society of Continu
Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of				(ESC) Fur Heart I 2008-29(18)-2276, 2215
Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of	7357			
Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of			1	Inferior Vena Cava Filters: Outcomes by Fragment 1 and 1
7358 10.1148/radiol.2017162005. Epub 2017 Apr 19. Tribe CR, Causes of Death in the Early and Late Stages of			1	Radiology 2017 Sen: 284(3):887-896 doi:
Tribe CR, Causes of Death in the Early and Late Stages of				10.1148/radiol.2017162005 Enul 2017 Apr 10
Paranlegia Paranlegia 1963 May 1-10 47	7358			Tribe CR. Causes of Death in the Farly and Late Stores of
			I	Paraplegia. Paraplegia. 1963 May;1:19-47.

Exhibit	Marked for ID	Admitted in Evidence	Description	
7359			Trigilio-Black CM, Ringley CD, McBride CL, Sorense	en VJ.
			Thompson JS, Longo GM, Pipinos II, Johanning JM. I	
			Vena Cava Filter Placement for Pulmonary Embolism	
			Reduction in Super Morbidly Obese Undergoing Baria	
			Surgery. Surg Obes Relat Dis. 2007 Jul-Aug;3(4):461-	
			2007 Jun 4.	
7360			Tschoe M, Kim HS, Brotman DJ, Streiff MB. Retrieva	ble Vena
			Cava Filters: A Clinical Review. J Hosp Med. 2009	
			Sep;4(7):441-8. doi: 10.1002/jhm.439.	
7361			Tse G, Cleveland T, Goode S. Ten-Year Experience of	•
			Retrievable Inferior Vena Cava Filters in a Tertiary Re	
			Center. Diagn Interv Radiol. 2017 Mar-Apr;23(2):144-	
			10.5152/dir.2016.16022.	
7362			Turba UC, Glaiberman C, Picus D, Arslan B, Angle JF	
			Matsumoto AH. Management of severe vena cava filte	
			experience with Bard G-2 filters. J Vasc Interv Radiol.	
			Mar;19(3):449-53. doi: 10.1016/j.jvir.2007.11.020.	
7363			U.S. Preventive Services Task Force	
			https://www.uspreventiveservicestaskforce.org/Page/N	ame/grad
			e-definitions accessed on March 6, 2017.	
7364			Uberoi R, Tapping CR, Chalmers N, Allgar V. British	Society
			of Interventional Radiology (BSIR) Inferior Vena Cava	
			Filter Registry. Cardiovasc Intervent Radiol. 2013	, ,
			Dec;36(6):1548-1561. doi: 10.1007/s00270-013-0606-	2. Epub
			2013 Mar 20. Erratum in: Cardiovasc Intervent Radiol.	2017
			Dec 28.	,
7365			Urbankova J, Quiroz R, Kucher N, Goldhaber SZ. Inter	mittent
			pneumatic compression and DVT prevention in postope	erative
			patients. Thromb Haemost. 2005 Dec;94(6):1181-5.	
7366			Urena, R. and L. Greenwood, Bird's nest filter migratio	n to the
			right atrium. AJR Am J Roentgenol, 2004. 183(4): 103	7-9.
7367			Urias D, Silvis J, Mesropyan L, Oberlander E, Simunic	h T,
			Tretter J. Retrievable Inferior Vena Cava Filters in Ger	iatric
			Trauma: Is There an Age Bias? Injury. 2017 Jan;48(1):	148-152.
			doi: 10.1016/j.injury.2016.07.008. Epub 2016 Jul 15.	
7368			Van Ha, T.G., Complications of inferior vena caval filte	ers.
			Semin Intervent Radiol, 2006. 23(2): 150-5.	
7369			Vaziri K, Bhanot P, Hungness ES, Morasch MD, Prysto	owsky
			JB, Nagle AP. Retrievable IVC Filters in High Risk Pat	ients
			Undergoing Bariatric Surgery. Surg Endosc. 2009	
)	Oct;23(10):2203-7. doi: 10.1007/s00464-008-0307-0. H	pub
			2009 Jan 28.	

Exhibit	Marked for ID	Admitted in Evidence	Description	
7370			Veerapong J, Wahlgren CM, Jolly N, Bassiouny H. Su percutaneous retrieval of an inferior vena cava filter m	igrating
			to the right ventricle in a bariatric patient. Cardiovasc Radiol. 2008 Jul;31 Suppl 2:S177-81. doi: 10.1007/s009278-0. Epub 2008 Jan 17.	0270-007-
7371			Velmahos GC, et al: Prevention of venous thromboem after injury: an evidence-based report: part II: analysis factors and evaluation of the role of vena caval filters. 49:140-144, 2000	of risk
7372			Vena Caval Filter Consensus Conference. Recommend reporting standards for vena caval filter placement and follow-up. The Participants in the Vena Caval Filter Conference. J Vasc Surg 1999:30:573-9.	patient
7373			Vergara, G.R., W.F. Wallace and K.R. Bennett, Sponta migration of an inferior vena cava filter resulting in car tamponade and percutaneous filter retrieval. Catheter Cardiovasc Interv, 2007. 69(2): 300-2.	
7374			Vijay K, Hughes JA, Burdette AS, et al. Fractured Bard Recovery, G2, and G2 express inferior vena cava filter incidence, clinical consequences, and outcomes of remattempts. J Vasc Interv Radiol 2012; 23:188-94.	s:
7375			Vladimir, F.G., et al., Complications and Outcomes As With the Use Of Retrievable Vena Cava Filters: A Rev the Manufacturer and User Facility Device Experience (MAUDE) Database. NESVS: 2005 Annual Meeting - Abstracts, 2005.	iew of Database
7376			Vossen, J.A., et al., Recurrent fracture of a recovery int vena cava filter with pulmonary migration. Yale J Biol 2012. 85(2): 255-9	
7377			Walsh J, Safety and Effectiveness of Inferior Vena Cav Used to Protect Against Pulmonary Embolus: A Techno Assessment.	ology
			http://ctaf.org/sites/default/files/assessments/1247_file_ters_final_W.pdf	IVC_Fil
7378			Waltz P, Zuckerbraun BS. Commentary – Inferior Vena Filters in Trauma Patients – For Whom the Benefit Tol. JAMA Surg. 2017 Jan 1;152(1):81. doi: 10.1001/jamasurg.2016.3121.	ls?
7379			Wang SL, Lloyd AJ. Clinical review: inferior vena cava in the age of patient-centered outcomes. Ann Med. 2013 Nov;45(7):474-81.	

Exhibit	Marked for ID	Admitted in Evidence	Description	
7380			Wang W, Spain J, Tam MD. Acute Abdominal Pain	A G
			Retrievable Inferior Vena Cava Filter Insertion: Case	After
			Caval Perforation by an Option Filter. Cardiovasc Intelligence Caval Perforation by an Option Filter.	Report of
			Radiol. 2011 Aug;34(4):883-5. doi: 10.1007/s00270-0	ervent
			Z.	110-0080-
7381			Wang W, Zhou D, Obuchowski N et al. Fracture and	
			of Celect Inferior Vena Cava Filters: A Retrospective	Migration
			741 Consecutive Implantations. J Vasc Interv Radiol.	Review of
			2013;24:1710-1722.	
7382				
			Waring WP, Karunas RS. Acute Spinal Cord Injuries	and the
			Incidence of Clinically Occurring Thromboembolic D Paraplegia. 1991 Jan;29(1):8-16.	isease.
7383			Webb I V Duck DT Fulls CD M 111 TW C	
			Webb LX, Rush PT, Fuller SB, Meredith JW. Greenfi	eld Filter
			Prophylaxis of Pulmonary Embolism in Patients Unde	rgoing
			Surgery for Acetabular Fracture. J Orthop Trauma. 1992;6(2):139-45.	
7384			1992,0(2).139-43.	
			Wehrenberg-Klee E, Stavropoulos SW. Inferior Vena	Cava
			Filters for Primary Prophylaxis: When are they indicat	ed?
			Semin Intervent Radiol. 2012 Mar;29(1):29-35. doi: 10	0.1055/s-
7385			0032-1302449.	
7303			Weinberg I, Abtathian F, Debiosi R, et al: Effect of De	latyed
			Inferior Vena Cava Filter Retrieval after Early Initiatio	n of
7386			Anticoagulation. 2014 Am. J. Cardiology; 113:389-394	1.
7300			Weinberg I, Kaufman J, Jaff MR. Inferior vena cava fil	lters.
7387			JACC Cardiovasc Interv. 2013;6(6):539-547.	
7567			Whedon JM, Beaver TA, Hernandez RA, Burchard KV	V
			Paradoxical Thromboembolism After Blunt Lower Ext	remity
			Trauma: A Management Strategy to Prevent Additional	1
		1	Sequelae Where Anticoagulation is Contraindicated. A	m Surg.
7388			2014 Nov;80(11):E309-11.	
7300			White RH, Brunson A, Romano PS, Li Z, Wun T. Outc	omes
			after vena cava filter use in noncancer patients with acu	te
			venous thromboembolism: A Population-Based Study.	
		1	Circulation. 2016 May 24;133(21):2018-29. doi:	
7389			10.1161/CIRCULATIONAHA.115.020338. Epub 2016	Apr 5.
1369		İ	White RH, Geraghty EM, Brunson A, Murin S, Wun T	Spencer
		1	F, Romano PS. High Variation Between Hospitals in Ve	na Cava
		1	filter Use for Venous Thromboembolism. JAMA Intern	Med.
		4	2013 Apr 8;173(7):506-12. doi:	
7200			10.1001/jamainternmed.2013.2352.	
7390		1	White RH: The epidemiology of venous thromboemboli	sm.
			Circulation 107:14-18, 2003.	

Exhibit	Marked for ID	Admitted in Evidence	Description	
7391			Wicky S, Doenz F, Meuwly JY, Portier F, Schnyder P A. Clinical Experience with Retrievable Gunther Tulip	Vena
7200			Cava Filters. J Endovasc Ther. 2003 Oct;10(5):994-10	00.
7392			Winters JP, Morris CS, Holmes CE, Lewis P, Bhave A	D,
			Najarian KE, Shields JT, Charash W, Cushman M. A	
·			multidisciplinary quality improvement program increase	ses the
			inferior vena cava filter retrieval rate. Vasc Med. 2017	
			Feb;22(1):51-56. doi: 10.1177/1358863X16676658. E ₁ Nov 3.	pub 2016
7393			Wojcik R, Cipolle MD, Fearen I, Jaffe J, Newcomb J,	Pasquale
			MD. Long-Term Follow-up of Trauma Patients with a	Vena
			Caval Filter. J Trauma. 2000 Nov;49(5):839-43.	
7394			Wones R, Pinney SM, Buckholz JM, Deck-Tebbe C, F	revberg
			R, Pesce A. Medical Monitoring - A Beneficial Remed	v for
			Residents Living Near an Environmental Hazard Site	JOccup
			Environ Med. 2009 Dec;51(12):1374-83. doi:	1
			10.1097/JOM.0b013e3181c558f1.	
7395			Wood, E.A., et al., Reporting the Impact of Inferior Ve	na Cava
			Perforation by Filters. (Abstract from the 2012 America	an
			Venous Forum Annual Meeting). J Vasc Surg, 2012. 55	5(1): 301
7396			Woodward, E.B., et al., Delayed retroperitoneal arterial	
			hemorrhage after inferior vena cava (IVC) filter insertion	n: case
			report and literature review of caval perforations by IV	C filters.
			Ann Vasc Surg, 2002. 16(2): 193-6.	
7397			Wu A, Moon E, Wang DS, Hertz B, Wang W. Bard Me	ridian
			Filter Fracture. Cardiovasc Intervent Radiol. 2015	
			Feb;38(1):251-2. doi: 10.1007/s00270-014-0935-9. Epu	ib 2014
7200			Jun 20.	
7398			Wu EC, Barba CA. Current Practices in the Prophylaxis	s of
			Venous Thromboembolism in Bariatric Surgery. Obes S	Surg.
7399			2000 Feb;10(1):7-13; discussion 14.	
1399			Wu EC, Barba CA. Endovascular Treatment of Late Ac	rtic
			Perforation due to Vena Cava Filter. Obes Surg. 2000	
7400			Feb;10(1):7-13; discussion 14.	
/400			Wu, G.S., et al., Inferior vena cava filter migration with	severe
7401			deformity of filter. J Vasc Interv Radiol, 2009. 20(9): 12	257-9
7701			Yamagami T., Kato T., Hirota T., Yoshimatsu R., Matsu	imoto
			T., Nishimura T. Prophylactic implantation of inferior v	ena
			cava filter during interventional radiological treatment f	or deep
			venous thrombosis of the lower extremity. Br J Radiol.	
			2006;79:584-591.	

Exhibit	Marked for ID	Admitted in Evidence	Description	
7402			Young T, Tang H, Hughes R. Vena caval filters for th	e.
)			prevention of pulmonary embolism. Cochrane Databa	se Syst
			Rev. 2010 Feb 17;(2):CD006212. doi:	55 5751
			10.1002/14651858.CD006212.pub4.	
7403			Zektser M, Bartal C, Zeller L et al. Effectiveness of in	ferior
			vena cava filters without anticoagulation therapy for	
			prophylaxis of recurrent pulmonary embolism. Ramba	ım
			Maimonides Med J. 2016 Jul 28;7(3).	
7404			Zhou, D., et al., Penetration of Celect inferior vena car	va filters:
			retrospective review of CT scans in 265 patients. AJR	Am J
			Roentgenol, 2014. 202(3): 643-7.	
7405			Zhou, D., et al., Retrospective review of 120 celect inf	erior vena
			cava filter retrievals: experience at a single institution.	J Vasc
			Interv Radiol, 2012. 23(12): 1557-63	, 430
7406			Zhu Indications, complications and outcomes of G2 re	trievable
			IVC filters in 765 patients: A single institute experience	e.
			Abstract No. 3. Journal of Vascular and Interventional	
			Radiology. February 2010Volume 21, Issue 2, Suppler	
			Pages S3–S4.	,
7407			Zhu X, Tam MD, Bartholomew J, Newman JS, Sands	MJ.
			Wang W. Retrievability and device-related complication	ons of the
			G2 filter: a retrospective study of 139 filter retrievals.	J Vasc
			Interv Radiol. 2011 Jun;22(6):806-12. doi:	
			10.1016/j.jvir.2011.01.430. Epub 2011 Apr 8.	
7408			Zolfaghari D, Johnson B, Weireter LJ, Britt LD. Expan	ided Use
			of Inferior Vena Cava Filters in the Trauma Population	. Surg
			Annu. 1995;27:99-105.	
7409			Goldman, Limitations and Strengths of Spontaneous R	eports
			Data (1998)	
7410			1997 GAO Report Excerpt (Medical Device Reporting	
			Improvements Needed in FDA's System for Monitorin	Q
			Problems With Approved Devices)	
7411			2008 Surgeon General's Call to Action re PE and DVT	
7412			April 14, 2017 Report of Dr. Fasching, Medical Literat	ure -
			James, B, Medical Device Failure Analysis, ASM Hand	lbook.
			Volume 23, Materials for Medical Devices, ASM International	national.
			Materials Park, OH, 2012, p. 346.	
7413			April 14, 2017 Report of Dr. Fasching, Medical Literation	ure -
		1.	Angel LF, Tapson V, Galgon RE, Restrepo MI, Kaufma	an J.
			Systematic Review of the use of Retrievable Inferior Ve	ena Cava
			Filters. J Vasc Intev Radiol 2011; 22:1522-1530.	

Exhibit	Marked for	Admitted in	Description	
	ID	Evidence	•	
7414			April 14, 2017 Report of Dr. Fasching, Medical Literature -	
			Hull JE, Robertson SW. Bard Recovery Filter: Evaluation and	l
			Management of vena Cava Limb Perforation, Fracture, and	
			Migration. J Vasc Intev Radiol 2009; 20:52-60.	
7415			April 14, 2017 Report of Dr. Fasching, Medical Literature -	
			Tam MD, Spain J, Lieber M, Geisinger M, Sands MJ, Wang V	V.
			Fracture and Distant Migration of the Bard Recovery Filter: A	
			Retropective Review of 363 Implantations for Potentially Life	-
			Threatening Complications. J Vasc Intev Radiol 2013; 23:199-205.	-
7416			April 14, 2017 Report of Dr. Fasching, Medical Literature -	
			Kuo WT Robertson SW, Odegaard JI Hofmann LV. Complex	
			Retrieval of Fractured, Embedded, and Penetrating Inferior	
			Vena Cava Filters: A prospective Study with Histologic and	
			Electron Microscopic Analysis. J Vasc Interv Radiol 2013;	
			24:622-630.	
7417			April 14, 2017 Report of Dr. Fasching, Medical Literature -	
			McMeeking RM, Assessment of the Designs of Bard Inferior	
			Vena Cava Filters: The Recovery, G2, G2 Express, Eclipse,	
			Meridian, and Denali Models, Re: MDL3.3.17.	
7418			April 14, 2017 Report of Dr. Fasching, Medical Literature -	
			Hodgson DE. Fabrication, Heat Treatment and Joining of	
			Nitinol Components. SMST-2000 Proceedings of the	
			International Conference on Shape Memory and Superelastic	
			Technologies (Pacific Grove, CA, April 30 to May 4, 2000), P.	
7			11-24.	
7419			April 14, 2017 Report of Dr. Fasching, Medical Literature -	
			Trepanier C, Tabrizian M, Yahia LH, Bilodeau L, Piron DL.	ĺ
			Improvement of the Corrosion Resistance of NiTi Stents by	ĺ
			Surface Treatments. Mat. Res. Soc. Symp. Proc. Vol. 459	
7420			(1997). 363-368.	
7420			April 14, 2017 Report of Dr. Fasching, Medical Literature -	
			Trepanier C, Tabrizian M, Yahia LH, Bilodeau L, Piron DL.	
			Effect of Modification of Oxide Layer on NiTi Stent Corrosion	
7421			Resistance. J. Biomed. Mat. Research, 1998; 43:433-440.	\perp
1421			April 14, 2017 Report of Dr. Fasching, Medical Literature -	
			Steegmueller R, Fleckenstein T. Schuessler A. Is	
			Electropolishing equal Electropolishing? A Comparison Study	
			for Nitinol Stents. Proceed. Mat. & Proc. for Med. Dev. Conf.,	
7422			November 14-16, Boston, MA, 2006, p. 163-168.	$ \bot $
1744			April 14, 2017 Report of Dr. Fasching, Medical Literature -	
			https://emea.cordis.com/ma/product/smart-control-self-	
			expanding-nitinol-stent#overview	

Exhibit	Marked for ID	Admitted in Evidence	Description	, , , , , , , , , , , , , , , , , , ,
7423			April 14, 2017 Report of Dr. Fasching, Medical Litera Patel MM, Gordon RF, An Investigation of Diverse St Finishes on Fatigue Properties of Superelastic Nitinol Proceedings of International Conference on Shape Me Superelastic Technology, ASM International, 2006, p.	urface Wire, emory and
7424			April 14, 2017 Report of Dr. Fasching, Medical Litera Kuo WT Robertson SW, Odegaard JI Hofmann LV. C Retrieval of Fractured, Embedded, and Penetrating Inf Vena Cava Filters: A prospective Study with Histologic Electron Microscopic Analysis. J Vasc Interv Radiol 2 24:622-630.	ture - omplex erior c and
7425			April 14, 2017 Report of Dr. Fasching, Medical Literar McMeeking RM, Begley MR, Mechanical Reliability Assessment of the Bard G2 Filter, Re: Ebert v CR Bard 2014.	
7426			April 14, 2017 Report of Dr. Fasching, Medical Literat McMeeking RM, Begley MR, Finite Element Modelin Bard Filters, June 2011.	cure - g of the
7427			April 14, 2017 Report of Dr. Fasching, Medical Literat Gong XY, Pelton AR, Finite Element Analysis on Nitis Medical Applications, Proceedings of IMECE-2002, V 2002.	nol
7428			April 14, 2017 Report of Dr. Fasching, Medical Literat Rebelo N, Gong XY, Hall A, Pelton AR, Duerig TW, F Element Analysis on the Cyclic Properties of Superelas Nitinol, Proceedings 2004 ABAQUS Users' Conference 601-613.	Finite tic
7429			April 14, 2017 Report of Dr. Fasching, Medical Literat Pelton AR, Schroeder V, Mitchell MR, Gong XY, Barr Robertson SW, Fatigue and Durability of Nitinol Stents Mechl Behavior Biomed Mater, 1, 153-164 (2008)	ey M, s, J of
7430			April 14, 2017 Report of Dr. Fasching, Medical Literate McMeeking RM, Begley MR, Mechanical Reliability Assessment of the Bard IVC Recovery Filters, Re: Katr Newton et. al. v CR Bard, March 2011.	
7431			March 17, 2017 Report of Dr. Fasching, Medical Litera Ritchie, Assessment of the Structural Integrity of Bard I Filters: Recovery, G2, G2-Express and Eclipse, March 2 Re: MDL 3.2.17	VC
7432			March 17, 2017 Report of Dr. Fasching, Medical Litera Lin ZC, Denison A, Nitinol Fatigue Resistance – A Stro Function of Surface Quality, Proceedings from the Mate Processes for Medical Devices Conference, 8-10 Sept 2 ASM International, 2003.	ng erials &

Exhibit	Marked for ID	Admitted in Evidence	Description
7433			March 17, 2017 Report of Dr. Fasching, Medical Literature - McMeeking RM, Assessment of the Designs of Bard Inferior Vena Cava Filters: The Recovery, G2, G2 Express, Eclipse, Meridian, and Denali Models, Re: MDL3.3.17.
7434			Vogelzang, Providing Context: Medical Device Litigation and Inferior Vena Cava Filters (2016)
7435			Greenfield, et al., Recommended reporting standards for vena cava filter placement and patient follow-up (1999)
7436			Hull, Bard Recovery Filter Evaluation and Management (2009)
7437			Comparison of complication rates associated with permanent and retrievable inferior vena cava filters: a review of the MAUDE database.
7438			Looby, S., Cardiovascular Interventional Radiology, 2007 Jan – Feb 30(1): 59 – 65. Gunther Tulip retrievable inferior vena caval filters, indications, efficacy, retrieval, and complications. Study of 147 patients with Tulip filter 2001 to 2005, failed retrievals in 20%
7439			Social Media- FaceBook
7440			Social Media- Instagram
7441			Social Media- LinkedIn
7442			Income Tax returns produced by Plaintiff
7443			Plaintiff's Answer to Defendants First Set of Non-Uniform Interrogatories, 7/28/2017
7444			Plaintiff's Responses to C. R. Bard, Inc.'s First Request for Production, 7/28/2017
7445			Plaintiff's Responses to BPV's Supplemental Reuqest for Production, 8/14/2017
7446			Plaintiff's Answer to Defendant's Supplemental Non-Uniform Interrogatories, 8/15/2017
7447			Plaintiff's Responses to C. R. Bard, Inc.'s Request for Production, 8/15/2017
7448			Plaintiff's Responses to Bard's Supplemental Reuqest for Production, 8/15/2017
7449			Attorney John A. Dalimonte Answers to Defendants' Interrogatories and Response to Production of Documents
7450			Emails produced by John Dalimonte re communications with the FDA
7451			Plaintiff's Profile Form and accompanying documents, 3/30/2016
7452			Plaintiff's Fact Sheet and accompanying documents, 7/29/2016
7453			Plaintiff's Amended Fact Sheet and accompanying documents, 1/11/2017
7454			Plaintiff's Amended Fact Sheet and accompanying documents, 1/31/2017

Exhibit	Marked for ID	Admitted in Evidence	Description	
7455			Plaintiff's Supplmental Fact Sheet and accompanying documents, 5/22/2017	
7456			Plaintiff's Supplmental Fact Sheet and accompanying documents, 1/25/2018	
7457			Bard's Defense Profile Form and accompanying docur 4/28/2016	nents,
7458			Bard's Defense Fact Sheet and accompanying docume 8/29/2016	nts,
7459			Defendants' Response to Plainitffs' Brief in Opposition	to Bard's
7460			Request to Depose PLC Counsel Exhibit A Defendants' Response to Plainitffs' Brief in Opposition Request to Depose PLC Counsel Exhibit A	to Bard's
7461			Request to Depose PLC Counsel Exhibit B Defendants' Response to Plainitffs' Brief in Opposition	to Bard's
7462			Request to Depose PLC Counsel Exhibit C Defendants' Response to Plainitffs' Brief in Opposition	to Bard's
7463			Request to Depose PLC Counsel Exhibit D Defendants' Response to Plainitffs' Brief in Opposition	to Bard's
7464			Request to Depose PLC Counsel Exhibit E Defendants' Response to Plainitffs' Brief in Opposition	to Bard's
7465			Request to Depose PLC Counsel Exhibit F July 31, 2017 Report of Dr. Fasching, Pictures from Fig	pure 1
7466			July 31, 2017 Report of Dr. Fasching, Pictures from Fig.	rure 2
7467			July 31, 2017 Report of Dr. Fasching, Pictures from Fig.	rure 3
7468			July 31, 2017 Report of Dr. Fasching, Pictures from Fig.	ure 4
7469			July 31, 2017 Report of Dr. Fasching, Pictures from Fig.	rure 5
7470			July 31, 2017 Report of Dr. Fasching, Pictures from Fig.	ure 6
7471			July 31, 2017 Report of Dr. Fasching, Pictures from Fig.	rure 7
7472			July 31, 2017 Report of Dr. Fasching, Pictures from Fig	ure 8
7473			July 31, 2017 Report of Dr. Fasching, Pictures from Fig	ure 9
7474			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 1
7475			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 2
7477			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 3
7477			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 4
7479			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 5
7480			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 6
7481			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 7
7482			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 8
7483			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 9
7484			April 14, 2017 Report of Dr. Fasching, Pictures from Fig.	gure 10
7485			April 14, 2017 Report of Dr. Fasching, Pictures from Fig.	gure 11
7486		- 4	April 14, 2017 Report of Dr. Fasching, Pictures from Fig.	gure 12
7487			April 14, 2017 Report of Dr. Fasching, Pictures from Fig.	gure 13
7 10 /			April 14, 2017 Report of Dr. Fasching, Pictures from Fig.	gure 14

Exhibit	Marked for ID	Admitted in Evidence	Description	
7488			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 15
7489			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 16
7490			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 17
7491			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 18
7492			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 10
7493			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 20
7494	/		April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 21
7495			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 22
7496			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 23
7497			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 24
7498			April 14, 2017 Report of Dr. Fasching, Pictures from I	Figure 25
7499			April 14, 2017 Report of Dr. Fasching, Pictures from l	Figure 26
7500			April 14, 2017 Report of Dr. Fasching, Pictures from I	Figure 27
7501			April 14, 2017 Report of Dr. Fasching, Pictures from I	Figure 28
7502			April 14, 2017 Report of Dr. Fasching, Pictures from I	Figure 29
7503			April 14, 2017 Report of Dr. Fasching, Pictures from I	igure 30
7504			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 31
7505			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 32
7506			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 33
7507			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 34
7508			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 35
7509			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 36
7510			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 37
7511			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 38
7512			April 14, 2017 Report of Dr. Fasching, Pictures from F	Figure 39
7513			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 40
7514			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 41
7515			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 42
7516			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 43
7517			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 44
7518			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 45
7519			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 46
7520			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 47
7521 7522			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 48
			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 49
7523			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 50
7524 7525			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	igure 51
7526			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 52
7527			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 53
7528			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 54
7529		<i>I</i>	April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 55
7530		<i>F</i>	April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 56
1330		<i>F</i>	April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure 57

Exhibit	Marked for ID	Admitted in Evidence	Description	
7531			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 58
7532			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 59
7533			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 60
7534			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 61
7535			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 62
7536			April 14, 2017 Report of Dr. Fasching, Pictures from	
7537			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 64
7538			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 65
7539			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 66
7540			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 67
7541			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 68
7542			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 69
7543			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 70
7544			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 71
7545			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 72
7546			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 73
7547			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 74
7548			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 75
7549			April 14, 2017 Report of Dr. Fasching, Pictures from	Figure 76
7550			April 14, 2017 Report of Dr. Fasching, Pictures from 1	Figure 77
7551			April 14, 2017 Report of Dr. Fasching, Pictures from 1	Figure 78
7552			April 14, 2017 Report of Dr. Fasching, Pictures from 1	Figure 79
7553			April 14, 2017 Report of Dr. Fasching, Pictures from I	Figure 80
7554			April 14, 2017 Report of Dr. Fasching, Pictures from I	igure 81
7555		-	April 14, 2017 Report of Dr. Fasching, Pictures from I	igure 82
7556			April 14, 2017 Report of Dr. Fasching, Pictures from I	igure 83
7557			April 14, 2017 Report of Dr. Fasching, Pictures from I	igure 84
7558			April 14, 2017 Report of Dr. Fasching, Pictures from I	igure 85
7559			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 86
7560			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 87
7561			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 88
7562			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 89
7563			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 90
7564			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 91
7565			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 92
7566			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 93
7567			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 94
7568			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 95
7569			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 96
7570			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 97
7571			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 98
7572			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure 99

Exhibit	Marked for ID	Admitted in Evidence	Description	
7573			April 14, 2017 Report of Dr. Fasching, Pictures from 100	Figure
7574			April 14, 2017 Report of Dr. Fasching, Pictures from 101	Figure
7575			April 14, 2017 Report of Dr. Fasching, Pictures from 102	Figure
7576			April 14, 2017 Report of Dr. Fasching, Pictures from 103	Figure
7577			April 14, 2017 Report of Dr. Fasching, Pictures from 104	Figure
7578			April 14, 2017 Report of Dr. Fasching, Pictures from 105	Figure
7579			April 14, 2017 Report of Dr. Fasching, Pictures from 1 106	Figure
7580			April 14, 2017 Report of Dr. Fasching, Pictures from I	Figure
7581			April 14, 2017 Report of Dr. Fasching, Pictures from I 108	igure
7582			April 14, 2017 Report of Dr. Fasching, Pictures from I	igure
7583			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7584			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7585			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7586			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7587		1	April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7588			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7589			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7590			April 14, 2017 Report of Dr. Fasching, Pictures from F. 117	igure
7591			April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure
7592		4	April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure
7593		1	April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure
7594		1	April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure

Exhibit	Marked for ID	Admitted in Evidence	Description	
7595			April 14, 2017 Report of Dr. Fasching, Pictures from 122	Figure
7596			April 14, 2017 Report of Dr. Fasching, Pictures from 123	Figure
7597			April 14, 2017 Report of Dr. Fasching, Pictures from 124	Figure
7598			April 14, 2017 Report of Dr. Fasching, Pictures from 1 125	Figure
7599			April 14, 2017 Report of Dr. Fasching, Pictures from 1 126	Figure
7600			April 14, 2017 Report of Dr. Fasching, Pictures from I 127	Figure
7601			April 14, 2017 Report of Dr. Fasching, Pictures from I 128	igure
7602			April 14, 2017 Report of Dr. Fasching, Pictures from I 129	Figure
7603			April 14, 2017 Report of Dr. Fasching, Pictures from I	Figure
7604			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7605	,		April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7606			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7607			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7608			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7609			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7610			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7611			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7612			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7613			April 14, 2017 Report of Dr. Fasching, Pictures from F 140	igure
7614			April 14, 2017 Report of Dr. Fasching, Pictures from F 141	igure
7615			April 14, 2017 Report of Dr. Fasching, Pictures from F 142	igure
7616			April 14, 2017 Report of Dr. Fasching, Pictures from F. 143	igure

Exhibit	Marked for ID	Admitted in Evidence	Description	
7617			April 14, 2017 Report of Dr. Fasching, Pictures from 144	Figure
7618			April 14, 2017 Report of Dr. Fasching, Pictures from 145	Figure
7619			April 14, 2017 Report of Dr. Fasching, Pictures from 146	Figure
7620			April 14, 2017 Report of Dr. Fasching, Pictures from 147	Figure
7621			April 14, 2017 Report of Dr. Fasching, Pictures from 148	Figure
7622			April 14, 2017 Report of Dr. Fasching, Pictures from 149	Figure
7623			April 14, 2017 Report of Dr. Fasching, Pictures from 148	Figure
7624			April 14, 2017 Report of Dr. Fasching, Pictures from 149	Figure
7625			April 14, 2017 Report of Dr. Fasching, Pictures from 150	Figure
7626			April 14, 2017 Report of Dr. Fasching, Pictures from 1	Figure
7627			April 14, 2017 Report of Dr. Fasching, Pictures from I	Figure
7628			April 14, 2017 Report of Dr. Fasching, Pictures from I	igure
7629			April 14, 2017 Report of Dr. Fasching, Pictures from I	igure
7630			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7631			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7632			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7633			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7634			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7635			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7636			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7637			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7638		4	April 14, 2017 Report of Dr. Fasching, Pictures from F	igure

Exhibit	Marked for ID	Admitted in Evidence	Description	
7639			April 14, 2017 Report of Dr. Fasching, Pictures from 164	Figure
7640			April 14, 2017 Report of Dr. Fasching, Pictures from 165	Figure
7641			April 14, 2017 Report of Dr. Fasching, Pictures from 1 166	Figure
7642			April 14, 2017 Report of Dr. Fasching, Pictures from 1 167	Figure
7643			April 14, 2017 Report of Dr. Fasching, Pictures from I	Figure
7644			April 14, 2017 Report of Dr. Fasching, Pictures from I	Figure
7645			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7646			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7647			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7648			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7649			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7650			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7651			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7652			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7653			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7654			April 14, 2017 Report of Dr. Fasching, Pictures from F	igure
7655			179 April 14, 2017 Report of Dr. Fasching, Pictures from Fig. 120	igure
7656			180 April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure
7657			181 April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure
7658			182 April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure
7659		1	183 April 14, 2017 Report of Dr. Fasching, Pictures from Fi	gure
7660			184 April 14, 2017 Report of Dr. Fasching, Pictures from Fi 185	gure

Exhibit	Marked for ID	Admitted in Evidence	Description	
7661			April 14, 2017 Report of Dr. Fasching, Pictures from 1 186	Figure
7662			April 14, 2017 Report of Dr. Fasching, Pictures from l 187	Figure
7663			April 14, 2017 Report of Dr. Fasching, Pictures from I 188	Figure
7664			April 14, 2017 Report of Dr. Fasching, Pictures from I 189	Figure
7665			April 14, 2017 Report of Dr. Fasching, Pictures from I 190	igure
7666			April 14, 2017 Report of Dr. Fasching, Pictures from I 191	igure
7667			April 14, 2017 Report of Dr. Fasching, Pictures from F 192	igure
7668			April 14, 2017 Report of Dr. Fasching, Pictures from F 193	igure
7669			April 14, 2017 Report of Dr. Fasching, Pictures from F 194	igure
7670			Fasching MDL Report dated May 11, 2017; Interaction sharp chamfer, Figures 14a, 17a, 85a	n with
7671			Fasching MDL Report dated May 11, 2017; Fracture o of a high stress area, Figures 63a (Arm 2), 94 (Arm 1), (Arm 1)	
7672			Fasching MDL Report dated May 11, 2017; Inclusions initiation site: Figures 83 a & b, 44 b, and 123 b	at
7673			Fasching MDL Report dated May 11, 2017; Initiations surface defect, Figures 142 a & b; 146 a & b, 65 b.	not at
7674			April 14, 2017 Report of Dr. Briant, Pictures from Figu	ire 1
7675			April 14, 2017 Report of Dr. Briant, Pictures from Figu	ire 2
7676			April 14, 2017 Report of Dr. Briant, Pictures from Figu	ire 3
7677			April 14, 2017 Report of Dr. Briant, Pictures from Figu	ire 4
7678			April 14, 2017 Report of Dr. Briant, Pictures from Figu	
7679			April 14, 2017 Report of Dr. Briant, Pictures from Figu	ire 6
7680			April 14, 2017 Report of Dr. Briant, Pictures from Figu	ire 7
7681			April 14, 2017 Report of Dr. Briant, Pictures from Figu	re 8
7682			April 14, 2017 Report of Dr. Briant, Pictures from Figu	re 9
7683			April 14, 2017 Report of Dr. Briant, Pictures from Figu	re 10
7684			April 14, 2017 Report of Dr. Briant, Pictures from Figu	re 11
7685			April 14, 2017 Report of Dr. Briant, Pictures from Figu	
7686			April 14, 2017 Report of Dr. Briant, Pictures from Figu	
7687			April 14, 2017 Report of Dr. Briant, Pictures from Figu	
7688			April 14, 2017 Report of Dr. Briant, Pictures from Figu	re 15
7689			April 14, 2017 Report of Dr. Briant, Pictures from Figu	re 16

Exhibit	Marked for ID	Admitted in Evidence	Description
7690			April 14, 2017 Report of Dr. Briant, Pictures from Figure 17
7691			April 14, 2017 Report of Dr. Briant, Pictures from Figure 18
7692			April 14, 2017 Report of Dr. Briant, Pictures from Figure 19
7693			April 14, 2017 Report of Dr. Briant, Pictures from Figure 20
7694			April 14, 2017 Report of Dr. Briant, Pictures from Figure 21
7695			April 14, 2017 Report of Dr. Briant, Pictures from Figure 22
7696			April 14, 2017 Report of Dr. Briant, Pictures from Figure 23
7697			April 14, 2017 Report of Dr. Briant, Pictures from Figure 24
7698			April 14, 2017 Report of Dr. Briant, Pictures from Figure 25
7699			April 14, 2017 Report of Dr. Briant, Pictures from Figure 26
7700			April 14, 2017 Report of Dr. Briant, Pictures from Figure 27
7701			April 14, 2017 Report of Dr. Briant, Pictures from Figure 28
7702			April 14, 2017 Report of Dr. Briant, Pictures from Figure 29
7703			April 14, 2017 Report of Dr. Briant, Pictures from Figure 30
7704			April 14, 2017 Report of Dr. Briant, Pictures from Figure 31
7705			April 14, 2017 Report of Dr. Briant, Pictures from Figure 32
7706			April 14, 2017 Report of Dr. Briant, Pictures from Figure 33
7707			April 14, 2017 Report of Dr. Briant, Pictures from Figure 34
7708			April 14, 2017 Report of Dr. Briant, Pictures from Figure 35
7709			April 14, 2017 Report of Dr. Briant, Pictures from Figure 36
7710			April 14, 2017 Report of Dr. Briant, Pictures from Table 1
7711			April 14, 2017 Report of Dr. Briant, Pictures from Table 2
7712			April 14, 2017 Report of Dr. Briant, Pictures from Table 3
7713			April 14, 2017 Report of Dr. Briant, Pictures from Table 4
7714			April 14, 2017 Report of Dr. Briant, Pictures from Table 5
7715			April 14, 2017 Report of Dr. Briant, Pictures from Table 6
7716			April 14, 2017 Report of Dr. Briant, Pictures from Table 7
7717			April 14, 2017 Report of Dr. Briant, Pictures from Table 8
7718			http://www.preservetrial.com
7719			https://clinicaltrials.gov/ct2/show/study/NCT02381509
7720			July 12, 2017, Expert Report of Paul Briant, Ph.D., P.E.
7721			June 29, 2017, Expert Report of Daniel Cousin, M.D.
7722			July 31, 2017, Expert Report of Audrey Fasching, Ph.D., P.E.
7723			July 10, 2017, Expert Report of Audrey Fasching, Ph.D., P.E.
7724			July 9, 2017, Expert Report of Piotr Sobieszczyk, M.D.
7725			April 13, 2017, Expert Report of Christine L. Brauer
7726			April 14, 2017, Expert Report of Paul Briant, Ph.D., P.E.
7727			April 14, 2017, Expert Report of Audrey Fasching, Ph.D., P.E.
7728			April 14, 2017, Expert Report of David W. Fiegal, Jr., M.D., M.P.H.
7729			April 14, 2017, Expert Report of Clement J. Grassi, M.D.
7730			April 14, 2017, Expert Report of Christopher S. Morris, M.D.
7731			April 14, 2017, Expert Report of Ronald A. Thisted, Ph.D.

Exhibit	Marked for ID	Admitted in Evidence	Description	
7732			April 14, 2017, Expert Report of Donna-Bea Tillman,	Ph.D.
7733			May 12, 2017, Expert Report of Christine L. Brauer	
7734			May 12, 2017, Expert Report of Audrey Fasching, Ph.	D., P.E.
7735			May 12, 2017, Expert Report of Donna-Bea Tillman,	Ph.D.
7736			CV of Christine L. Brauer	
7737			CV of Paul Briant, Ph.D., P.E.	
7738			CV of Daniel Cousin, M.D.	
7739			CV of Audrey Fasching, Ph.D., P.E.	
7740			CV of David W. Fiegal, Jr., M.D., M.P.H.	
7741			CV of Clement J. Grassi, M.D.	
7742			CV of Christopher S. Morris, M.D.	-
7743			CV of Piotr Sobieszczyk, M.D.	
7744			CV of Ronald A. Thisted, Ph.D.	
7745			CV of Donna-Bea Tillman, Ph.D.	
7746			Photos from Dr. Morris re SNF	
7747			Bard Filter Compliation Rates	
7748			NMT's 510(k) (K963014) for modifications to the SNI	/Straight
			Line System (Summary)	/ Straight
7749			FDA concurrence letter for K963014	
7750			FDA concurrence letter for K970099	
7751			1989 FDA Guidance re Medical Device Labeling	
7752			2005 FDA Guidance re Good Pharmacovigilance Pract	ices and
			Pharmacoepidemiologic Assessment	l di la
7753			2014 Draft FDA Guidance re Benefit-Risk Factors Wh	en
		3-23-18	Determining Substantial Equivalence in Premarket Not	ifications
			510k with Different Technological Characteristics	
7754			2014 FDA Guidance re Distinguishing Medical Device	Recalls
			from Medical Device Enhancements	
7755			2011 Draft FDA Guidance re Responding to Unsolicite	d
			Requests for Off-Lael Information	
7756			2017 FDA Guidance Deciding When to Submit a 510k	for a
			Change to an Existing Device	
7757			2002 FDA Guidance re Determination of Intended Use	for 510k
			Devices	
7758	İ	3-25-18	2014 FDA Guidance re 510k Evaluating Substantial	
77.50			Equivalence in Premarket Notifications	
7759			CDRH Preliminary Internal Evaluations - Volume I	
7760			2017 Public Health Interests and First Amendment	
77(1			Consideration Related to Manufacturer Communication	S
7761		ł	2015 Draft Public Notification of Emerging Postmarket	Medical
7762			Device Signals	
7762			2016 FDA Guidance Medical Device Reporting for	
			Manufacturers	

Exhibit	Marked for ID	Admitted in Evidence	Description	· · · · · · · · · · · · · · · · · · ·
7763			Braun Vena Tech Jugular – 2010	
7764			Braun Vena Tech Jugular – 2015	
7765			Braun Vena Tech Femoral – 2015	
7766			Cook Celect Platinum Jugular and Femoral – 2015 de guide	oloyment
7767			Boston Scientific Greenfield Stainless Steel and Titan 2011 brochure with performance stats	ium –
7768			Cordis Optease Femoral Jugular Antecubital – 2017	
7769			ALN Jugular-Brachial and Femoral-Popliteal – 2013 r	procedure
7770			Braun Vena Tech Convertible Femoral & Jugular – Fe 2016	bruary
7771			Braun Vena Tech LP Femoral – October 2010	
7772			Greenfield Stainless Steel – November 2001	
7773			Argon Option IFU - 2017	
7774			Argon Option Elite IFU - 2017	
7775			Cook Celect Femoral 2008	
7776			Cook Celect Femoral & Jugular 2009	
7777			Cook Celect Platinum Femoral & Jugular 2012	
7778			Cool Giantruco-Roehm Bird's Nest Femoral & Jugular	2008
7779			Cool Giantruco-Roehm Bird's Nest Radoipaque band F & Jugular 2008	emoral
7780			Cook Gunther Tulip Jugular 2003	
7781			Cook Gunther Tulip Jugular 2005	
7782			Cook Gunther Tulip Jugular & Femoral 2006	
7783			Cook Gunther Tulip Femoral 2006	
7784			Cook Gunther Tulip Jugular 2008	
7785			Cook Gunther Tulip Jugular & Femoral 2009	
7786			Greenfield Over the Wire Femoral & Jugular 2004	
7787			Cordis Optease Femoral Jugular Antecubital – 2013	
7788			ALN Filter with Hook Jugular 2014	
7789			Volcano Crux VCF Femoral Jugular 2016	
7790			Coumadin Package Inserts	
7791			Lovenox Package Inserts	
7792			Various Anticoagulant Package Inserts	
7793			G2 Filter exemplar	
7794]	Screenshot from FDA, Manufacturer and User Facility Experience Database - (MAUDE), available online at https://www.fda.gov/MedicalDevices/DeviceRegulation dance/PostmarketRequirements/ReportingAdverseEven	andGui
			dance/PostmarketRequirements/ReportingAdverseEven 27891.htm	ts/ucm1

Exhibit	Marked for ID	Admitted in Evidence	Description	
7795		7	Screenshot from FDA, MAUDE - Manufacturer and U Facility Device Experience, available online at	Jser
		3-23-18	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfirch.cfm	maude/sea
7796			Removable Embolus Blood Clot Filter and Filter Deliv System, January 1, 2008, US Patent No. 7,314,477 B1	very
7797			G2 Bench testing videos	
7798			2010 FDA Safety Communication: Removing Retrieval Inferior Vena Cava Filters	able
7799			2014 FDA Safety Communication: Removing Retrieval Inferior Vena Cava Filters	able
7800			Kessler Invoices	
7801			Demonstrative (Chart of Complication Rates)	
7802			Demonstrative (IVC Filter Implant and Explant Anima	tions)
7803			Demonstrative (IVC Filter Clot Trapping Animations)	itions)
7804			Demonstrative (Diagram of Venous System)	
7805			Demonstrative (Picture of Bard G2 Filter)	
7806			Demonstrative (Pulmonary Embolism Statistics)	
7807			Demonstrative (Animations of Plaintiff's Medical Cour	rea)
7808			Demonstrative (Timeline of Plaintiff's Medical Course	
7809			Demonstrative Slides for Dr. Paul Briant	<u> </u>
7810			Flip Chart and/or demonstrative exhibit describing repo	orting
			trends for Dr. Ronald Thisted	nting
7811			Briant Demonstrative Exhibit, Definitions – Stress, Stra Stiffness	ain and
7812			Briant Demonstrative Exhibit, Exponent and McMeeki Calculation Approach Comparison	ng
7813			Briant Demonstrative Exhibit, IVC and Surrounding Ti	CCIIAC
7814			Briant Demonstrative Exhibit, Exponent and McMeekin	ng Strain
7815			Calculation Input Comparison	•
7816			Briant Demonstrative Exhibit, Exponent Model Validat	tion
7010			Briant Demonstrative Exhibit, Exponent and McMeekir Results Comparison	ng Strain
7817			Briant Demonstrative Exhibit, Summary of Exponent v	Owana
			McMeeking Analysis	ersus
7818			US Patent No. 6,007,558 titled Removable Embolus Blo	ood Clot
			Filter assigned on 12/28/1999	ood Clot
7819			G2 technical drawings	
7820			American National Standard ANSI AAMI ISO 25539-3	(2011)
7821			Demonstrative depiction of inferior vena cava	(2011)
7822			Demonstrative depiction of dynamic environment of inference variables.	erior
7823			Demonstrative depiction of pulmonary embolism	

Exhibit	Marked for ID	Admitted in Evidence	Description	
7824			Demonstrative depiction of IVC filter catching a clot	*****
7825			Demonstrative depiction of the development of a deep	vein
			thrombosis	
7826			Demonstrative depiction of abdominal anatomy	
7827			Demonstrative depiction of IVC filter placement	
7828			Demonstrative depiction of IVC filter retrieval	
7829			Demonstrative depiction of CT scans	
7830			Demonstrative depiction of IVC filter migration	
7831			Demonstrative depiction of IVC filter appearing to mig	grate
7832			Demonstrative depiction of timeline of plaintiff's relev	
			medical events	
7833			Demonstrative depiction of the plaintiff's IVC filter at	
			placement	
7834			Demonstrative depiction of the plaintiff's IVC filter at	retrieval
7835			Demonstrative depiction of the plaintiff's IVC filter in	
7836			Demonstrative depiction of the plaintiff's IVC filter in	2009
7837			Demonstrative depiction of the plaintiff's IVC filter in	
7838			Demonstrative depiction of the plaintiff's IVC filter in	
7839			Demonstrative depiction of the plaintiff's IVC filter in	
7840			Demonstrative depiction of the plaintiff's IVC filter in	
7841			Demonstrative depiction of the plaintiff's IVC filter in	
7842			Demonstrative depiction of the fragments of the plainti	
			filter in 2009	_
7843			Demonstrative depiction of the fragments of the plainti filter in 2010	ff's IVC
7844			Demonstrative depiction of the fragments of the plainti	ff's IVC
			filter in 2011	
7845			Demonstrative depiction of the fragments of the plainti filter in 2012	ff's IVC
7846			Demonstrative depiction of the fragments of the plaintifilter in 2013	ff's IVC
7847			Demonstrative depiction of the fragments of the plaintifilter in 2014	ff's IVC
7848			Demonstrative depiction of fragment in the plaintiff's I in 2015	VC filter
7849			Demonstrative depiction of fragment in the plaintiff's I in 2016	VC filter
7850			Demonstrative depiction of fragment in the plaintiff's I in 2017	VC filter
7851			Demonstrative depiction of fragment in the plaintiff's I in 2018	VC filter
7852			Demonstrative depiction of the IVC filter fragment in the plaintiff's heart	ne

Exhibit	Marked for ID	Admitted in Evidence	Description
7853			Demonstrative depiction of the procedure to remove the
			plaintiff's IVC filter
7854			Demonstrative depiction of the percutaneous procedure to
			remove the IVC filter strut from the plaintiff's heart
7855			Demonstrative depiction of the surgical procedure to repair the
			plaintiff's tricuspid valve
7856			Demonstrative depiction of the surgical procedure to remove the
			IVC filter strut from the plaintiff's heart
7857			Demonstrative depiction of endotheliolization of filter strut
7858			Demonstrative depiction of leads in the heart
7859			Demonstrative depiction of non-filter mechanical devices in the heart
7860			Demonstrative depiction of kidney stones
7861			Demonstrative depiction of abdominal hernias
7862			Demonstrative depiction of colitis
7863			Demonstrative depiction of pericarditis
7864			Demonstrative depiction of costochondritis
7865			Demonstrative depiction of medical literature regarding
7003			complications of IVC filters
7866			Demonstrative depicture of medical literature regarding efficacy of IVC filters
7867			Demonstrative depiction of the medical literature regarding complications associated with the G2 Filter
7868			Demonstrative depiction of the medical literature regarding
			complications associated with the Simon Nitinol Filter
7869			Demonstrative depiction of the medical literature regarding
			complications associated with the Recovery Filter
7870			Demonstrative depiction of the medical literature regarding
			complications associated with non-Bard IVC filters
7871			Demonstrative depiction of IVC filter design considerations
7872			Demonstrative depiction of the Recovery Filter
7873			Demonstrative depiction of the G2 Filter
7874			Demonstrative depiction of the Simon Nitinol Filter
7875			Demonstrative depiction of differences between the Recovery
			Filter and the G2 Filter
7876			Demonstrative depiction of Instructions for Use regarding non-
			Bard IVC filters
7877			Demonstrative depiction of the G2 Filter Instructions for Use
7878			Demonstrative depiction of MAUDE database disclaimers
7879			Demonstrative depiction of spontaneous adverse event reporting biases and limitations

Exhibit	Marked for ID	Admitted in Evidence	Description	
7880			Demonstrative depiction of errors in Prevalence of Fr	noture and
			Fragment Embolization of Bard Retrievable Vena Ca	acture and
			and Clinical Implications Including Cardiac Perforation	va Filters
			Tamponade	on and
7881			Demonstrative depiction of errors in Fracture and dist	
			migration of the Bard Recovery filter: a retrospective	ant
			363 implantations for notantially life the set	review of
7882			363 implantations for potentially life-threatening com	plications
			Demonstrative depiction of errors in Prevalence and c	linical
			consequences of fracture and fragment migration of the	e Bard
7883			G2 filter: imaging and clinical follow-up in 684 impla	ntations
, 555			Demonstrative depiction regarding hierarchy of scient evidence	ific
7884			1	
7004			Demonstrative depiction of where the medical literatur	re
			regarding IVC filters falls within the hierarchy of scien	ntific
7885			evidence	
7003			Demonstrative depiction comparing the medical literat	ure
7006			regarding the G2 Filter and the Simon Nitinol Filter	i
7886			Demonstrative depiction comparing the medical literat	ure
7007			regarding the Recovery Filter and the G2 Filter	ĺ
7887			Demonstrative depiction comparing the medical literat	ure
7000			regarding the G2 Filter and non-Bard IVC filters	
7888			Demonstrative depiction comparing complication rates	of the
			G2 Filter to rates of complication identified in the 2001	SIR
			Guidelines	
7889			Demonstrative depiction comparing complication rates	of the
			G2 Filter to rates of complication identified in the 2017	SIR
			Guidelines	Sirc
7890			Demonstrative depiction of the process by which the 20	001
			Quality Improvement Guidelines for Percutaneous Perr	nanent
			Inferior Vena Cava Filter Placement for the Prevention	of
			Pulmonary Embolism were created	01
7891			Demonstrative depiction of the process by which the 20	002
			Quality Improvement Guidelines for Percutaneous Pern	nonant
1		ŀ	Inferior Vena Cava Filter Placement for the Prevention	of
			Pulmonary Embolism were created	01
7892			Demonstrative depiction regarding the 2011 Quality	
ĺ			Improvement Guidelines for the Performance of Inferio	l Varia
			Cava Filter Placement for the Prevention of Pulmonary	rvena
		-	Embolism	
7893			Demonstrative depiction regarding the 2014 ACR-SIR I	<u> </u>
			Parameter for the Performance of Inferior Vena Cava (I	ractice
		li	Filter Placement for the Prevention of Pulmonary Embo	VC)
			Embo recent for the Prevention of Pulmonary Embo	lism

Exhibit	Marked for ID	Admitted in Evidence	Description	
7894			Demonstrative depiction regarding the 2016 ACR-SIR	-SPR
			Practice Parameter for the Performance of Inferior Ve	na Cava
			(IVC) Filter Placement for the Prevention of Pulmona	rv
			Embolism	
7895	?		Demonstrative depiction regarding the 2017 ACR-SIR	-SPR
			Practice Parameter for the Performance of Inferior Ven	na Cava
			(IVC) Filter Placement for the Prevention of Pulmonar	v
			Embolism	
7896			Demonstrative depiction of Bard's internal complication	on rates
			for the G2 Filter	on rates
7897			Demonstrative depiction of Bard's internal complication	n rates
			for the Recovery Filter	on raics
7898			Demonstrative depiction of sales of the Simon Nitinol	Filter
7899			Demonstrative depiction of sales of the G2 Filter	1 11161
7900			Demonstrative depiction of sales of Bard's retrievable	IVC
			filters	IVC
7901			Demonstrative depiction of bench testing regarding the	C2
			Filter	G2
7902			Demonstrative depiction of animal testing regarding th	C2
			Filter	e G2
7903			Demonstrative depiction of clinical trial testing regardi	1
		į	G2 Filter	ng the
7904			Demonstrative depiction of Bard's interaction with the	rr.
			regarding the G2 Filter before clearance on August 29,	10A
7905			Demonstrative depiction of Bard's interaction with the	Z005
			regarding the G2 Filter after clearance on August 29, 20	FDA
7906			Demonstrative depiction of Bard's interaction with the)US
			regarding the G2 Filter	FDA
7907			Demonstrative depiction of Bard's interaction with the	ED 4
			regarding the clinical trial EVEREST	FDA
7908			Demonstrative depiction regarding EVEREST clinical to	. ,
			material	rial
7909				<u> </u>
,,,,,			Demonstrative depiction of post-market adverse event tregarding the G2 Filter	racking
7910				
			Demonstrative depiction of Bard's actions concerning c	audal
7911			migration investigation	
7912			Demonstrative depiction of Weber effect	
7913			Demonstrative depiction of adverse event reporting tren	ds
, , 1 .			Demonstrative depiction of the physicians who read image	iging
7914			regarding the plaintiff's G2 Filter	
7915			Demonstrative regarding mission statement / core value	S
1713		[1	Placeholder/demonstrative for Bard's community	
		8	activities/engagement	

Exhibit	Marked for ID	Admitted in Evidence	Description
7916			21 CFR 803.50 - Individual adverse event reports;
			manufacturers
7917			Dr. Vogelzang's invoices
7918			Dr. Desai's invoices
7919			Screenshots of NWIR Filter Clinic website
			- http://ivcfilter.nm.org/about-ivc-filters.html
7920			Screenshots of NWIR Filter Clinic website
			- http://ivcfilter.nm.org/for-physicians.html
7921			Screenshots of NWIR Filter Clinic website
			- http://ivcfilter.nm.org/after-placement.html
7922			NWIR Calculator Screenshots
	3. -		- http://ivcfilter.nm.org/calculator.html
7923			Meridian Femoral IFU, 10/10
7924	***************************************		2017 Arizona Bioindustry Association Publication
7925			Bard Filter Rate information for Recovery, G2, and G2X
7926			Demonstrative depiction of permanent IVC filters
7927			Demonstrative depiction of retrievable IVC filters
7928			Demonstrative: Tillman- 2004-2005 recovery filter regulatory
			history
7929	i		Demonstrative: Tillman- regulatory process
7930			Demonstrative: Tillman Opinions
7931			Demonstrative: Everest
7932	,		Demonstrative: The Design Environment
7933			Demonstrative: Powerpoint slides prepared by Dr Morris
7934			Demonstrative: Summary of TR EX 5022
7935			Demonstrative: Briant- compilation of exhibits 7708 and 7717
7936			Demonstrative: Briant- compilation of exhibits 7703 and 7704
7937			Fasching Demonstrative – Recovery & G2 Filter Fracture Data Summary
7938			
7939			Overview of Dr. Grassi's opinions
1939			Description of the process by which the 2001 SIR Guidelines were written
7940			Table 1 from the 2001 SIR Guidelines
7941			Table 2 from the 2001 SIR Guidelines
7942			Demonstrative Placeholder
7943			Demonstrative Placeholder
7944			Demonstrative Placeholder
7945			Demonstrative Placeholder
7946			Demonstrative Placeholder
7947			Demonstrative Placeholder
7948			
7948			Social Media Compilation
			Exhibit Placeholder Dr. Fegal Heirarchy Demo
7950			Exhibit Placeholder

Exhibit	Marked for ID	Admitted in Evidence	Description
7951			Exhibit Placeholder
7952			Exhibit Placeholder
7953			Exhibit Placeholder
7954			Exhibit Placeholder
7955			Exhibit Placeholder
7956			Exhibit Placeholder
7957			Exhibit Placeholder
7958			Exhibit Placeholder
7959			Exhibit Placeholder
7960			Exhibit Placeholder
7961			Exhibit Placeholder
7962	-		Exhibit Placeholder
7963			Exhibit Placeholder
7964			Exhibit Placeholder
7965			Exhibit Placeholder
7966			Exhibit Placeholder
7967			Exhibit Placeholder
7968			2017.07.12 - Deposition of Michael Streiff Exhibit 04
7969			2017.07.12 - Deposition of Michael Streiff Exhibit 05
7970			2017.07.12 - Deposition of Michael Streiff Exhibit 07
7971			Aujesky, A prediction rule to identify low risk patients with pulmonary embolism
7972			Goldhaber, Acute pulmonary embolism clinical outcomes in the International Cooperative Pulmonary Embolism Registry
7973			Soloff, Acute pulmonary embolism
7974			Trujillo-Santos, Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism
7975			Shoeb, Assessing Bleeding Risk in Patients Taking Anticoagulants
7976			Carson, Clinical Course of PE
7977			Coon, Deep venous thrombosis and pulmonary embolism prediction prevention and treatment
7978			Nieto, Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry
7979			Levine, Hemorrhagic Complications of Anticoagulant Treatment
7980			Rubboli, Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy
7981			Horlander, Pulmonary Embolism Mortality in the United States 1979 to 1998
7982			Streiff 2000 - Vena Caval Filters- A comprehensive review

Exhibit	Marked for ID	Admitted in Evidence	Description
7983			Streiff 2003 - Outpatient therapy with low molecular weight
			heparin for treatment of venous thromboembolism
7984			Streiff 2003 - Vena Caval Filters- A Review for Intensive Care
			Specialists
7985			Streiff 2003 -Diagnosis and treatment of deep venous
			thrombosis and pulmonary embolism
7986			Streiff 2005 Hann 2005 - The role of vena caval filters in the
			management of venous thromboembolism
7987			Streiff 2006 - Kaufman 2006 - Guidelines for the use of
			retrievable and convertible vena cava filters - SIR
7988			Streiff 2006 - Kaufman Guidelines for the use of retrievable and
			convertible vena cava filters - SIR Multidisciplinary Consensus
			Conference
7989			Streiff 2007 - A Management of Venous Thomboembolism A
			Systematic Review for Practice Guidelines
7990			Streiff 2007 - Segal - Management of Venous
			Thromboembolism A Systematic Review for a Practice
			Guideline
7991			Streiff 2007 - The NCCN guidelines on venous
			thromboembolism
7992			Streiff 2008 - Kim A comparison of clinical outcomes with
			retrievable and permanent inferior vena cava filters
7993			Streiff 2008 Catheter-directed thrombolysis of inferior vena
			cava thrombosis in a 13-day old neonate and review of literature
7994			Streiff 2009 - Development of a research agenda for inferior
			vena cava filters- multidisciplinary research consensus panel.
7995			Streiff 2009 - Tschoe 2009 - Retrievable vena cava filters- A
			clinical review
7996			Streiff 2010 -Raman Inferior vena cava filters in the
			management of cancer-associated venous thromboembolism- a
			systematic review
7997			Streiff 2012 - Thromboprophylaxis in nonsurgical patients
7998			Streiff 2013 - Rajasekhar 2013 - Use of vena cava filters and
			venous access devices
7999			Streiff 2013 - Rajasekhar 2013 - Vena cava filters for
			management of venous thromboembolism- A clinical review
8000			Streiff 2013 - Thromboprophylaxis in nonsurgical patients
8001			Streiff 2015 - Predicting the risk of recurrent venous
			thromboembolism (VTE)
3002			Nijkeuter, The Natural Course of Hemodynamically Stable
			Pulmonary Embolism
8003			Konstantinides, Trends in incidence versus case fatality rates of
			pulmonary embolism

Exhibit	Marked for ID	Admitted in Evidence	Description	
8004			Jimenez, Trends in the Management and Outcomes of Pulmonary Embolism Analysis From Acute Pulmona Embolism	ry
8005			Nieto, Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism	
8006			Witt, What to do after the bleed resuming anticoagulation after major bleeding	
8007			Marconi - Five year follow up of pulmonary embolism	
8008			Kuo - Image Guided Interventions	
8009			Olin - Pulmonary Embolism	
8010	4,44		Wood - Major Pulmonary Embolism	
8011			Gerber - The incidence of and risk factors for venous thromboembolism and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation	
8012			Petty - Complications of Long Term Anticoagulation	
8013			Lankiewicz - Urgent reversal of warfarin with prothrombin complex concentrate	
8014			Schulman - Definition of major bleeding in clinical investigations of antihemostatic medicinal products i surgical patients	n non-